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SUMMARY
Pyruvate dehydrogenase is a multienzyme complex consisting 
of three enzymes, a decarboxylase (El), an acetyltransferase (E2) and 
a dehydrogenase (E3). A fourth enzyme of unknown function component 
X or protein X has recently been identified. Several similarities 
between E2 and protein X have been demonstrated.
Further investigation into this unique polypeptide has shown 
monospecificity of antiserum raised against gel purified protein X 
and E2. In various cell lines, antiserum to protein X failed to 
recognise the E2 component, similarly with E2 antiserum no cross 
reactivity with protein X polypeptide was observed.
Although E2 and protein X are antigenetically distinct, 
comparison of the N-terminal amino acid sequence of the E2 and X 
polypeptides revealed significant homology between the two 
components. Limited amino acid sequence data on bovine heart 
protein X indicated that this protein contains a single lipoyl domain 
located at its N-terminus and belongs to a family of homologous 
enzymes, all of which possess acetyltransferase activity. Limited 
proteolysis of PDC with the specific protease trypsin selectively 
released the lipoyl domains from E2 and protein X. Release of these 
domains from the E2 core assembly resulted in the loss of overall 
complex activity. Although the peptides participate in the overall 
catalytic cycle of the enzyme, their release from the core 
effectively decreases the concentration of the peptides with the 
resultant loss of overall complex activity. Further studies on PDC 
with trypsin resulted in the loss of the enzymes ability on. prolonged
incubation with acetylating substrate to diacetylate the active site
on E2 and thus protect this site from modification and inactivation 
-with N-ethylmaleimide.
A possible role for protein X in eukaryotic PDC has been
determined. Limited proteolysis of PDC by.protease ARG C .
XV
selectively digests the lipoyl domain from protein X without
significantly affecting the overall enzymes activity. Cleavage of
the lipoyl domain from protein X results in the lowering of the
affinity of the E3 component for the core assembly. Release o.f.E3
from the core assembly exposed the active site on E3 rendering it
14
susceptible to an NADH dependent labelling with [ C] NEM. After
limited proteolysis of PDC with ARG C, E3 activity studies revealed
an NADH dependent inactivation of E3 by various active site
inhibitors. By treatment of the complex with high salt (conditions
14
which are known to release E3) enhanced labelling of E3 by [ C]
NEM was observed and NADH dependent inactivation of E3 confirmed,
leading to the conclusion that protein X binds E3 to the core
assembly and protects the active site on E3.
PDC is regulated by phosphorylation (inactivation) and
dephosphorylation (activation) on the El O^subunit. Limited
proteolysis of PDC with ARG C resulted in a more rapid inactivation
of the complex and incorporation into the El subunit
suggesting that the regulatory subunit of the associated kinase had
been affected. An interesting observation was the presence of
2+
thiamine pyrophosphate and Mg protected the El c<. subunit from
proteolysis by ARG C.
A mammalian A  gt11 gene expression library has been screened 
with antiserum to protein X. A partial cDNA clone of protein X has 
been isolated and nucleotide sequence obtained. Comparison of 
nucleotide sequence obtained from protein X and Saccharomyces . 
cerevisiae and nucleotide sequence frctm the mammalian protein X clone 
revealed over 70% homology at the carboxyl-terminal of yeast protein 
X confirming the origin of the mammalian X clone.
Attempts to determine the route of acetyl.group transfer' 
between El and E2, El and X or between E2 and X have been made.
Disruption of the interaction between these components by reductively
14 o
acetylating E2 and X with [ C] pyruvate at -20 C or by employing
xvi
substrate analogues to observe this interaction has had limited 
o
success. At -20 G the turnover of the enzyme was successfully 
reduced although no disruption of the interaction between the 
components could be observed. The use of substrate analogues failed 
to show any preferential acylation between E2 and X or preferential 
interaction with El.
14
Finally, by monitoring the [ C] reductive acetylation 
of PDC in the presence of Coenzyme A, participation of protein X in 
the normal catalytic cycle was established.
CHAPTER ONE
INTRODUCTION
11. Introduction
1.1 Multienzyme complexes
Enzymes are biological catalysts which usually function 
sequentially promoting consecutive chemical reactions linked by 
intermediate products. When a number of enzymes are associated to 
form a defined entity which can catalyse a series of linked 
biochemical conversions this is termed a multienzyme complex. Well 
characterised examples are: tryptophan synthase from Escherichia
coli (Yanofsky and Crawford, 1972), fatty acid synthetase from both 
yeast (Lynen, 1972) and mammalian sources (Stoop et al., 1978) and 
the 2-oxo acid dehydrogenase complexes present in all organisms 
studied to date (Reed, 1974; Perham, 1975). A full description of 
several other multienzyme complexes may be found in reviews by Reed 
and Cox (1966) or Hardie and Coggins (1986).
Organisation into a multienzyme complex can provide a 
number of functional advantages including enhancement of catalytic 
or regulatory efficiency and substrate channelling (Perham, 1975).
As a form of compartmentalisation, intermediates may be positioned 
on or within the complex in such a way that would exclude 
competition by another biochemical pathway, or prevent decomposition 
in aqueous solution of an unstable intermediate. Interaction of 
the component polypeptides, as in the case of tryptophan synthase, 
may produce aggregates that have catalytic properties not present in
separate chains. Assembly of inter-related enzymes also makes it
\
\
physically easier for the products of jone enzyme to act as a 
substrate for the next enzyme in sequence. This may well increase 
the efficiency of the overall process,, even if the intrinsic 
catalytic activity of each component is not altered by the 
association.
2The increased efficiency of a complex as compared to that of 
separate enzymes dispersed at random is most obvious when, all 
intermediate products are strongly bound to the complex. In such a 
case reactions of the intermediate products of one enzyme with the next 
one are more probable. Moreover, substrate can be channelled through 
a series of reactions to avoid competition with other enzymes for the 
intermediate products or to reduce sensitivity to inhibitors in the 
surrounding medium. Such a system would function as a mechanism for 
selecting the metabolic fates of the substrate.
1.1.1 Association of enzymes
The integration of metabolic function in cells and its 
regulation can largely be explained in terms of structural interaction 
and separations between elements (enzymes and substrates) of the 
diverse metabolic pathways (Welch, 1977). It is possible that no 
organisation exists between enzymes in some metabolic pathways and that 
metabolic interactions or regulatory behaviour are diffusion controlled 
rather than specifically modulated by the local structure or 
microenvironment of the cellular compartment in question.
The rates of all chemical reactions are limited by the time it 
takes for the two reactants to encounter each other. This time 
depends on the shape of the reactants, the viscosity of the medium, the 
distance between the two particles and other parameters of the system. 
Considering the small distances involved in living cells, the diffusion 
coefficients of both large and small biological molecules, and assuming 
that water is the medium, the calculated encounter times are very fast 
compared to the turnover of all but the most rapidly-catalysed 
bioreactions. It has been suggested, therefore, that many metabolic 
pathways do not require special conditions or structures to allow 
enzymes to encounter their substrates or effectors.
3However, several authors have calculated that the 
difference between diffusion and enzyme turnover times may not be as 
large as first indicated if one imposes several corrections on the 
calculation of diffusion times (Welch, 1977). Another problem 
arises if randomly distributed enzymes depend solely on the 
diffusion of substrates. Atkinson (1969) has noted that unless 
special strategies are employed the volume occupied by total 
metabolites would be so large that the solvent capacity of the cell 
would be rate limiting.
Intracellular microenvironments, where local high 
concentrations of metabolites could be maintained, with a low total 
cellular metabolite concentration, can be created by arranging 
enzymes of a single biochemical pathway next to one another (Srere 
et al., 1973). Thus a high rate of enzyme activity could be 
maintained in a region of high metabolite concentration while the 
total average cellular concentration of the metabolite and therefore 
its volume of occupancy would be low. Increased rates of reaction 
have been reported when immobilised multi-step enzyme systems are 
compared to their soluble counterparts. Presumably a high local 
concentration exists as the substrate is produced in the immobilised 
system (Srere et al., 1973). However, the mechanism to explain 
these observations is not known precisely since diffusion times are 
thought to be much smaller than turnover times and some energy input 
seems necessary to maintain this situation of apparent 
non-equilibrium.
One reason for the acceptance that metabolic events are 
controlled by random diffusion stems from the fact that electron 
microscopy reveals areas of cell structure which have little or no 
obvious organisation. These areas include the cytosol and the
mitochondrial matrix. However, recent investigations of cytosolic 
structural elements have revealed a complex trabecular structure in 
both cytosol and the nucleus (Schliwa et al., 1981). In addition, 
experiments which have demonstrated interactions between soluble 
enzymes and subcellular structures have given rise to more intense 
considerations of metabolic control without the intervention of the 
diffusional process (Masters, 1981). Welch (1977) has presented 
forcefully the theoretical basis supporting the role of organised 
enzyme systems in metabolism and Srere (1982) has indicated that the 
inner membrane matrix compartment of mitochondria may have a degree 
of structural organisation in which the matrix proteins are adjacent 
and loosely-bound to the inner membrane. This proposal has 
important consequences relating to the control (diffusional or 
structural) of the main energy producing pathway of most aerobic 
cells and the biogenesis of mitochondria.
Association of enzymes with one another and with structural 
proteins in cells may be far more extensive than is generally 
imagined. Increased efficiency and new three dimensional 
arrangements with elaborate control mechanisms may arise from such 
organisation. Isolation and purification of multienzyme complexes 
cannot be assumed to preserve the integrity of these aggregates. 
Therefore, it is possible that their natural occurrence is more 
frequent than reported (Reed and Cox, 1966). It is also possible 
the enzymes exist as smaller aggregates which when diluted on 
cellular disruption form large complexes which are not normal 
cellular entities.
1.2 2 -Oxo acid dehydrogenase multienzyme complexes
The 2-oxo acid dehydrogenase multienzyme complexes are 
associations of three enzymic activities, a substrate-specific 
dehydrogenase (El), a distinct dihydrolipoyl acyltransferase (E2)
5and dihydrolipoamide dehydrogenase (E3), a flavoprotein which is 
common to all three complexes.
Each complex catalyses a coordinated sequence of steps that 
can be represented by the overall reaction. (
O O
LI II
R-C-CO H + CoA + NAD -- > R-C-S-CoA + NADH + H + CO
2 2
Where R = CH (pyruvic acid) or HO C-(CH ) (2-oxoglutarate)
3 2 2 2
or the 2-oxo acids derived from the metabolism of valine, isoleucine
and leucine ( CK-oxoisovaleric, £>(-oxoisocaproic and <X-oxo-3
-methylvaleric acids). The acyltransferase constitutes the core of
the complexes to which the El and E3 component enzymes are attached
by non-covalent bonds. The' total number of subunits is large and,
depending on the type of complex and its source, is generally in the
range of 60 to 100. These complexes may be self assembling and
form ordered, symmetrical structures. There are no fewer than six
coenzymes and prosthetic groups involved in the sequence of
2+
reactions catalysed by the complexes, viz; Mg , thiamine
pyrophosphate (TPP), lipoic acid, coenzyme A (CoASH), flavin adenine
+
dinucleotide (FAD) and nicotinamide adenine dinucleotide (NAD ).
In different organisms they are subject to regulation by 
ligand binding (Reed, 1974), covalent modification (Linn et al.,
1969) control of gene expression (Langley and Guest, 1978), 
proteinase action (Linn et al., 1974), product inhibition (Garland 
and Randle, 1964), hormonal control (Reed and Yeaman, 1987;
McCormack and Denton, 1984; Denton and Hughes, 1978) and glucose 
oxidation i.e. in starvation or diabetes (Wieland, 1983). The 
specific reactions catalysed by pyruvate dehydrogenase complex and 
the functionally analogous 2-oxoglutarate dehydrogenase (OGDC) and 
branched chain 2-oxo acid dehydrogenase complexes (BC0ADC) are shown 
in Table 1.1.
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61.2.1 Role of 2-oxo acid multienzyme complexes
Pyruvate dehydrogenase complex (PDC) provides acetyl CoA, an 
important biosynthetic metabolite used in the synthesis of fatty acids, 
leucine and steroids in eukaryotes. In most aerobic organisms, the 
oxidation of acetyl CoA via the tricarboxylic acid cycle provides a 
major source of reducing power in the form of NADH and metabolically 
utilizable energy in the form of ATP. The 2-oxoglutarate dehydrogenase 
complex (OGDC) is a major constituent of the tricarboxylic cycle 
regulating the flux of this pathway in its latter stages. OGDC 
catalyses the formation of succinyl CoA which is required in the 
biosynthesis of porphyrins, lysine and methionine.
The branched-chain 2-oxo acid dehydrogenase complex (BCOADC) 
catalyses the committed step in the degradation of branched-chain amino 
acids. In mammals this is nutrionally important in dealing with 
excess valine, leucine and isoleucine in the diet (Goldberg and Chang, 
1978). These amino acids are ultimately converted to acetyl CoA 
(ketogenic), succinyl CoA (glucogenic) and propionyl CoA (glucogenic). 
BCOADC may also be involved in the catabolism of methionine and 
threonine since it is reported that 2-oxobutyrate (Pettit et: al., 1978) 
and 4-methylthio-2-oxobutyrate can also be used as substrates by the 
complex (Jones and Yeaman, 1986). A deficiency in BCOADC activity in 
humans results in Maple Syrup Urine disease. The 2-oxo acid 
dehydrogenase complexes have been purified from a variety of 
prokaryotic and eukaryotic sources and a selected list follows.
*
1.2.2 Purification of 2-oxo acid multienzyme complexes from various
sources
PDC has been isolated from E. -coli (Reed and Mukherjee, 1969; 
Danson et al., 1979). Pseudomonas aeruginosa (Jeyasselan 
et al., 1980), Bacillus stearothermophilus (Henderson and Perham,
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1980), Bacillus subtilis (Hodgson et al., 1983), Saccharomyces 
cerevisiae (Kresze and Ronft, 1981), ox kidney (Kr.esze and Steber, 
1979; Cate and Roche, 1979), porcine liver (Roche and Cate, 1977) 
and ox heart (Stanley and Perham, 1980). OGDC has been purified 
from E. coli (Reed and Mukherjee, 1969), ox kidney (Reed and Oliver, 
1968) and pig heart (Koike and Koike, 1976). BCOADC has been 
isolated from Pseudomonas putida (Sokatch et al., 1981b), bovine 
liver and heart mitochondria (Danner et al., 1979; Pettit et al.,
1978) and Ascaris suum (Sokatch et al., 1981a).
1.2.3 Reaction mechanism of the 2-oxo acid dehydrogenase 
multienzyme complexes
As discussed previously (Section 1.2), the acyltransferase 
component of the multienzyme complexes forms a central core around 
which are arranged multiple copies of the El and E3 enzymes. The
sequence of reactions catalysed by pyruvate dehydrogenase is shown
schematically in Figure 1.1. Using pyruvate dehydrogenase complex 
as an example the reaction mechanism is discussed more fully.
1.2.4 Pyruvate dehydrogenase (El)
The reaction catalysed by pyruvate dehydrogenase (El) is
the rate determining step governing overall PDC activity (Bates et
al., 1977; Danson jet al., 1978). Pyruvate is decarboxylated
initially in a reaction involving the coenzyme thiamine
pyrophosphate. Lipoic acid, covalently-bound to the £ -amino group
*
of a lysine on the E2 component by an amide bond is then reductively 
acetylated with the concomitant opening of 'the dithiolane ring '
generating a free thiol. It has been\shown recently by ' H nmr that
8acetylation occurs initially at the S position of the lipoic acid 
6
and not at the S position although isomerisation can occur in . 
aqueous solution (Yang and Frey, 1986). , •
o
II
c h 3 — c — s SH
Figure 1.2 Mechanistic pathways for the reductive acetylation of lipoyl 
cofactors by 2-(l-hydroxyethylidene)-TPP at the active site 
of pyruvate dehydrogenase (E^) (Frey et al./ 1989)
Mammalian El of PDC and El of BCOADC are tetramers 
consisting of two subunits o(.and J3> while El of mammalian OGDC is a 
homodimer. The role of each subunit in the complexes has not yet 
been fully assigned but t h e s u b u n i t  is thought to bind the <=< 
subunit to the E2 core (Yeaman and Reed, 1987).
El catalyses the decarboxylation of pyruvate in a reaction 
that is dependent on thiamine pyrophosphate (TPP). The product of 
this reaction, 2-(1-hydroxyethylidene)-TPP [CH^C(OH)=TPP] remains 
tightly bound to El. The mechanism of reductive transacetylation 
between El-CH^C(OH)-TPP and a lipoyl group to give TPP and 
S-acetyldihydrolipoamide is the subject of much discussion 
(Fig. 1.2). The debate centres on the involvement of acetyl TPP as 
a compulsory intermediate in the decarboxylation and dehydrogenation 
of pyruvate (Pathway A Fig. 1.2) (Das et al., 1961; Daigo and Reed, 
1962). An alternative intermediate has been proposed in which the 
enamine CH^C(OH)=TPP reacts as a carbanion with lipoamide to form 
the tetrahedral adduct in a single step (Pathway B, Fig. 1.2) 
(Breslow and McNelis, 1962; White and Ingraham, 1962). Recent 
data have not clearly demonstrated the mechanism involving reductive 
acetylation intermediates (Frey et al., 1989) and further 
experimentation is required to address these questions.
It was observed that phosphorylation inhibited the ability
of the enzyme to catalyse the formation of the intermediate
14
2-(1-hydroxyethylidene)s;TPP with [1- C] pyruvate as substrate,
14
but not with [2- C] hydroxyethyl TPP as substrate (Roche and 
Reed, 1972). Since phosphorylation occurs on the ElO^subunit and 
not on t h e subunit, it was suggested that the o^subunit catalysed 
the formation of 2-(l-hydroxyethylidene)=TPP. However this 
proposal has been questioned by Walsh et al. (1976) who reported 
that phosphorylation of the pig heart enzyme inhibits NADH-dependent
9transfer of acetyl groups from enzyme-linked acetyldihydrolipoamide 
to TPP. These results await clarification, perhaps when the 
isolated enzymatically active ^X»and ^su b u n i t s  are available.
I
1.2.5 Lipoate acetyltransferase (E2)
The lipoate acetyltransferase is involved in a series of 
reactions which includes reductive acetylation, deacetylation and 
finally reoxidation of the covalently-bound lipoamide moieties.
This is facilitated by the lipoyl-lysyl "swinging arms" visiting the 
active sites of one or more El, E2 and E3 components. The lipoate 
acetyltransferase specifically catalyses the reversible 
transacetylation of the enzyme bound 8-acetyldihydrolipoamide with 
formation of acetyl CoA (Yang and Frey, 1986). The- E2 component 
also catalyses the intramolecular transfer of acetyl residues 
between lipoic acid prosthetic groups of different E2 components in 
the same complex (Bates et al., 1977; Collins and Reed, 1977). A
detailed account of the structure of E2 can be found in Section 
1.5.3.
The amino acid sequences of lipoate acetyltransferase and 
the corresponding succinyltransferase of the 2-oxoglutarate complex 
in E. coli have been deduced from the nucleotide sequences (Stephens 
et al., 1983b; Spencer et al., 1984) and have been used to identify 
a possible active site.
Little is known about the mechanism of acetyl group 
transfer by E2. There is no evidence for acetylation of the enzyme 
at sites other than lipoyl domains. However it has been suggested 
that conserved histidine residues in E2 of PDC and E2 of OGDC could 
have a catalytic function because they are located in the most 
highly conserved segments of the two acyltransferases (Spencer 
et al., 1984). Much more is known about chloramphenicol 
acetyltransferase (CAT) which catalyses the O^-acetylation (and
10
inactivation) of chloramphenicol in antibiotic resistant bacteria 
(Shaw, 1983; Kleanthous et al., 1985). A specific histidine 
residue that is preferentially modified by non-specific and active 
site directed inhibitors has been identified and this residue is 
thought to function as a general base in catalysis.
Comparisons between the amino acid sequences of lipoamide 
acetyltransferase and lipoamide succinylltransferase of Ei^  coli and 
several chloramphenicol acetyltransferases (CAT) have revealed some 
well-aligned homologies which may be indicative of an underlying 
structural similarity between the catalytic (acetyltransferase) 
domain of E2 and CAT. The region containing the active-site 
histidine residue in CAT is particularly well conserved in each E2 
and has led to a proposed catalytic mechanism, involving a histidine 
residue in each E2 as a likely active-site residue (Guest, 1987).
1.2.6 Dihydrolipoamide dehydrogenase (E3)
The regeneration of oxidised lipoic acid is promoted by 
dihydrolipoamide dehydrogenase, (E3) an FAD-linked homodimer.
During the catalytic cycle, the tightly-bound FAD moiety becomes 
transiently reduced with final production of NADH. This enzyme 
also employs, as part of its reaction mechanism, the alternative 
oxidation and reduction of a disulphide bridge at its active site 
(Massey et al., 1960; Massey and Veeger, 1961). This disulphide 
bridge has provided a focus for chemical studies of the active site
(Brown and Perham, 1972, 1974; Pai and Schulz, 1983; Arscott et_
**
al., 1981). It consists of a reactivd cysteine disulphide, which 
functions in catalysis; the two half cysteines are separated in the 
polypeptide chain by only four residues and evidence for involvement 
of this group in catalysis comes from studies in the presence of 
arsenite and NADH, in which flavin is oxidised completely (Williams, 
1976; Danson et al., 1984).
11
A similar flavoprotein to lipoamide dehydrogenase,
glutathione reductase also catalyses a specific pyridine
nucleotide-disulphide oxidoreduction (Williams, 1976). Both
structural and mechanistic similarities have been extensively
documented. Thus each contains a redox active-disulphide bond
(Searls and Sanadi, 1960; Massey and Veeger, 1961; Massey and
Williams, 1965) which is located in a highly conserved section of
polypeptide chain (Jones and Williams, 1975). Two electron
reduction of either enzyme produces a charge transfer complex
between a thiolate anion (as the donor) and oxidised flavin (as the
acceptor). A base in the active-site accepts a second proton
(Mathews and Williams, 1976; Mathews et al., 1977). In catalysis,
these enzymes cycle between the oxidised El and the two electron
reduced EH^ state (Massey et al., 1960).
Catalysis by lipoamide dehydrogenase involves a sequential
flow of electrons from dihydrolipoamide to the active centre
disulphide and on reoxidation the electrons pass very rapidly via 
+
the FAD to NAD (Thorpe and Williams, 1974). In glutathione 
reductase the sequence is reversed, beginning with NADPH and ending 
with thiol disulphide interchange between the active centre dithiol 
and glutathione.
As with lipoamide dehydrogenase the two thiols produced 
upon two electron reduction of glutathione reductase are not 
chemically equivalent and are readily distinguishable following
chemical modification. The thiol closer to the amino terminus is
* •%
involved in thiol-disulphide interchange while the other interacts
with FAD (Thorpe and Williams, 1976; Williams et al., 1976).
Site-directed mutagenesis and molecular modelling have been
used to identify a set of amino acid side chains in glutathione
+
reductase that confer specificity for the coenzyme NADP (Scrutton
12
et al., 1990). Systematic replacement of these amino acids, all of
+
which occur in the NADP binding domains, leaves the substrate
specificity unchanged but converts the enzyme into one displaying a
+
marked preference for the coenzyme NAD . It is probable that 
similar experiments can now be performed to redesign the coenzyme 
specificity of any nicotinamide nucleotide-specific enzyme that 
contains a conserved dinucleotide binding domain.
1.2.7 Possible function of lipoamide dehydrogenase (E3)
Lipoamide dehydrogenase has been isolated from many sources 
and has been found to be remarkably resistant to heat inactivation, 
proteolysis and urea treatment. E3 isolated from E_j_ coli and 
Saccharomyces cerevisiae strongly resemble the pig heart enzyme in 
size and amino acid composition (Williams, 1976; Henrich et al.,
1983). Stephens and co-workers have found considerable homology 
between the predicted nucleotide sequence of E3 from E^ _ coli and 
peptides from pig heart E3 (Stephens et al., 1983c). In fact 
exchange of E_;_ coli E3 component with pig heart lipoamide 
dehydrogenase supports overall activity and assembly into a hybrid 
multienzyme complex (Perham, 1975; Guest, 1978).
Lipoamide dehydrogenase has been isolated from organisms 
e.g. Trypanosoma brucei which do not possess pyruvate dehydrogenase 
or 2-oxoglutarate dehydrogenase complexes (Fairlamb, 1982; Danson 
et al., 1987). A similar situation exists in halophilic (Danson 
et al., 1984, 1986), thermoautophilic and methanogenic (Danson,
1984) archaebacteria. This enzyme has been purified also from 
Halobacterium halobium (Danson et al., 1986) and it was found to be 
similar to its counterpart in non-archaebacterial species in subunit 
arrangement and in its catalytic and kinetic properties.
13
Lipoamide dehydrogenase isolated from T. brucei was found 
to be associated with the plasma membrane and such an attachment may 
suggest a function specific to that location (Danson et_ al.,
1987). There is growing evidence that dihydrolipoyl dehydrogenase, 
in addition to its established role in 2-oxo acid dehydrogenase 
complexes, is implicated in sugar transport in E. coli (Richarme and 
Heine, 1986). Its possible function in other membranes remains 
entirely speculative. However, the view that many processes at the 
plasma membrane may involve disulphide-thiol interchanges serves to 
heighten the interest in the biological function of this enzyme with 
its catalytic redox-active disulphide bond (Danson, 1987).
1.3 Pyruvate dehydrogenase complex
The conversion of pyruvate to acetyl CoA catalysed by PDC 
serves both bioenergetic and biosynthetic roles. It is essentially 
an irreversible reaction _in vivo, occupying a key position in 
cellular metabolism controlling the supply of acetyl groups in 
mitochondria arising from the oxidation of carbohydrates and amino 
acids (Fig. 1.3). In many tissues including heart,muscle, brain 
and kidney, the acetyl CoA is almost exclusively metabolised through 
the citric acid cycle whilst in other tissues such as adipose 
tissue, mammary gland and liver a significant proportion is utilised 
in the synthesis of fatty acids and sterols. In animals, acetyl 
CoA cannot be employed in gluconeogenesis and thus conversion of 
pyruvate to acetyl CoA represents a net loss of carbohydrate 
reserves. Regulation of this step is of critical importance to the 
general energy balance and fuel economy of the cell. To control 
the activity of this important enzyme a range of regulatory 
mechanisms has evolved ensuring appropriate control as detailed in 
Section 1.3.4.
Glucose
Lactate
Glucose Glycogen
_
LactatePyruvate
Glucose
Fatty acids
Glucose Pyruvate
P-cnoloyruvate
I citfis
Oxaloacetate acid 
^  cycle
Fmnarate
CitrateCitrateOxaloacetate
2-oxoglutarate
Succlrvate
Figure 1.3 Major routes of pyruvate metabolism in mammalian cells
1, PDC; 2, pyruvate carboxylase; 3, citrate synthase;
4/ lactate dehydrogenase; 5, glycolysis; 6 , transamination; 
7, gluconeogenesis; 8 , lipogenesis.
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1.3.1 Subunit composition of PDC from E. coli
Early research was carried out on the multienzyme complex
purified from E. coli (Perham et al., 1987; Miles and Guest,
1987). The experience gained from studies on the PDC from
prokaryotic sources has been of considerable value in stimulating
parallel and subsequent research on mammalian PDC.
Analysi-s of purified PDC from coli by SDS gel
electrophoresis (SDS-PAGE) reveals that it consists of three
different types of polypeptide chain. Resolution of PDC from E.
coli into its constituent enzymatic activities using a combination
of gel filtration at high pH and chromatography on hydroxylapatite
columns in 4M urea (Koike et al., 1963), permitted assignment of the
specific functions of individual polypeptide chains: pyruvate
dehydrogenase (El) (a dimer, subunit M^ _ 100000), lipoate
acetyltransferase (E2), (subunit M 80000) and lipoamide
r
dehydrogenase (E3), a homodimer (subunit M 56000) (Perham and
r
Thomas, 1971; Vogel and Henning, 1971; Eley et al., 1972). The
M of the E2 chain estimated by sedimentation equilibrium in 
r
guanidinium-HCl is approximately 52000, suggesting that the value of
M 80000 obtained by SDS gel electrophoresis is anomalous (Eley et 
r
al., 1972; Hayakawa et al., 1969; Linn et al., 1972).
More recently gene sequence analysis of the pyruvate and
2-oxoglutarate complexes of EL_ coli have been reported (Stephens
et al., 1983a,b,c; Spencer et al., 1984; Packman et al., 1984).
These studies have resolved many of the controversial features
regarding size and number of lipoyl domain structures of the
acetyltransferase and have confirmed that the apparent M for the
r
E2 component as inferred from SDS-PAGE was significantly 
overestimated. The molecular genetics of the 2-oxo acid complexes 
will be discussed more fully in Section 1.6.
Table 1.2 Subunit composition of bovine heart pyruvate 
dehydrogenase complex
Enzyme Mr
Subunits
No
Subunits per molecu 
of complex
Native Complex 8,500,000
E 1 154,000 4
E1 c< 2 4.2,000 60
Ei jB 2 3 7,000 60
e 2 3,100,000 60 52,000 60
e3 1 10,000 2 55,000 12
Kinase 100,000 1 47,000
1 45,000
Phosphatase 150,000 1 97,000
1 50,000
Protein X 51,000 1 51,000 8-12
The above table is adapted from Reed and Pettit (1981) and Stepp et al. 
(1983)
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1.3.2 Subunit composition of mammalian PDC
PDC isolated from bovine kidney and heart have M values
r
6 6 
approximately 7.0 x 10 and 8.5 x 10 , respectively (Linn
et al., 1972). The M values of the various polypeDtide chains --------------- r
and the proposed stoichiometry of the bovine heart complex are
presented in Table 1.2. The El component consists of non identical
subunits , M 42000, and A, M 37000, which form 
r f r
<*2 /B tetramers of M 154000. The core enzyme consists of
60 identical polypeptide chains of M 52000. E3 has an overall
r
M 110000, comprising two identical subunits, M 55000, each 
r r
containing a molecule of FAD. The stoichiometries of PDC kinase
and phosphatase are not exactly known. The kinase and phosphatase
have been purified to homogeneity and each of these enzymes consists
of two subunits which have M values of 47000 and 45000 for the
r
kinase (designated 0 4 . and f3 respectively) and 97000-110000 and 
50000 for the phosphatase (Pratt et al., 1982; Stepp et al., 1983).
1.3.3 Structure and function of PDC
The major contributor to organisation and catalytic 
efficiency of the respective 2-oxo acid complexes is their specific 
E2 components. This enzyme serves three major roles:(l) it forms a 
central symmetrical core; (2 ) it is an acyltransferase catalysing 
the formation of the acyl CoA product and (3) it provides attachment 
sites for lipoic acid prosthetic groups which are required to 
interact with the different active sites of all the constituent 
enzymes of the complex.
A number of researchers (Hale and Perham, 1979; Bliele 
et al., 1979; Kresze et al., 1980; Bliele et al., 1981) have 
demonstrated using limited proteolysis, that the E2 component 
consists of several functional domains (Fig. 1.4). These include a
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compact inner catalytic domain which, in addition to containing the 
active site, binds to other E2 catalytic domains to maintain the 
central core and is also responsible for binding the El and E3 
components of the complexes.
!
The second type of domain is an extended, outer domain 
which contains the lysine group to which the lipoic acid moiety is 
attached. The 1ipoyl-bearing domains apparently interdigitate 
between the El and E3 components. Each E2 also contains a distinct 
region of polypeptide which is responsible for binding the E3 
component (Packman and Perham, 1986). These different domains are 
joined by linker regions of polypeptide, which vary in length and 
are characterised by being rich in proline and alanine residues 
(Stephens et al., 1983b). 'H nmr spectroscopy has shown these 
linker regions to be highly flexible, giving characteristic sharp 
resonances (Perham et al., 1981, Packman et al., 1984) which are 
diminished in genetically engineered complexes lacking one or more 
tandemly arranged lipoyl domains and their associated linker regions 
(Radford et al., 1987).
The complexes vary in the number of lipoyl domains which 
are contained within the E2 polypeptide. E2 from PDC of E. coli is 
remarkable in that it contains three highly conserved lipoyl 
domains, located in tandem repeat at the N-terminus of the 
polypeptide (Stephens et al., 1983b). Surprisingly deletion of two 
of the three lipoyl domains still allows assembly of a functional 
complex with full catalytic activity (Guest et al., 1985). Clearly 
additional domains are not required for the catalytic function of 
the complex, posing an interesting question as to the function of 
the two additional lipoate domains.
Table 1.3 Primary structure surrounding the 1ipoyl-lysine 
residues in proteins
Source Enzyme
*
Rat, Bovine PDC E2 V E T D K A T V G F E V Q E E G
I I
*
Bovine OGDC E2 I E T D K T S V Q V P S P A N G
*
Bovine Human BCOADC E2 V Q S D K A S V T I T S R Y D G
*
E. coli PDC E2 V E G D K A S M E V P A P F A G
S Q
*
E. coli OGDC E2 I E T D K V V L  E V  P A S A D G
*
Chicken Glycine- L E S V K A A S E L Y S P L T G
cleavage 
H-protein
The above table was adapted from Yeaman (1989).
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Ox kidney PDC has been reported to possess two lipoic acid 
moieties per E2 chain (Cate and Roche, 1979) although earlier 
conflicting observations suggested the presence of only a single 
lipoic acid group (White et al., 1980; Hamada et al., 1975).
Recent evidence suggests that the E2 polypeptide of mammalian PDC 
contains two functional lipoate residues (Hodgson et al., 1988).
This has been demonstrated by cross-linking studies using phenylene 
bis-maleimide in the presence of 2-oxo acid substrate to form 
dimers, trimers and higher aggregates between lipoate residues, 
whereas E2 of OGDC is only capable of forming dimers consistent with 
the presence ofosingle lipoate residue. The observation of the 
formation of dimers, trimers and higher aggregates is best explained 
by the presence of two or more lipoate groups. Furthermore the 
predicted protein sequence of a partial cDNA clone of rat liver PDC 
E2 (Gershwin et al., 1987) is consistent with the possible presence 
of a second lipoate domain. More recently a full-length cDNA clone 
for E2 from human liver pyruvate dehydrogenase has been isolated and 
sequenced (Thekkumkara et al., 1988) which has confirmed the 
presence of two homologous lipoyl domains (Coppel et al., 1988).
The sequence surrounding the lipoate attachment site has 
now been determined from several bacterial and mammalian complexes 
(Stephens et al., 1983b; Spencer et al., 1984; Bradford et al., 
1987; Hummel et al., 1988). The lipoate region is highly conserved 
as illustrated in Table 1.3.
Comparison of the lipoate acetyltransferase component of 
E. coli with mammalian acetyltransferase using electron microscopy 
reveals two polyhedral forms of the E2 component, the cube and the 
dodecahedron, both designs based on cubic point group symmetry.
The E2 component of pyruvate and 2-oxoglutarate 
dehydrogenases of E. coli and mammalian 2-oxoglutarate dehydrogenase 
have cubic design. The acetyltransferase and succinyltransferase 
components are similar in size and cube-like Appearance as 
demonstrated by sedimentation equilibrium analysis and electron 
microscopy (Reed and Oliver, 1968).
1.3.4 Lipoyl domains of PDC not associated with E2
A recently discovered polypeptide of mammalian PDC has been
the subject of intense investigation in recent years (De Marcucci
and Lindsay, 1985; Jilka et al., 1986). This polypeptide,
component X, has a close physical and functional union with the E2
core structure. In similar fashion to E2, component X can be
reductively acetylated in the presence of El and is rapidly
deacetylated in the presence of CoASH (De Marcucci et al., 1986).
It can also be modified by N-ethylmaleimide (NEM) only in the
presence of pyruvate or NADH. PDC was treated with N-ethyl 
14
12,3- C] maleimide in the presence of pyruvate and gel purified
component X was subjected to acid hydrolysis. The radiolabelled
products were resolved on an amino acid analyser and found to
co-elute with the product from similarly modified and hydrolysed
14
lipoate acetyltransferase confirming the [ C] acetylated group on 
component X as a lipoyl moiety (Hodgson et al., 1988).
1.3.5 Design of 2-oxo acid dehydrogenase complexes
The structural organisation of the 2-oxo acid dehydrogenase 
complexes can now be considered. Is there any correlation between
the number of lipoyl domains per E2 chain and the symmetry of the E2 
core? (Table 1.4). PDC and OGDC have three lipoyl and one lipoyl
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domain per E2 chain respectively, although both have E2 cores of 
octahedral symmetry. The ability to create, by in vitro genetic 
manipulation of the ace F gene, active Ej_ coli PDC with one, two or 
three lipoyl domains means that the symmetry is not limited by the 
number of lipoyl domains per E2 chain. Similarly, mammalian PDC, 
the Gram positive organism B. stearothermophilus and yeast enzymes 
contain one lipoyl domain, whereas human E2 contains two. However 
the E2 chain of Azotobacter vinlandii, which is Gram-negative like 
E. coli, also contains three lipoyl domains. As more E2 sequences 
are determined it will be interesting to see if correlation is at 
least sustained for Gram positive and Gram negative organisms. 
Significant homologies, however, indicate that the octahdral and 
icosahedral core forming E2 chains of prokaryotes and eukaryotes 
have arisen by divergent evolution from a common ancestor.
It is apparent from Table 1.4 that PDC from Gram positive 
organisms and eukaryotes are similar in symmetry and subunit 
structure and distinguishable from PDC complexes of Gram negative 
organisms in both regards. Thus the former have E2 cores of 
icosahedral symmetry and El components composed of El o<Cand ElyS 
subunits whereas the latter have E2 cores of octahedral symmetry and 
an El component composed of a single polypeptide chain.
Normal association of El o<and El J3> chains with an E2 core
of icosahedral symmetry does not extend to BCOADC. In subtilis,
the BCOADC possesses an icosahedral E2 core with associated
El o< /3 tetramers while mammalian BCOADC has an E2 of 
2 ' 2
octahedral symmetry with El cKand El /3 subunits. With increased 
detail of the principal features of the structure and assembly of 
2-oxo acid complexes from other organisms a clear picture may emerge 
of the divergence from a common evolutionary ancestor (Perham and 
Packman, 1989).
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1*3.6 Regulation of mammalian PDC
Mammalian PDC is subject to product inhibition by acetyl
CoA and NADH with reversal of inhibition occurring in the presence 
+
of CoASH and NAD respectively (Garland and Randle, 1964; Tsai
et al., 1973). Mammalian PDC is also regulated by ATP-dependent
phosphorylation (Reed, 1974; Denton jit al., 1975) in which the El<*.
subunit (M^ _ 42000) is covalently modified by a specific PDC
kinase, with concomitant loss of overall complex activity. In pig
heart PDC (Sugden et al., 1978), ox heart and kidney PDC (Yeaman
et al., 1978), inactivation is correlated with the phosphorylation
of a specific serine residue in the El enchain. A specific
phosphatase which is only loosely associated with the complex,
exists to remove the phosphate group and restore activity (Reed,
1974). The activities of the PDC kinase and PDC phosphatase
enzymes are regulated by various metabolites. The kinase is .
2+
activated by Mg , acetyl CoA and NADH and is inhibited by ADP,
2+
pyruvate and CoASH. The phosphatase is activated by Mg and 
2+
Ca and inhibited by NADH (Reed et al., 1980) (Fig. 1.5).
2+
Ca also inhibits kinase activity (Denton et al., 1975).
Recently it has been postulated that PDC phosphatase, in the
presence of E2, possesses an additional calcium binding site. It
is possible that the second site is at the interface between the
2+
phosphatase and E2, with Ca acting as a bridging ligand for 
specific attachment of the phosphatase to E2 or alternatively a
conformational change may be produced ip either enzyme, thus .
• 2+  ■ 
producing the second Ca binding siteJ. Favourable topographical
positioning of the phosphatase and phosphorylated El on E2 . .
2+
apparently facilitates, the Mg dependent dephosphorylation 
(Reed and Yeaman, 1987).
ATP
Pyruvate
dehydrogenase
Kinase
ADP
Pyruvate
dehydrogenase
active
Mg2+,Ca2+Acetyl-CoA,K 
NADH,K+ 
ADP,K+
Pyruvate 
TPP 
RS-SR
El (X (P) 
Inactive
— r Phosphatase
Figure 1.5 Schematic representation of the covalent modifications 
of pyruvate dehydrogenase and its regulation by various 
metabolites (Reed et al., 1980)
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The steady state activity of the complex is sensitive to 
the ratios [ATP]/[ADP], [AcSCoA]/[CoA] and [NADH]/[NAD+].
Pyruvate dehydrogenase and its two converter enzymes, kinase and
phosphatase, comprise a monocyclic interconvertible enzyme
+
cascade. The mechanism whereby acetyl CoA, CoASH, NAD and NADH
modify the activity of the kinase is controversial. It is possible
that the kinase or its substrate has regulatory binding sites for
these effectors but equally it is possible that these compounds act
through binding to their substrate sites on E2 and E3. In view of
the importance of the attachment of the kinase to the
acetyltransferase core assembly for kinase activity, the mechanism
of modification of the kinase by E2 may cause conformational changes
on the kinase effecting the regulatory properties of this subunit.
A novel mechanism has been proposed whereby lipoate may act
as a transmitter of regulatory interactions. This suggestion was
originally made by Kerbey et al. (1976) and subsequently supported
by Cate and Roche (1978). These latter authors have in a series of
articles postulated a mechanism in which the regulatory effects on ...
PDC kinase are mediated through changes in the acetylation and the
oxidation reduction states of the E2 lipoyl moieties but, with the
discovery of component X, they conclude that these changes may also
be mediated by the lipoyl groups on component X (Jilka et al.,
1986). Reduction of lipoyl moieties bound to E2 appears to
activate the kinase and acetyl CoA stimulation of the kinase
requires acetylation of the lipoyl groups (Roche and Cate, 197$)•
*
The activating effects of low pyruvate concentrations in the 
presence of TPP could similarly be explained in terms of acetylation 
or reduction of lipoyl groups (Cate and Roche, 1978, 1979).
However, this suggestion is in contradiction to the findings of Reed 
et al. (1980). With highly-purified pyruvate
22
dehydrogenase kinase and its dephosphotetradecapeptide substrate, it 
was demonstrated that the rate of phosphorylation was stimulated by 
acetyl CoA and NADH and inhibited by ADP and pyruvate. As E2 was 
absent in the preparation of the enzyme, these results indicate that 
the effectors can act directly on the kinase and not via lipoyl 
moieties bound to E2.
1.3.7 Sites of phosphorylation
During ATP-induced inactivation of pyruvate dehydrogenase
complex phosphorylation occurs at three serine residues in the El
subunit of the pyruvate dehydrogenase (El) component (Yeaman et_ al.,
1978; Sugden et al., 1979). Three sites of phosphorylation on
theO^subunit have been identified by tryptic digestion of 
32
P-labelled PDC from bovine kidney and heart, a small 
monophosphorylated peptide containing site 1 , a diphosphorylated 
tetradecapeptide (sites 1 and 2 ) and a monophosphorylated 
nonapeptide (site 3). Sites 1 and 2 are located in the same region 
of the peptide chain (Fig. 1.6).
Mammalian BCOADC is also subject to regulation by 
phosphorylation/dephosphorylation (Reed and Yeaman, 1987) but unlike 
PDC has only two serine residues on the El cx(subunit which undergo 
phosphorylation. As with PDC, phosphorylation of site 1 in BCOADC 
is responsible for inactivation of the complex. The role of the 
additional sites of phosphorylation on PDC and BCOADC has still to 
be firmly established.
Phosphorylation at site 1 in PDC occurs most rapidly and 
closely parallels the inactivation of the complex (Sugden et al., 
1978; Yeaman et al., 1978). Phosphorylation at sites 2 and 3, in 
addition to site 1 , markedly inhibit the rate of reactivation of
Figure 1.6 Phosphorylation sites on the Elofeubunit of pyruvate 
dehydrogenase
Site 1 Site 2
TYR-HIS-GLY-HIS-SER(P)-MET-SER-ASP-PRO-GLY-VAL-SER(P)-TYR-ARG
Site 3
-TYR-GLY-MET-GLY-THU-SER(P)-VAL-GLU-ARG
From Yeaman and Reed,(1987)
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complex by PDC phosphatase (Sugden e_t al., 1978; Kerbey and Randle,
1979). Partially phosphorylated complex is reactivated more 
rapidly than fully phosphorylated complex. On this basis these 
authors have proposed a role for multi-site phosphorylation as a 
mechanism for regulating the conversion of inactive complex into 
active complex (Randle et al.y 1981).
This proposal has been criticised by Reed and his 
colleagues (Reed et al., 1980). From an observation by Teague 
et al. (1979), they concluded that the presence of phosphate groups 
on sites 2 and 3 in bovine kidney did not significantly affect its 
rate of reactivation by PDC phosphatase. These authors obtained 
evidence that dephosphorylation on sites 1, 2 and 3 occurred at 
different rates and relative rates of dephosphorylation were in the 
order site 2, site 3, site 1. They also found that
phosphorylation of site 2 functions as well as phosphorylation of
site 1 in inactivating the enzyme while phosphorylation at site 3 
did not cause inactivation. The physiological significance of 
phosphorylation at site 2 is unknown. Phosphorylation of El 
results in essentially total loss of its enzymatic activity. No 
allosteric activators of the phosphorylated enzyme have been been 
reported (Hucho et al., 1972).
1.4 Component X
In mammalian pyruvate dehydrogenase complex, a distinct 
polypeptide of unknown function has been observed in recent years. 
Although this component had been noted previously (Stanley and 
Perham, 1980), it was considered originally to be a degradation 
product of E2 or possibly the associated PDC kinase activity.
24
The presence of this polypeptide may be unique to 
eukaryotic pyruvate dehydrogenase as no similar polypeptide has been 
detected in the analogous 2-oxo acid complexes, 2-oxoglutarate 
dehydrogenase and the branched-chain 2-oxo acid dehydrogenase. A 
similar polypeptide is present in yeast PDC (Kresze and Ronft,
1981). Although the relationship between component X of mammalian 
PDC and the polypeptide observed in yeast has not been confirmed 
conclusively, several similarities between the two polypeptides 
suggest that they may be functionally equivalent.
14
Incubation of pyruvate dehydrogenase complex with [2- C] 
pyruvate promotes reductive acetylation of covalently-bound lipoyl 
residues on the acetyl transferase (E2) core structure while 
apparently acetylating also an additional minor species of M
r
51000 (Bleile et al., 1979, 1981). Rapid deacetylation of
acetyltransferase (E2) and the M 51000 polypeptide on the
r
addition of CoASH gave rise to the belief initially that the 
polypeptide was a degradation product of E2.
1.4.1 Immunological studies on component X
The initial indicator that component X was a distinct 
polypeptide came from immunological studies. Production of subunit 
specific antisera in conjunction with sensitive immune replica and 
immune mapping studies (De Marcucci and Lindsay, 1985) indicated 
that component X was an immunologically distinct polypeptide.
Subunit-specific antisera to component X showed no cross 
reactivity with E2 as antigen and vice versa. In contrast 
antibodies prepared to component X by Roche's group (Jilka et al., 
1986) did detect some cross-reactivity with E2 which was 
subsequently absorbed out to recognise only component X antigen.
It is therefore, unlikely, that component X is a degradation product 
of E2.
25
Further confirmation of the distinct nature of component X
came from immune mapping studies. Immune mapping permits the
sensitive and specific detection of proteolytic fragments derived
from a single subunit. For example only proteolytic fragments of
E2 will be recognised even in the presence of a variety of cleavage
products from the other components of the multienzyme complex. It
was apparent that after digestion with elastase the E2 component
degrades to two major peptides of M 45000 and M 42000 which
r r
are largely resistant to further digestion although after a longer
time period a third, immunologically less reactive, M 29000
r
species is observed. Similar fragments have been observed
previously (Kresze and Steber, 1979) by Coomassie blue staining
after elastase digestion of purified E2 and PDC. These authors
reported that the 42000 fragment contained the lipoyl binding
domain while the 29000 fragment corresponds to the intersubunit
binding region of E2. In contrast component X-derived fragments
have M values of 29000 and 26000 which are cleaved rapidly to 
r
smaller peptides of M 15000 and below, the M 15000 peptide
r r
possibly containing the lipoyl binding domain of component X 
(Hodgson et al., 1986; Rahmatullah et al., 1989).
1.4.2 Peptide mapping .
In separate studies De Marcucci e_t al. (1986) provided 
further independent evidence from one dimensional peptide 'maps•
that E2 and X were structurally distinct polypeptides;
5 125
Two dimensional peptide mapping studies with I-labelled
14 ■
and C-labelled E2 and X polypeptides also demonstrate that the '
proteins are structurally distinct (Jilka et al., 1986). For - * 
example component X has been shown, to produce two major fragments. \
26
M 30000-27000 and 28000-25000 which are not observed with limited r
proteolysis of E2. Limited proteolysis of E2 does not reveal an
M 51000 fragment confirming that the M 51000 polypeptide is 
r r
not a degradation product of the lipoate acetyltransferase M^ _ 70000 
(De Marcucci et al., 1986).
1.4.3 Mitochondrial location of component X
Immune blotting studies of a variety of cellular extracts 
from Buffalo rat liver (BRL) bovine kidney (NBL-1) and pig kidney 
(PK-15) cells as well as purified mitochondrial, nuclear and 
cytosolic fractions of (BRL) cells have revealed that component X is 
a normal cellular component confined to the mitochondrial 
compartment. The mitochondrial localisation of protein X was 
further investigated. At high levels of digitonin, mitochondrial 
disruption of the inner membrane is induced with the concomitant 
release of inner membrane enzymes into the supernatant. It was 
observed that components of PDC were released into the soluble 
fraction only when the concentration of digitonin was high. From 
this it was concluded that component X is confined exclusively to 
the mitochondrial compartment, supporting the idea it is associated 
with PDC in intact cells and not an unrelated protein which is bound 
adventitiously to the complex during its isolation (De Marcucci, O. 
unpublished results).
One possibility considered initially was that component X is 
an isoenzyme of E2 as the site of acetylation on component X like on 
E2, is lipoic acid. In this respect, there could be two subpopulations 
of PDC arising from complexes containing either E2 or X core subunits.
27
However, at present, immunological inspection of PDC from several 
cell lines and rat tissues does not favour that idea, as component X
shows no apparent preferential distribution between these cell types
i .
(Hodgson et al., 1988). *
Although component X can be acetylated in the presence of 
pyruvate and deacetylated on the addition of CoASH, component X does 
not appear to have acetyltransferase activity (Jilka et al., 1986; 
Behai et al., 1989). Antisera prepared against the dihydrolipoyl 
acetyltransferase core was used to identify regions of 
acetyltransferase activity on E2 and component X. Failure of the 
acetyltransferase antiserum to detect component X was taken to be 
indicative that component X lacked acetyltransferase activity. This 
observation has been confirmed by nucleotide sequencing of component 
X from Saccharomyces cerevisiae (Behai et al., 1989).
1.4.4 Cross reactivity of anti-component X IgG with a 48000
protein in the cytosolic fraction of BRL cells
Subcellular fractions obtained after fractionation by
differential centrifugation (Attardi and Ching, 1979) and analysed by
immunoblotting with antisera to component X revealed that the
antiserum cross-reacted with a M 51000 polypeptide present in
r
whole cells and mitochondrial fractions - protein X. An additional
stronger cross reacting antigen of M 48000 was also observed in
r
whole cell extracts and in post nuclear supernatant fractions but was 
absent from mitochondrial fractions. It has not yet been 
established if this antigen is a strongly cross reacting species or a 
major contaminant from the original X antigen preparation from the 
SDS gel (Neagle et al., 1989).
28
1.4.5 Association of component X with E2 core
Further evidence for the nature of the association of
component X with PDC is found when the intact complex is dissociated
|in 1M salt at alkaline pH (Linn et al., 1972), or 0.25M MgCl^
(Kresze and Steber, 1979). Under these conditions the E2 core
6
remains intact with an overall M value of 3.1 x 10 while
r
homodimers of E3 (M 110000) and active tetramers of El (M
r r
154000) are released from the complex. It is apparent the M
r
51000 polypeptide, component X, stays tightly associated with E2 on 
dissociation of the multienzyme aggregate.
Specific binding of component X IgG to native PDC has 
indicated also that there was at least some region, of the component 
X subunit exposed at the periphery of the multienzyme complex. It 
was also observed that binding of antibody to component X caused 
little or no inhibition of overall complex activity (De Marcucci, O. 
and Lindsay, J.G. unpublished results) or on the rate of limited 
proteolysis by a specific protease (Neagle, J. unpublished results). 
Therefore the antibody has not proved useful for elucidating the 
function of X.
1.4.6 Cross linking of lipoyl groups on PDC
Studies employing electron microscopy have shown that the 
lipoyl domains on E2 subunits of PDC are located on peripherally 
extended regions of polypeptide (Bliele et al., 1979) and analysis by 
proton NMR has revealed these regions to be highly mobile relative to 
other parts of the complex (Wawrzynczak et al., 1981). This 
mobility would allow interaction of the lipoic acid at spatially 
distant active sites during the catalytic sequence. Pyruvate 
induced S-acetylation of lipoyl groups on PDC generates a thiol on 
the adjacent sulphur atoms of the dithiolane ring which is then 
susceptible to modification by maleimides (Brown and Perham, 1976).
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Reductive acetylation followed by reaction with phenylene-0 
bismaleimide has been used to achieve efficient cross-linking of the 
E2 subunits in PDC from E. coli via their covalently-attached lipoic 
acid residues (Collins and Reed, 1977).
Immunoblotting of cross-linked subunits of mammalian PDC 
with anti-X serum revealed that a number of aggregates containing X 
subunits were formed during cross-linking. A cross-linked species 
with an apparent of approximately 105000, containing only 
component X was most probably a homodimer of X. Two higher M
r
species were observed in which cross-linked X co-migrated with E2
cross linked products. Their estimated M values of 182000 and -
r
127000 were consistent with the composition for these aggregates of
E2/E2/X and E2/X respectively.
These results indicate that component X is exposed on the
surface of the E2 core and the lipoyl domains of E2 and X interact in
all possible combinations (Hodgson et al., 1988). An interesting
observation was that no higher aggregates of component X, M 150000
r
and M 200000 were observed. This observation may indicate that 
r
component X has a single lipoyl domain and may exist as a dimer.
1.4.7 Stoichiometry of component X
14
The rate of incorporation of [2- C] pyruvate into E2 and 
component X is very rapid. (Estimates of incorporation of acetyl 
groups into E2 and X can be obtained by excising the bands of E2 and 
X after resolution by SDS-PAGE.) Measurement of incorporation of~
14 . i
[2- C] pyruvate into E2 and X indicate- that component X contains 
16 _+ 2% of the radiolabel bound to E2(Neagle, J. unpublished
results). This Value would allow for an estimated 8-T2 molecules of 
component X per E2 'core' which approaches the levels of E3 in the 
complex and argues against its possible role as a regulatory 
component of the complex (De Marcucci and Lindsay, 1985).
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However, recent evidence suggests that E2 contains two 
lipoyl domains per E2 chain (Hodgson et al., 1988; Cate and Roche, 
1979). This value would suggest 16-24 molecules of component X per 
E2 'core'. Although two lipoyl domains per E2 chain may be present 
they may not be fully occupied with lipoyl groups which could explain 
the observations of one lipoyl group per E2 subunit (Barrera et al., 
1972; White 
et al., 1980).
The data described above is only an estimate of the levels 
of incorporation of substrate into E2 and X. In E^ _ coli, PDC,
0.5-0.7 moles of acetylating substrate is incorporated into each 
lipoyl domain on E2. This result led Perham and co-workers to the 
incorrect conclusion that there were two lipoyl domains per E2 chain
(Danson and Perham, 1976). A similar result is observed with 
mammalian PDC. E2 loads a total of approximately 2 moles of 
acetylating substrate per E2 polypeptide. This result is much lower 
than anticipated, considering the complex's ability to diacetylate E2 
and X, four moles of acetylating substrate would be expected to be 
incorporated into E2.
A more rigorous determination of incorporation of substrate 
into E2 and X needs to be performed before an accurate assessment can 
be made of the stoichiometry of component X in the complex.
1.4.8 Possible functions of component X in mammalian PDC .
Inactivation of PDC by phosphorylation results in a parallel *
*
decrease in the rate of acetylation of &2 and X indicating that the 
latter protein can participate in the acetylation/ deacetylation 
reactions of the complex. This result suggests that the reductive 
acetylation of protein X must proceed through the formation of 
2-hydroxyethylidene on the El component. It -is not clear if X acts 
as an intermediate in this process i.e. if El can transfer acetyl
groups directly onto component X and then pass them onto E2, reactlbn 
2, 3 and 4 (Fig. 1.7) where it is an essential intermediate of the • 
catalytic process. Alternatively, X may be an- associated enzyme in 
equilibrium with E2 reactions 1, 3 and 4 (Fig. 1.7). Component X 
may be directly involved in transferring acetyl groups onto CoASH, 
reaction 5 (Fig. 1.7) or onto other unknown physiological acceptors 
reaction 6 (Fig. 1.7).
Roche and coworkers (1978) originally advanced the idea that 
PDC may be regulated by the degree of acetylation of the complex.
In support of this concept they have shown pyruvate dehydrogenase 
kinase activity to be stimulated at low levels of acetylation of the 
complex. They have suggested the involvement of a few lipoyl groups 
in this effect and suggested that it is the participation of the 
lipoyl group from protein X which functions as a regulatory subunit 
of the kinase (Cate and Roche, 1978, 1979; Rahmatullah and Roche, 
1987).
More recently Roche and co-workers have abandoned this idea 
in favour of a role for component X in binding E3 to the E2/X core. 
They have demonstrated that protease argC preferentially degrades 
component X in the absence of the E3 component Rahmatullah et al«> 
1989) and it is argued that failure of the E3 component, but not El, 
to bind to protease argC-digested core suggests that component X is 
involved in the association of the E3 component (Gopalakrishnan et
al., 1989). Further evidence from this group argues that in intact 
complex the E3 component protects component X from proteolysis with 
argC and proteolysis of component X in imtact complex parallels the 
loss of enzymatic.activity.
A procedure for separating component X from the E2 core has 
now been described (Powers-Greenwood et al., 1989). In conditions^ 
of high urea and high salt concentrations an E2 oligomer, free of
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component X, can be purified by elution from a Sephacryl S-400 column 
equilibrated in the same chaotropic reagents. The E2 oligomer
retains acetyltransferase activity and is also able to bind the El
component of pyruvate dehydrogenase complex. A reduced binding of 
the E3 component to the E2 oligomer is observed supporting the idea 
that protein X is involved in the binding of E3.
1.5 Eukaryotic gene expression
Until the last decade, classical and molecular genetic 
approaches were largely confined to the simpler prokaryotic
systems. With the introduction of recombinant DNA technology, the
development of appropriate plasmid and phage vectors and engineered 
bacterial hosts which are able to accept non-bacterial DNA, advances 
in mammalian genetics have made great strides in recent years.
1.5.1 Recombinant DNA technology
Recent progress in molecular biology has made it possible to 
alter the genetic information in bacterial cells by inserting 
non-bacterial DNA, thereby producing non-bacterial proteins. These 
bacteria contain recombinant DNA, i.e. they contain along with their 
own genes part or all of a gene from an animal cell. It is now 
possible to isolate a single gene from a mammalian cDNA or genomic 
library and insert into a suitable bacterial host. As these 
bacteria multiply they produce millions of copies of their own genes 
and of the inserted animal gene. If the animal gene is fused in 
such a way that a bacterium can treat the gene as its own the bacterium 
will produce the protein specified by the animal gene - a fusion 
protein. The protein produced by the recombinant DNA can be 
recognised by screening the plaques with antibodies raised against 
the animal protein. A more detailed study of screening^ isolation 
and purification of plaques can be found in Section 6 .6 .6 .
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1.5.2 Molecular genetics of mammalian PDC
Recently several papers have been published reporting the 
molecular cloning and sequence analysis of cDNAs encoding all or part 
of the constituent polypeptides of the eukaryotic 2-oxo acid 
dehydrogenase complexes.
Nucleotide sequence of cDNA molecules encoding all or part 
of the E2 components of mammalian PDC and BCOADC has been reported 
recently (Gershwin et al.f 1987; Hummel et al., 1988; and Lau 
et al., 1988). In rat liver PDC, the E2 polypeptide shows a high 
degree of similarity both with its counterparts from E. coli and with 
the E2 component of human and bovine BCOADC (Gershwin et al.,
1987). The E2 clone from rat liver apparently encodes most of the 
polypeptide but is lacking the majority of the N-terminal lipoyl 
domain and a small C-terminal segment of the polypeptide. The 
complete nucleotide sequence for the dihydrolipoamide 
acetyltransferase component of human PDC has been obtained 
(Thekkumkara et al., 1988; Coppel et al., 19 88). The presence of 
an amino terminal lipoyl domain and a carboxy terminal catalytic 
domain are confirmed. The 1ipoy1-bearing domain contains two 
repeating units, each harbouring a lipoic acid-binding lysine.
Thus, mammalian PDC E2 component differs as to the number of lipoic 
acid binding sites from other E 2 components from prokaryotic and 
eukaryotic organisms. A dihydrolipoamide dehydrogenase (E3)‘ binding 
site has been identified on human PDC E2 which reveals 90% homology 
with the E3 site in rat liver (Gershwin et al., 1987). -
1.5.3 Human pyruvate dehydrogenase-(El) . .
The nucleotide sequence of human pyruvate dehydrogenase El ^  
and ^  subunits has been determined by Koike e_t al.' (1988). The 
nucleotide sequence for the El£>( subunit has also been obtained by •
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Dhal et al. (1987) and Robinson et al. (1988). Although the
reported Elo^nucleotide sequences are significantly different,
several important consistent features are found in each sequence.
From the nucleotide sequence it was deduced that the proteins Elo(
and Ely3 were synthesised with typical mitochondrial import leader
sequences (Schatz, 1983). The amino acid sequences of
NH -terminal regions of the two subunits of human PDC El were 
2
highly homologous with these of mature porcine PDC (Koike et_ al.,
1988). The amino acid sequences of phosphorylation sites determined 
in the ElO^subunit were also conserved in bovine and porcine enzymes 
(Koike et al. 1988).
1.5.4 Genetics of eukaryotic protein X
The gene encoding the protein X component of pyruvate 
dehydrogenase complex from Saccharomyces cerevisiae has been cloned 
and sequenced recently (Behai et al., 1989). Comparison of the 
deduced amino acid sequences of yeast protein X and dihydrolipoamide 
acetyltransferase indicates that the two proteins evolved from a 
common ancestor. A high degree of homology exists between component 
X and the acetyltransferase at their N-terminal regions corresponding 
to the lipoyl domain; however, protein X lacks a highly conserved 
sequence near the carboxy terminus which is thought to be part of the 
active site of all dihydrolipoamide acetyltransferases which confirms 
the finding of Jilka et al. (1986) who observed that component X 
lacked acetyltransferase activity.
Also, comparison of the nucleotide sequence of the 
C-terminus region of protein X with the C-terminus of mammalian E2 
reveals little homology which may suggest a possible role for 
component X in the complex which bears little relationship to the 
function of E2.
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1.5.5 Genetics of prokaryotic and eukaryotic lipoamide 
dehydrogenase
The gene encoding E3 has been cloned and sequenced from a 
variety of sources - selected list follows:
E. coli (Stephens et_ al., 1983c), A. vinelandii (Westphal 
and De Kok, 19 88), yeast (Ross et al., 1988), pig adrenal medulla 
(Otulakowski and Robinson, 1987), human liver (Pons et al., 1988) and 
human small cell carcinoma (Otalakowski and Robinson, 1987). ~ These 
E3 proteins exhibit extensive similarity. In yeast the amino acid 
sequence surrounding the putative active site cystine (Reed et al.,
1989) is identical with the sequence reported (a purified protein 
from pig heart) (Williams et al., 1982).
1.6 Genetics of 2-oxo acid dehydrogenase multienzyme complexes
An alliance of biochemistry and genetics has frequently
proved the most powerful tool for investigating the control of gene
expression and the mechanism and biological role of their products.
Analysis of defective enzymes produced by mutants can allow
conclusions as to which amino acids residues are essential to the
mechanism of action e.g. the research performed on tryptophan
synthetase (Yanofsky and Crawford, 1972) or on glutathione reductase
(Scrutton jet al., 1990).
The genetics of the 2-oxo acid dehydrogenase complexes is
well advanced in E. coli but developed to lesser and varying degrees
in other organisms. All of these studies have provided useful
*
information concerning some aspects of t^ he synthesis, assembly, 
operation and in vivo role of the 2-oxo acid.dehydrogenase complexes.
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1.6.1 Genetics of 2-oxo acid dehydrogenase complexes in E. coli
The structural genes for the pyruvate dehydrogenase (El) and 
lipoate acetyltransferase (E2) components of PDC, aceE and aceF 
respectively, are closely linked in the leu region of the Ej_ coli
linkage map (Bachmann and Brooks, 1980). The corresponding genes 
(sucA and sucB) for the El and E2 components of the OGDC are closely 
linked to the gal region (Henning and Hertz, 1964; Herbert and 
Guest, 1969). There is a single gene lpd for lipoamide dehydrogenase 
(E3) and this maps next to the aceEF genes. A single structural 
gene for E3 is consistent with the finding that when the respective 
lipoamide dehydrogenases were purified from each of the complexes, 
they had identical peptide 'maps' and the same sequence for 42 amino 
acid residues (Perham et al., 1978).
Amber mutations in the aceE and sucA genes have polar 
effects on the aceF and sucB genes respectively and this defines the 
direction of transcription of aceEF and sucAB. The lpd gene maps 
immediately distal to the aceF gene, but can be transcribed 
independently of the aceEF and sucAB genes (Guest and Creaghan, 1974).
Mutations in aceE or aceF result in a deficiency in PDC 
activity and a requirement for acetate to sustain aerobic growth on 
glucose minimal medium. Mutations in sucA and sucB result in 
defective OGDC and a requirement for succinate to sustain aerobic 
growth on glucose minimal medium. A mutation in the lpd gene 
results in a deficiency in the activity of both complexes and a 
requirement for supplementation with acetate and succinate 
simultaneously for aerobic growth on glucose minimal medium. All 
these classes of mutant can grow anaerobically on unsupplemented 
glucose minimal medium because the complexes are not required for 
glucose fermentation, and other mechanisms are induced anaerobically 
for producing acetate e.g. the phosphoroclastic reaction :
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Pyruvate— $► acetyl CoA + acetyl P + formate (Pascal et al., 1981) and 
succinate, viz: the reduction of oxaloacetate via fumarate (Haddock
and Jones, 1977). Mutants requiring succinate for aerobic growth on 
glucose will also grow when supplemented with a mixture of lysine and 
methionine. This is probably because succinyl CoA is required for 
the biosynthesis of these amino acids and their presence diminishes 
the requirement of succinyl CoA derived from other endogenous sources 
for functions such as porphyin synthesis.
The structural genes of E^ _ coli PDC, aceEF and lpd, have 
been cloned with phage A  vectors (Guest and Stephens, 1980). The 
expression of the PDC operon was investigated by infecting UV 
irradiated coli host with transducing phage A  housing the aceEF 
and lpd genes (Guest et al., 1989). These structures confirmed the 
existence of a single promoter for the aceE and aceF genes and an 
independent promoter for the lpd gene. The lpd gene was shown to be 
transcribed with the same polarity as the ace genes. The relative 
rates of expression of the three genes from the bacterial promoters 
were estimated to be 0.94: 1.0: 1.4-2.3, El: E2: E3 on a molar basis.
1.6.2 Genetic studies on E2 of PDC from prokaryotes
The PDC of E_j_ coli has a three-fold repeat of the lipoyl 
domain on its E2 chain which forms the N-terminal half of the 
polypeptide (Stephens et al., 1983). Strong homology in the amino 
acid sequences of these repeated domains, derived from the DNA 
sequence of the aceF gene (Stephens e_t al., 1983b) and the fact that 
all three domains can be isolated as functional entities after 
limited proteolysis of this PDC (Packman et al., 1984) strongly 
suggests that each domain is independently folded and can function in 
the reductive acetylation reaction of the entire complex.
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Genetic reconstruction of the E2 chain (Graham et al., 1986)
which permitted lowering of the number of lipoyl domains from 3 to 2
and from 2 to 1 per E2 polypeptide does not affect the assembly of a 
functional PDC. This is consistent with the view that the lipoyl 
domains are units of protein structure which can fold and function 
independently. These reconstructed lipoyl domains are catalytically 
active because they are hybrids created from homologous domains which 
are designed to resemble the original domains as closely as possible. 
The truncated E2 chains within the limits of experimental error are not 
impaired in catalytic efficiency. Thus, when an E2 construct 
containing only a single lipoyl domain is produced from plasmid PGS110
in E^ _ coli, fully-active PDC is formed with normal octahedral
symmetry. In this sense, therefore, the two extra lipoyl domains can 
be regarded as surplus to requirements.
At present separate functions have yet to be assigned to the 
El cKand E l s u b u n i t s  in decarboxylation and acetyl transfer reactions 
in any PDC complex. The combination of site-directed mutagenesis of 
the enzyme together with binding and activity studies of TPP and its 
analogues is at present being used to understand the mechanism of the 
decarboxylation reaction.
i
In the El components of 2-oxo acid dehydrogenase complexes, as 
in all known TPP-binding enzymes, a common 30 residue motif, probably 
a JB c< j2> fold, akin to that previously identified for NAD(P)-binding 
enzymes interacts with the diphosphate moiety of the bound cofactor 
(Hawkins et al., 1989). The ElO^subunit appears to bind the cofactor 
TPP (Stepp and Reed, 1985), in accord with the presence of the 
structural motif that has been identified in all known sequences of all 
TPP utilising enzymes. The resistance of the Ely3 subunit to 
proteolysis in the intact B. stearothermophilus complex (Lowe et al., 
1985) and its role in protecting the mammalian E2 component from 
enzymatic digestion (Ramatullah _et al., 1989) suggests ElJB> has some 
part to play in the binding of the El c< subunit to the E2 core.
1.7 Aims of project
Attempts to define the precise function of component X in 
mammalian PDC by protein chemical criteria have met with only limited 
success to date. A particular difficulty is that protein X is' 
tightly associated with the E2 core assembly and it is not possible 
to separate these two polypeptides in the native state thus 
permitting standard reconstitution analysis in the presence or 
absence of component X.
An alternative strategy, which involves the isolation and 
characterisation of the gene encoding the protein X subunit offers 
long-term possibilities for a detailed investigation of protein X 
function. In S. cerevisiae, the molecular genetics are particularly 
advantageous in that isolation of a specific gene permits the 
creation of mutants which are specifically defective in that 
function. Gene replacement/disruption techniques is currently being 
exploited by Reed and co-workers.
In our laboratory it was decided to clone protein X gene 
from mammalian (human) sources for the reason detailed below:
(a) At the time the project was initiated it was not clear that 
yeast PDC had a functionally equivalent subunit for protein 
X.
(b) The availability of high quality antiserum to mammalian 
protein X and the availability of a human cDNA gene 
expression library allowed for an established protocol for 
the identification and isolation of specific clones to be
Sv
followed. 1 ■
(c) It was hoped that nucleotide and predicted amino acid 
sequence obtained from a protein X clone would establiish.a 
relationship with, the E2 component and therefore shed light 
on a possible function for protein X.
AO
In parallel with these molecular biological studies, it was 
also decided to adopt a number of biochemical strategies to elucidate 
possible functions of protein X.
In particular, low temperature and substrate analogues were 
employed in attempts to selectively disrupt the catalytic cycle at 
specific stages and thereby gain a clear understanding of the 
involvement of protein X in the catalytic process.
Finally, in view of the proteolytically-sensitive nature of 
the protein X subunit, extensive use of selective proteolysis with 
trypsin and argC were employed in an attempt to elucidate the 
function of the polypeptide in the complex. Initially, these 
studies involved reevaluation of the reports of Roche and co-workers 
that argC treated enzyme was defective in E3 binding but subsequently 
involved considerable progress on their original observations, 
leading to a possible role for component X in the complex.
CHAPTER TWO
MATERIALS and METHODS
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2. Materials and Methods
2-1 Materials
2.1.1 Chemicals
The following reagents were obtained from Sigma Chemical
Co., Poole, Dorset, U.K.: substrates and coenzymes for enzymatic
assays, PMSF, TEMED, benzamidine-HCl, Coomassie brilliant blue type
R, N-ethylmaleimide, Mops, leupeptin, Tween 20 and all proteases
used in this study.
Poly(ethylene glycol) 6000 was obtained from Serva,
TM
Heidelberg, W. Germany. Iodogen was from Pierce Labs.,
Rockford, Illinois, U.S.A. DMSO, DTT were purchased from 
Koch-Light Laboratories, Colnbrooke, Berks, U.K. Sodium salicylate 
was obtained from Aldrich Chemical Co., Ltd., Gillingham, U.K.
All other chemicals including reagents for polyacrylamide 
gel electrphoresis were Analar grade from BDH Chemicals Ltd., Poole, 
U.K. or were of the highest grade available commercially.
2.1.2 Tissue Culture Materials
Eagle’s medium (Glasgow modification), bovine kidney
(NBL-1), pig kidney (PK-15) and Buffalo rat liver (BRL) cell lines
were obtained from Flow Laboratories, Irvine, U.K.
New born calf serum and foetal calf serum were purchased
from Gibco, Paisley, U.K.
"Versene" solution [0.6mM-EDTA, 0.17M-NaCl,
lOmM-Na HPO , 2.4mM-KH PO , 0.002% (w/v) phenol red, pH7.8]
2 4 2 4
and "Trypsin" solution [(0.25%) (w/v) trypsin, lOmM-NaCl, ImM-sodium 
citrate, 0.002% (w/v) phenol red, pH7.8] were supplied as sterile 
solutions by the tissue culture unit of our department.
Disposable plasticware was obtained from Sterilin, 
Teddington, U.K.
2.1.3 Radiochemicals
14 125
N-ethyl [2,3- C] maleimide (6mCi/mmol), Na[ I]I
14
(carrier free)], [2- C] pyruvate (10.4Ci/mmol) were obtained from 
Amersham International, Bucks, U.K.
[$- P] ATP (l00-130Ci/mmol) was also purchased from 
Amersham International.
2.1.4 Enzymes and Proteins
The following commercial protein preparations were obtained 
from Sigma Chemical Co.: protein A (Staphylococcus aureus, Cowan I
strain), bovine serum albumin, horse-radish peroxidase, TPCK-treated 
trypsin. Lipoamide dehydrogenase (diaphorase) from pig heart was 
from Boehringer Corpn. (London) Ltd., Sussex, U.K.
Marker proteins for M^_ determinations by SDS-PAGE were 
obtained from Pharmacia Ltd., Milton Keynes.
2.1.5 Animals
Ox hearts were obtained from Paisley Abattoir, Sandyford 
Road, Paisley. The hearts were chilled on ice and brought to the 
laboratory within 2 h of slaughter.
2.1.6 Miscellaneous
Nitrocellulose paper (0.45um pore size) was obtained from
Schleicher and Schiill, Dassel, W. Germany or obtained from Amersham
TM
International, Bucks., U.K. (Hybond C extra). Centricon 
microconcentrates were from Amicon Ltd., Upper Mill,
Gloucestershire, England.
Normal rabbit serum was from the Scottish Antibody 
Production Unit., (S.A.P.U.), Lanarkshire, U.K.
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2.1.7 Photographic materials
"Lighting Plus" intensifying screens were purchased from Du 
Pont Cronex, Stirling, U.K.
Plast-X cassettes, for exposure of X-ray films were 
obtained from Anthony Monk (England) Ltd., Sutton in Ashfield, U.K.
X-Omat S and XAR-5 X-ray films, Kodak FX-40 liquid fixer 
and Kodak LX-2 4 X-ray developer were purchased from Kodak Ltd., 
Dallimore Road, Manchester, U.K.
2.1.8 Materials used in screening a \  gtll gene expression library
L. Broth
per litre lOg Bacto-Tryptone (Difco 0123-01)
5g Bacto yeast extract (Difco 1880-17) 
lOg NaCl
LB Agar (plates)
per litre as above + 15g Bacto agar (Difco 0140-01)
LB Agar (top)
per litre as above + 7g Bacto agar
20% (w/v) Maltose
20g of maltose dissolved in 100ml of distilled water and
filter sterilised. 1ml of 20% (w/v) maltose solution is
added to every 10 0ml of medium.
SM Buffer
This medium is for phage storage and dilution, 
per litre 5.8g NaCl
s
2g MgSO \
4
50ml lmM-Tris-HCl (pH7.5)
5ml 2% (w/v) gelatin 
Sterilise by autoclaving
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Tris buffered saline (TBS) pH7.5 
per litre 9.86g NaCl
1.2g Tris
TBS + 3% (w/v) bovine serum albumin (BSA)
3g of BSA added to 100ml TBS 
TBS + 0.05% (v/v) Tween 20
50ul of Tween 20 added to 100ml TBS 
TBS + 3% (w/v) BSA + peroxidase conjugated anti rabbit IgG 
For 100ml lOOul of peroxidase conjugated rabbit IgG
added to 100ml TBS + 3% (w/v) BSA (1:1000 dilution)
Colour developing solution 
60mg 4-chloro-l-naphthol 
20ml ice cold methanol
100ml TBS containing 80ul of 30% (v/v) hydrogen peroxide 
Prepared just before use.
Agarose
for 100ml The required weight of agarose (% w/v) was
added to 100ml of water and melted under pressure for
o
7 min. When it had cooled to below 50 C ethidium 
bromide was added to a final concentration of 0.5ug/ml. 
Ethidium Bromide
per 10ml lOmg of ethidium bromide in 10ml of water
Lambda DNA-Hind III Fragment size No. of base pairs
markers preparation
per lOOul 1 23130
2 9416
Lambda DNA-Hind III 5ul 3 6557
markers 4 4361
TE Buffer 70ul 5 2322
6 2027
Sample buffer 25ul 7 564
lOOul 8 125
Lysis solution
0.5M-Tris-HCl pH9.0
0.25M-EDTA
2.5% (w/v) SDS
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8M Potassium acetate
per 100 ml 7 8 .4g of potassium acetate in 100ml of
water. Filter sterilised.
Proteinase K {
lmg of proteinase K was dissolved in 1ml of distilled water 
o
and stored at -20 C until required.
E. coli strains
+
Y1088 [ supE, supF, metB, trpR, hsdM , tonA21/
StrA, /\ lacU169, proC :: Tn5 (pMC9)] pMC9 is a
Q Q t
pBR322-lacI derivative carrying laci (lac repressor
over-producer and is penicillin resistant).
Y1089 [Alac (IOP2YA) U169, frroA+yAlon araP139y strA,
thi , hf 1A150 Chr :: TnlO ]. This strain is used to
isolate the fusion protein produced by an isolated \  gtll
clone.
* +
Y1090 [A lac U169 proA ,&lon_ araDl39 strA supF trpC22
:: Tnl° (pMC9) ]. This is used to screen Xgtll for the
production of antigenic determinants.
BNN103 (Xgtll) Source of Xgtll phage. Induction of 
o
gtll at 42 C and subsequent treatment of the bacteria 
with chloroform will release the phage into the media.
The structure of the expression vector Xgtll is shown below
HBlOl F , hsd S20 (r_ ml ) # recA13, ara-14,
—  • “B — B * ———————”
proA2 , lacYl, galK2 , rpsI-20 (Sm1), xyl-5, mtl-ly supE44y X
q A
JM101 A  lacpro, thiy supEy F‘ traP36y proAB, laci Z A  M15
M +
TGI SupE t hsd A  5 thi  ^lac-proAB) F' (traP36 proAB
q
laci lacZ &  M15
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2.1.9 Reagents used in purification and sequencing of recombinant 
DNA
10 x M9 salts
per litre 60g Na^HPCK
2 4
30g KH PO 
y 2 4
lOg NH Cl 
4
5g NaCl Store at 4°C
Glucose/minimal medium plates 
15g minimal agar in 900ml H^O 
100ml 10 x M9 salt 
lml 1M MgSC>4 
lml 1M thiamine HC1 
10ml 20% (w/v) glucose 
2 x TY medium
per litre 16g bacto tryptone
lOg yeast extract 
5g NaCl
2 x TY agar
Add 15g/litre bacto agar to 2 x TY medium
This should give sufficient agar for approx. 40 plates.
H plates
per litre lOg bacto tryptone
8g NaCl 
12g agar
H top agar
per litre lOg bacto tryptone
8g NaCl 
8g agar
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PEG/NaCl
2 0% (w/v) polyethylene glycol 8000 
2.5M NaCl 
TE buffer
lOmM-Tris HC1 pH8.0
ImM-EDTA
3M Na acetate
Prepare a concentrated solution of sodium acetate. Adjust
to pH6.0 with glacial acetic acid and dilute to 3M with
distilled H O.
2
IPTG (isopropyl-^3-D-thio-galactopyranoside) 
lOOmM (23.8mg/ml in H2°) • Prepare just before use.
X-gal (5-bromo-4-chloro-3 indolyl-yg-galactoside)
2% (w/v) in dimethylformamide. Prepare just before use. 
Phenol
Redistilled phenol is mixed with TE buffer 1:1. Use the
lower phenol phase. (Wear gloves and handle with care).
Agarose gel running dye (sample buffer)
2.7ml glycerol
0.3ml 10 x TBE buffer
lml 1% (w/v) SDS
lml 0.5M EDTA
lmg bromophenol blue
Sterile CaCl 
 2
o
Sterile 50mM caCl2 was prepared and stored at 4 C.
TBE buffer (electrophoresis buffer 10 x stock)
108g Tris base 
55g boric acid 
9.3g Na2EDTA.2H20
This gives a stock solution of pH8.3. Make to 1 litre 
with H20 .
48
Klenow reaction buffer (10 x) (annealing/reaction buffer) 
lOOmM Tris pH8.0 
50mM MgCl2
E. coli hosts ^
E. coli K12, JM101 A lacpro, thi, supE,F' trdD36, proAB, 
laciqz A  M15
E. coli K12 (JM101) carries a chromosomal pro deletion 
which ensures selection on M.M. plates.
Ampicillin
per 100ml 500ug of ampicillin dissolved in distilled
o
water and filter sterilised. Stored at -20 C. 
Chloroamphenicol
34mg/ml in ethanol used at a final concentration of 170ug/ml 
Chloroform/isoamyl alcohol
For 100ml 96ml of chloroform + 4ml isoamyl alcohol.
o
Stored at 4 C.
2.2 Methods
2.2.1 Measurement of protein concentration
The concentration of protein was routinely determined by 
the method of Lowry et al. (1951), as modified by Markwell et al. 
(1976). Standard curves were constructed using bovine serum 
albumin as standard. The absorbance was measured at 66 0nm.
2.2.2 Concentration of protein samples
Protein samples were concentrated by freeze drying or by 
spinning in Centricon TM tubes until the required volume was reached 
(Amicon Ltd.).
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Frequently, samples for SDS/polyacrylamide gel
electrophoresis were concentrated by the addition of 4 vol acetone
o
and stored overnight at -20 C.
Alternatively, to remove salts or other reagents which
interfered with electrophoretic migration, samples were concentrated
by adding 100% (w/v) TCA to a final concentration of 10% (w/v) and 
o
stored at 4 C for several hours. The protein pellets were washed 
with ether to remove traces of TCA, air dried and redissolved in an 
appropriate volume of Laemmli sample buffer.
2.2.3 Measurement of incorporation of radioactivity into proteins
(a) TCA precipitation
Aliquots (10-25jul) were spotted onto Whatman No. 1 filter
paper discs (2.5cm diam.) and immersed in ice cold 10% (w/v) TCA.
o
After stirring for 30 min at 4 C, the TCA solution was discarded
and the filters were washed twice with similar volumes of 1 0% (w/v)
TCA and once with absolute ethanol. Each wash was performed at 
o
4 C for 30 min. Finally, the discs were washed in ether and air 
dried. Once dry they were transferred to scintillation vials and 
counted with 5ml of Ecoscint scintillation fluid. Background 
radioactivity was estimated using blank discs that were mixed with
the sample discs during the final wash.
(b) Quantitative determination of radioactive polypeptides 
excised from gel slices
Samples of radioactive proteins were resolved by
SDS/polyacrylamide gel electrophoresis. The gels were stained with
Coomassie blue (see Section 2.2.4d). After destaining the gel was
dried under vacuum on Whatman No. 3mm filter paper and the protein
bands of interest were cut out with scissors. Slices were dropped
into glass scintillation vials and reswollen in 0.5ml of distilled 
water. After 10 min, the pieces of filter paper were removed as
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well as the remaining liquid and the slices were incubated overnight 
at 37°C with lml of 90% (v/v) Protosol in capped scintillation 
vials. Aliquots were removed and estimation of the radioactive 
incorporation determined on the addition of 5ml of Ecoscint 
scintillation fluid.
Pieces of gel of similar dimensions were cut from blank 
tracks and processed in an identical manner to determine background 
radioactivity.
2.2.4 Polyacrylamide gel electrophoresis
(a) Preparation of polypeptides prior to resolution by
SDS/polyacrylamide gel electrophoresis
Protein solutions were mixed with an equal volume of 
Laemmli sample buffer (0.0625M Tris-HCl, pH6 .8 , 2% (w/v) SDS,
10% (w/v) sucrose and 0.001% (w/v) Pyronin Y) containing 5% (v/v) 
2-mercaptoethanol or lOmM DTT and boiled for 5 min prior to 
electrophoresis. When protein samples were in pellet form they 
were solubilised in an appropriate volume of Laemmli sample buffer 
and boiled as above.
(b) Conditions for resolution of proteins by SDS-PAGE
Proteins were electrophoresed on SDS-containing
polyacrylamide gels using the discontinuous Tris-glycine system
according to Laemmli (1970). For analytical purposes, gels were
cast using a home-made apparatus in slabs 19.0cm x 9.5cm x 0.15cm,
TM
or when greater resolution was required using Biorad Protean 
16cm apparatus in slabs of 16.0cm x 14.0cm x 0.15cm.
SDS-PAGE was performed at a constant current of 40ma-60ma 
per gel until the Pyronin Y tracker dye was approx. 0.5cm from the
^  wbottom of the gel. The electrode buffer contained 0.192M glycine, X'
0.1% (w/v) SDS in 0.025M-Tris-HCl pH8.3.
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(c) Preparative SDS-PAGE
Preparative SDS gels were polymerised as a large, scale 
version of the analytical procedure described above by increasing 
the gel thickness to 3mm. This permitted application of up to 3mg 
of protein while maintaining most of the resolving power obtained on 
single track analytical gels.
Stock solutions 
Main gel buffer
36.6g Tris/HCl pH8.8
250;il of TEMED per 100ml of solution
Acrylamide
28g of acrylamide
0.735g of bisacrylamide per 100ml of water 
Stacking gel buffer
19.2ml, 0.1M Tris-HCl pH6.8 
0.8ml of 20% (w/v) SDS 
50ug of TEMED
Composition of SDS-PAGE gels 
10% Gel (ml) 12.5% Gel (ml)
Main gel Buffer 25
Acrylamide gel 71.5
20% (w/v) SDS 1.0
Stacking gel buffer 
Water 100
Total 197.5ml
25
89.3
1.0
82.2
197.5ml
5.2% stacking 
17.5
10.0
55__
82.5ml
After degassing, 150mg of ammonium persulphate was added to 
these solutions to initiate gel polymerisation. When the running 
gel was poured it was overlaid with propan-2-ol to maintain an even
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surface during setting of the gel. Propan-2-ol was discarded and
traces were removed by washing 3 or 4 times with distilled water.
The top of the running gel was dried with filter paper and the
stacking solution containing 150mg of ammonium persulphate poured
onto the polymerised running gel.
Gels were wrapped in damp towel roll and could be stored 
o
for up to 3 weeks at 4 C.
(d) Staining of gels with Coomassie blue
Gels were stained for protein in 0.1% (v/v) Coomassie
brilliant blue R250, 50% (v/v) methanol and 10% (v/v) acetic acid
for 1 h.
(e) Destaining of gels
Unbound stain was removed by washing the gel several times 
in 10% (v/v) methanol and 10% (v/v) acetic acid solution.
(f) Processing of SDS gels for fluorography
Gels to be processed for fluorography were previously
stained or directly fixed overnight by immersing in 25% (v/v)
propan-2-ol, 10% (v/v) acetic acid.
Fluorography was performed according to the method of
Chamberlain (1979) employing sodium salicylate as fluor. Slab gels
were dried under vacuum and exposed for a suitable period of time
o
using either X-OMAT S or XAR-5 Hyperfilm at -80 C.
(g) Processing of SDS gels for autoradiography
Gels were stained or fixed as described above. Before 
drying, gels were soaked for 30 min in a solution containing 25% 
(v/v) propan-2-ol, 10% (v/v) acetic acid and 0.5% (v/v) glycerol to 
reduce the risk of cracking during drying.
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(h ) Determination of M f value by SDS PAGE
The M values of polypeptides and peptides resolved by
SDS-PAGE was determined by calibrating with a set of standard
proteins on a 10% (w/v) slab gel. The standard proteins include
phosphorylase b (M 94400) ; BSA (M 68000) ; ovalbumin (M     r   r   r
43000); carbonic anhydrase (M 31000); soyabean trypsin
inhibitor (M 20100) and lysozyme (M 14000).
Relative mobility was calculated as the ratio:
Rf = distance migrated by the protein for each protein
distance migrated by the tracking dye
A plot of Rf against log (M^) of the standards yielded a
curved line that was used for calibration. Standards and PDC
samples were analysed on the same gel.
2.2.5 Purification of pyruvate dehydrogenase complex
(a ) Purification of pyruvate dehydrogenase complex from ox heart
Pyruvate dehydrogenase complex (PDC) was purified from ox
heart essentially as described by Stanley & Perham (1980) with the 
modifications stated below.
o
All operations were carried out at 4 C, starting with
o
250g of fresh ox heart or ox heart stored at -80 C (within 3 h of 
slaughter). Cubes of tissue were blended and extracted in 50mM 
Mops containing 2.7mM-EDTA, 3% (v/v) Triton X-100 and O.lmM-DTT; 
adjusted to pH7.0 with NaOH. The residual material was 
discarded. The extracts contained assejyable amounts of 
2-oxoglutarate dehydrogenase activity; however the presence of 
lactate dehydrogenase and NADH oxidase interfered with the
estimation of pyruvate dehydrogenase complex activity at the early 
stages of purification.
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The complex was precipitated by the addition of 0.12 vol of 
a 35% (w/v) poly(ethylene glycol) solution at pH6.45. Pellets were 
resuspended in 50mM Mops containing 1% (v/v) Triton X-100, 
2.7mM-EDTA, O.lmM-DTT, 1.5uM-leupeptin, adjusted to pH6.8 with NaOH 
by homogenisation with a loose-fitting teflon-glass homogenizer.
This extract was adjusted to ^mM-MgCl^ and 50mM-sodium phosphate 
before the addition of 0.12 vol poly(ethylene glycol) for a second 
precipitation.
The 2-oxo acid dehydrogenase complexes were separated by
differential precipitation with poly(ethylene glycol). Usually
between 0.04-0.06 vol 35% (w/v) poly(ethylene glycol) were required
to precipitate 90% of the 2-oxoglutarate dehydrogenase activity.
OGDC was pelleted at 18000 x g for 10 min. The resulting
supernatant fraction contained approximately 90-95% of the PDC
activity. Pyruvate dehydrogenase complex was concentrated by
centrifugation for 2.5 h at 176,000 x g in a Beckman Ti70 rotor or
by the addition of 0.15 vol of 35% (w/v) poly(ethylene glycol)
followed by centrifugation at 30,000 x g for 10 min. The pellet of
pyruvate dehydrogenase was purified further by solubilising in
column buffer (50mM-sodium phosphate buffer, pH7.0, 1% (v/v) Triton
X-100, 2.7mM-EDTA, 0.2mM thiamine pyrophosphate and ImM MgCl^) and
o
separating the residual 2-oxoglutarate dehydrogenase at 4 C by gel
filtration chromatography on a Sepharose CL-2B column (106cm x
3.5cm) equilibrated in column buffer at a flow rate of 24ml/h.
Approximately 60 x 12ml fractions were collected and assayed for
pyruvate dehydrogenase and 2-oxoglutar4te dehydrogenase
activities.. Fractions with maximal activity were pooled and
o
concentrated by centrifugation at 170,000 x g for 2.5 h at 4 C.
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The yellow pellets were resuspended by standing overnight
in a small volume of column buffer containing 0 .01% (w/v) NaN^,
o
0.lSjuM leupeptin. The enzyme was stored at 4 C at a final 
concentration of 20-30mg/ml.
(b) Preparation of E2/X core assembly
E2/X core assembly was prepared as described by Kresze and 
Ronft (19'8I>). Solid MgCl^ was added to PDC (200 i^g) in phosphate 
buffer, pH7.0 to give a final concentration of 0.25M MgCl^. After 
30 min, the treated PDC was resolved on a Superose 12 column 
equilibrated in phosphate buffer by FPLC.
2.2.6 Isolation of mitochondria and submitochondrial fractions
(a) . Isolation of rat liver mitochondria
Rat liver mitochondria were prepared by differential 
centrifugation (Chance and Hagihara, 1963).
Female rats (180-200g) were starved overnight and killed by
cervical dislocation. The livers were removed, excess blood removed
with blotting paper, and the livers were chopped finely with 
scissors before transfer into ice-cold isolation medium. Isolation 
medium contains 0.225M-mannitol, 0.075M-sucrose, 50C^uM-EGTA and 2mM 
MOPS. The solution was adjusted to pH7.2 with NaOH and stirred 
until the EGTA was completely dissolved; then the pH was adjusted 
to pH7.4.
Livers from 6 rats were homogenised in approximately 30ml
isolation medium per liver with a tight-fitting Potter-Elvehjem
homogeniser. After removal of the nuclei and cell debris at
o
800 x g for 7 min at 4 C, mitochondria were sedimented from the 
supernatant fluid by centrifugation at 6500 x g for 15 min.
Pellets were washed by manual resuspension in the same buffer and 
centrifuged at 6500 x g for 15 min. To remove residual
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contamination from nuclei, red blood cells and unbroken cells,
mitochondrial pellets were resuspended in one-half the initial
volume of isolation medium and re-centrifuged at 800 x g for 7 min.
The pellets were discarded and the supernatant fractions carefully
combined and centrifuged at 6500 x g for 15 min as previously. The
final pellets contained highly-purified mitochondria which were kept 
o
frozen at -20 C until required.
(b) Preparation of ox heart mitochondria
Ox heart mitochondria were isolated as described by Smith
(1967). Approx. 1.5-1.8g of mitochondrial protein were obtained
o
from 300g tissue. Mitochondrial pellets were stored at -80 C 
until use.
Ox heart mitochondria utilised in this study were prepared 
by F. McCallum in our laboratory.
(c) Preparation of cellular extracts and subcellular fractions
from Buffalo rat liver (BRL), bovine kidney (NBL-1) and 
porcine kidney (PK15) cells
Cellular extracts for immunoblotting analysis were prepared
under conditions designed to minimise proteolytic degradation.
Cells were grown in large roller bottles until they reached
confluence. Monolayers were washed twice with ice-cold
phosphate-buffered saline (20mM-sodium phosphate buffer, pH7.4,
0.15M-NaCl) prior to harvesting in a small volume of the same buffer
by scraping with a rubber policeman. Small amounts of the
suspension were immediately dissociated for SDS-PAGE by heating in
o
Laemmli sample buffer at 100 C for 5 min.
The majority of the cells were fractionated to obtain 
nuclear and mitochondrial fractions as described by Attardi and 
Ching (1979).
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To obtain particulate and cytosolic fractions, cells were 
fractionated by the method of Zurrendonk and Tager (1974) as 
modified by Mori jet al. (1981).
o
Aliquots (lml) of the cell suspensions were mixed at 0 C
with an isotonic digitonin solution at a final concentration of
o
0.25 to 5mg/ml. After standing at 0 C  for 2 min, the samples
were centrifuged for 1 min at 14,000 x g in an MSE Micro-Centaur
o
centrifuge. Samples were kept at -20 C until required.
2.2.7 Enzymatic assays
(a) Pyruvate dehydrogenase complex activity
The overall activity of pyruvate dehydrogenase complex was
determined spectrophotometrically by measuring NADH formation at 
o
340nm at 30 C (Brown and Perham, 1976). Assays were performed in
a final volume of 0.67ml in 50mM-potassium phosphate buffer, pH7.4
+
containing 2mM-TPP, lmM-MgCl^/ 2.5mM-NAD , 0.13mM-CoA, 2.6mM
cysteine-HCl and 2mM-sodium pyruvate. A unit of activity (Kat) was
defined as the amount of enzyme which produced lmol of NADH/sec at 
o
30 C under the conditions of assay.
(b) Pyruvate dehydrogenase kinase
Pyruvate dehydrogenase kinase (EC 2.7.1.99) was assayed by 
measuring the rate of inactivation of the complex in the presence of
0.2mM-ATP at 30°C (Hucho et al., 1972) or by estimation of the
32
rate of incorporation of P-labelled phosphoryl groups from 
-^P] ATP into serine residues on the El C<.subunit of PDC 
(Stepp et al., 1983). Incubation mixtures contained 20mM potassium 
phosphate buffer, pH7.5, lmM-MgCl^r O.lmM-EDTA, 2mM-DTT and 
20-50ug of PDC in 200ul of assay mix.
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o
After equilibration at 30 C for 1 min, the reaction was
Y  32
initiated by the addition of 0.02ml of 2.5mM [ Q  - P] ATP
(approx. 13,000 d.p.m./nmol). At the indicated times, aliquots
(20ul) were applied to filter discs (Whatman No. 1). The discs
were immediately dropped into 10% (w/v) TCA, washed, dried and
utilised for radioactivity counting as described in Section 2.2.3a.
(c) Lipoamide dehydrogenase (E3) activity
Reduced lipoic acid was prepared as described by Kochi and
Kikuchi (1976). Reduced lipoic acid (20ug) was added to 0.67ml of
50mM potassium phosphate buffer pH7.4 containing 2mM TPP, ImM 
+
MgCl^, 2.5mM-NAD . The reaction was initiated by the addition
of lOug PDC and the activity determined spectrophotometrically by
o
measuring NADH formation at 340nm at 30 C.
2.2.8 Elution of PDC subunits from SDS/polyacrylamide gels
Purified subunits of PDC were recovered from
SDS/polyacrylamide gels by a modified version of the procedure of
Tolan et al. (1980). 3mg PDC was resolved by 10% (w/v) SDS-PAGE
(Section 2.2.4b). Gels were stained with Coomassie blue and
destained with several changes of 10% (v/v) acetic acid, 2 0% (v/v)
methanol. Stained protein bands were cut from the gel and rinsed
with distilled water for about 30 min. After extruding gel strips
through the barrels of 2ml disposable syringes to fragment the gel,
the gel was transferred into scintillation vials and dried in a
vacuum dessicator over NaOH pellets to remove acid from the
destaining solution and to facilitate extraction. Dried gel pieces
were swollen in a minimal volume (2-3ml) of 50mM-triethanolamine, 1%
(w/v) SDS, ImM-DTT, adjusted to pH8.0 with HC1 (extraction buffer).
o
The suspensions were heated for 5 min at 65-70 C and the gel
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slurry extracted by continuous stirring at room temperature for
16-20 h. Fragments of gel were removed by centrifugation at
1,000 x g for 5 min to yield a clear blue-coloured extract. The
gel slurry was extracted once more in a similar manner before
pooling the extracts and concentrating them by freeze-drying.
Samples were redissolved in a minimal volume of water and
clarified by a brief centrifugation as before to remove any residual
fragments of gel. Proteins were precipitated by the addition of
o
4 vol of acetone and stored at -20 C, a procedure which also
partially removed the dye. Pellets were redissolved by boiling in
o
a small volume of 1% (w/v) SDS and stored at -20 C until required.
It was convenient to repeat the acetone precipitation step 
when large white precipitates of SDS were obtained after the first 
acetone precipitation.
The presence of SDS and traces of dye interfered with the 
estimation of protein concentration (Bradford, 1976; Lowry et al., 
1951). The amount of recovered proteins was determined 
approximately by quantitative scanning of Coomassie blue-stained 
bands of protein subjected to SDS-PAGE by comparison with BSA as a 
standard.
2.2.9 Immunological procedures
(a) Immune blotting (Immune Replica Analysis, Western Blotting)
The immune blotting procedure was employed to permit
immunological detection of polypeptides after their electrophoretic
transfer from SDS/polyacrylamide gels to nitrocellulose paper
(Towbin et al., 1979; Batteiger et al., 1982).
Polypeptides were resolved by SDS-PAGE (Section 2.2.4) and
transferred electrophoretically onto nitrocellulose paper at 400ma
TM
for 3 h or 40ma for 16-20 h using a Bio-Rad Trans-Blot -cell.
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Transfer buffer comprised 25mM-Tris, pH8.3, 192mM glycine, 0.02%
o
(w/v) SDS, 20% (v/v) methanol and was stored at 4 C before use.
After transfer the nitrocellulose paper was removed and
inculcated, face up, in 20mM Tris-HCl, pH7.2, 0.15M NaCl 0.5% (v/v)
Tween 20, 0.005% (w/v) NaN^ (blocking buffer) for 1 h at room
o
temperature or overnight at 4 C.
Nitrocellulose paper was then incubated in fresh blocking 
buffer supplemented with antiserum at a dilution of 1:50-1:100 and 
5% (v/v) heat-inactivated horse serum for 90 min at room 
temperature. Excess antibody was removed by washing with 5 changes 
of blocking buffer over a period of 60 min before incubation for
90 min at room temperature with blocking buffer containing
125 6
I-labelled protein A (approx. 3 x 10 c.p.m. per blot).
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Excess I-labelled protein was removed by several washes with
blocking buffer as above. The processed nitrocellulose was allowed
to dry at room temperature before analysis by autoradiography.
(b) Preparation of IgG
Three separate antisera, anti PDC, anti-E2 and
anti-component X (7ml each), were dialysed against 2 x 500ml of
20mM-Tris HC1, pH8.0, 28mM NaCl for 20 h. A DEAE Affigel Blue
column (40ml) was washed with 2 vol 8M urea followed by 3 vol 2M 
o
NaCl and^at 4 C^7 vol of dialysis buffer. Antiserum was loaded
onto the column and eluted at a flow rate of 12ml/h. 6ml fractions
were collected and the A280 mon^tore^ to detect eluted proteins.
Peak fractions containing IgG, which is the only major class of
serum protein not retained, were pooled, freeze dried and
reconstituted to 80% of their original volume. The serum was then
o
dialysed against 2 x 1 1 of dialysis buffer at 4 C.
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After each run, the DEAE Affigel Blue column was 
regenerated as described in the table below.
Temp Reagent Column Vol. Reason
RI 8M urea 2.3 Remove CN
RI 2M NaCl 3-4 Elute proteins
o
4 C Dialysis buffer 6-7 equilibrate
column
(c) Dot blots
Dot blots were employed to test the sensitivity of the 
serum IgG prepared from the DEAE affigel blue column and to compare 
the titre of purified IgG with the original antiserum. PDC was 
diluted in BSA (lOOjug/ml) ; further dilutions were made with water 
until lul of mixture, containing 50, 10, 5, 1 and 0.5ng of complex 
respectively could be spotted onto strips of nitrocellulose. The 
complex was challenged with the appropriate IgG or antisera and 
processed as described in the antibody screening method (Section 
2 .2 .12a).
2.2.10 Radiolabelling of proteins by Iodogen method 
TM
Iodogen (1,3,4,6-tetrachloro-3 , 6 oc-diphenylglycoluril),
is a mild solid phase reagent that efficiently reacts with aqueous
mixtures of I and tyrosine groups on proteins to produce
iodinated proteins (Fraher and Speck, 1978).
TM
Iodogen (lmg) was dissolved in lml of chloroform. The 
solvent was removed with a gentle air stream by rotating the 
reaction container until a thin film of Iodogen was formed on the 
base.
Proteins for iodination (lmg of protein A or 600/ig low M
r
value standards) were dissolved in 0.5ml O.IM-Tris-HCl buffer pH7.2, 
0.15M NaCl and transferred into the container with the Iodogen.
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After the addition of 200-400uCi [ I]NaI, incubations were
carried out for 15 min at room temperature with occasional mixing.
Reactions were terminated by removing the mixture from the container
and passing through a 10ml Sephadex G-25 column equilibrated in
O.IM-Tris-HCl pH7.2 and 0.15M NaCl. Fractions (lml) were collected
in disposable Eppendorf tubes. The iodinated protein was generally
found to be between fractions 4 and 7. This was confirmed by
counting 5ul aliquots. The peak fractions were pooled and stored 
o
at -20 C. Protein A for immunoblotting analyses was dispensed in
6
0.05-0.lml aliquots containing approximately 3 x 10 c.p.m. each.
2.2.11 Modification of enzyme-bound lipoyl groups in pyruvate 
dehydrogenase complex
(a) Acetylation Assay
The acetylation of covalently-associated lipoyl groups in 
PDC was assayed by measuring incorporation of radioactivity from
r 1 4[2- C] pyruvate into TCA-precipitable material (Cate and Roche, 
1979).
Standard mixtures (200ul) contained 50mM potassium 
phosphate buffer, pH7.2, 0.2mM-TPP, 0.5mM-MgCl^, 0.25mM-EDTA and
200ug PDC. Catalysis was initiated after 1 min preincubation at
o 14 ,
30 C by addition of O.lmM [2- C] pyruvate (10.4mCi/mmol).
Samples (lOul) were withdrawn at the indicated times,
spotted onto Whatman No. 1 filter paper discs and processed for
measurement of TCA-insoluble radioactivity (see Section 2.2.3).
In some experiments NEM was added to a final concentration
14
of 0.5mM before incubation with [2- C] pyruvate. Stock lOmM NEM 
solution in 50mM KP. (pH7.0) . was prepared freshly each time.
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(b) Deacetylation assays
PDC was incubated, as described in Section 2.2.lib, for 
30-40 min to allow the complete acetylation of the complex. CoASH 
was added to a final concentration of ImM and the deacetylation 
reaction was followed by removing 10pl aliquots of reaction 
mixtures, spotting onto filter paper discs and measuring 
TCA-insoluble radioactivity.
To study the effects of NEM on the deacetylation reaction, 
NEM (0.5mM) was added to PDC before preincubation with CoASH.
(c) NEM modification of PDC
PDC (6mg), dissolved in 600ul 50mM-potassium phosphate
+
buffer, pH7.5, 0.25% (v/v) Triton X-100, ImM-NAD , 5mM-MgCl2,
o
2mM-TPP, and 0.5mM-NEM, was incubated for 24 h at 4 C. Unreacted
reagents were removed by gel filtration d.n lml columns of Sephadex
G-25 equilibrated in 50mM-potassium phosphate buffer, pH7.5, 1%
+
(v/v) Triton X-100, ImM-NAD , 5mM-MgCl2, 2mM-TPP (Penefsky,
1977). This procedure blocked all NEM-sensitive sites available to
the complex in the absence of pyruvate in a time-dependent manner
(Hodgson, 1986).
14
(d) [ C] NEM modification of PDC subunits
PDC (200/ig) was added to 200^1 Laemmli sample buffer (minus
o
DTT or 2ME). The mixture was heated briefly to 100 C, prior to
I4incubation with 5^ uCi N-ethyl [2,3- C] maleimide. After 30 m m
at room temperature, precipitation was induced by the addition of
o
4 vol of acetone and the mixture incubated overnight at -20 C.
After spinning at full speed for 5 min in a Microfuge, the pellet 
was resuspended in Laemmli sample buffer containing lOmM-DTT.
Figure 2.1 Structure of expression vector XGTll
The structure of the expression vector Xgtll (laci-, 
cl857, nin 5, S100) is outlined. The position of the unique EcoRI 
site in the lac Z gene into which foreign cDNA sequences are 
inserted, and of the adjacent Kpnl and SstI (SacI) sites are 
shown. The transcriptional orientation of lac Z is indicated by 
the horizontal arrow and the size of the vector is shown in kilobase 
pairs, [adapted from Sambrooi/ et al., 1989].
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2 .2.12 Screening of a X gtll gene expression library with antibody 
probes
A human heptoma A  gtll cDNA gene expression library was a 
gift from J. De Wet (Fig. 2.1). [ The library was constructed from
cDNA copied from poly A RNA isolated from the human hepatoma line
li 7 which was grown on Balb/c athymic mice. The library contains
  D       —   .
approximately 8 x 10 independent clones, and 75% of the phage
carry inserts. Although the cDNAs were inserted into A  gtll with
EcoRI linkers it has been reported that approximately 20% of the
clones are missing one of the EcoRI sites which should bound the
insert. The screening method is essentially that of Young and
Davis (1983) with the major modification of the use of a chromogenic
agent to identify recombinant phage which give a positive
immunological response owing to the expression of fusion protein
which is recognised by the subunit-specific antisera.
(a) Antibody screening procedure
(b) Growing X  gtll
Host E. coli strain Y1090 was grown overnight at 37°C in
LB medium containing lOmM MgSO, and 0.2% (w/v) maltose. Phage
4
6
were diluted in SM buffer to give approximately 1 x 10 PFU per ml
and 10-100ul added to 200ul of the overnight culture of Y1090. 
o
After 15 min at 37 C 7.5ml soft agar was added and mixture poured
onto LB plates (150mm diam.) containing lOmM MgSO . The plates
4
o
were incubated for 2.5 h at 42 C with the lids removed for the 
final 15 min.
(c) Overlaying plaques with nitrocellulose filters 
Nitrocellulose filters, cut to the dimensions of the plates
(diam. 150mm) were soaked in lOmM IPTG. When dry, 0.5ng of antigen 
was spotted on to the edge of the filter adjacent to a pencil mark 
used to establish the orientation of the filter (the pencil mark
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face down onto the plate). The plates were carefully covered with 
the prepared nitrocellulose filters and the filters marked at the
edges with a syringe needle for identification. Inverted plates
o
with filters were incubated for a further 2 h at 37 C to lyse the |
cells. After 2 h the filters were removed and washed in TBS for
5 min. If required, fresh IPTG impregnated nitrocellulose filters
could be used to overlay the plates. Otherwise the plates were 
o
stored at 4 C. A further 5 min wash in 3% (w/v) BSA in TBS, 
pH7.5 was followed by an overnight wash in TBS, 3% (w/v) BSA +
0.02%, sodium azide and 1:100 dilution of either of the antibodies 
to the components of PDC. The BSA blocks non-specific sites on the 
nitrocellulose, reducing the background signal.
The first antibody mixture was decanted and stored at
o
-20 C as it can be used on several subsequent occasions. Filters 
were again washed in TBS for 10 min before the addition of TBS +
0.05% (v/v) Tween 20 for 5 sec. Prolonged exposure of the filter 
to the TBS/Tween 20 solution resulted in a loss of signal. On 
completion of the washing stage the TBS was discarded and TBS,
3% (w/v) BSA in TBS the second antibody, peroxidase conjugated 
goat-anti rabbit IgG was added to each filter and incubated for 
3 h. The second antibody was discarded and the filters incubated 
in colour development reagent containing 40ml of ice cold methanol,
200ml of TBS, 120ul of 60 vol hydrogen peroxide and 4-chloronaphthol 
to a final concentration of 5mM. When the purple background had 
started to develop the filters were removed and washed in water to 
stop the colour development reaction.
(d) Identification and rescreening of positive clones
A positive clone, usually identified by its doughnut 
appearance and darker blue colour, was pinpointed and picked by 
using the fine end of a sterile Pasteur pipette. The agar plug was
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added to 500ul of sterile SM buffer followed by one drop of
chloroform. The solution was vortexed for 30 sec before storage 
o
overnight at 4 C.
After a brief vortex the samples were microfuged for 8 min
and 200^1 removed to a sterile polytube, one drop of chloroform was
o
added and the phage stored at 4 C. The concentration of phage
was determined (Section 2.2.12e) and approximately 40,000 (75/ul)
used to infect 50/11 of a fresh overnight culture of Y1090. After 
o
15 min at 37 C, 3ml of LB soft agar was added and the mixture 
poured onto 90mm LB plates (pH7.5) and the screening process 
repeated (Section 2.2.12b).
After each screening the number of positive phage used to 
infect an overnight culture was reduced by a factor of 10 until 1 0 0% 
positives were obtained.
(e) Estimation of the number of plaque forming units (Titre)
The Ion protease deficient host Y1090 used to plate out 
gtll libraries for screening with antibody probes is not defective 
for host-controlled restriction and modification enzyme activities. 
Therefore, the initial packaging mix of libraries cloned in A  gtll 
should not be plated directly on Y1090 for screening, but should 
first be amplified through Y1088.
It is important to use Y1088 when determining the titre of 
the recombinant phage as it is important to repress the production 
of toxic polypeptides (in the form ofyS -galactosidase fusion 
proteins) encoded by the recombinant phage. Therefore, E. coli 
Y1088, which produces lac repressor, is used as the host to amplify 
the library.
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(f) Drop titre
A rapid method for determining the number of plaque forming 
units (p.f.u.)
A single colony of Y1088 was used to inoculate 10ml of LB
o
media and grown overnight at 37 C. 3ml of molten top LB agar was
added to 20 0ul of the overnigtit culture and the mixture poured over
a LB plate and allowed to dry. The plate was divided into four
sections and 20ul of different dilutions of recombinant phage added
to each of 3 sections. 20ul SM buffer was added to the fourth
section as a control. After the phage had dried onto the plate,
o
the plates were incubated overnight at 34 C.
(g) High titre lysate
200ul of a Y1088 overnight culture was added to 
5
approximately 10 p.f.u. of the isolated recombinant phage. After 
o
15 min at 39 C, 3ml of soft agar was added to the mixture and
o 2+
poured onto a prewarmed (37 C) LB + Mg plate. After 
o
incubation at 42 C for 6 h, lysis occurred and the plates were
o
overlaid with 3ml SM buffer and stored overnight at 4 C. The SM
buffer was decanted and centrifuged for 15 min at 8000 x g. The
o
supernatant fluid was removed and stored at 4 C. A drop of 
chloroform was added to prevent bacterial degradation of the lysate.
(h) Confirmation of positive clones using the high titre lysate 
An accurate titre was performed on the high titre lysate
(Section 2.2.12e). At a ratio of 50:50, p.f.u. from recombinant
and non recombinant \ gtll^ lOOpl of the mixture was then used to
o
infect 50ul of host Y1090 which were grown overnight at 37 C in LB
o
medium. After 15 min at 37 C 3ml of soft agar was added and the
mixture poured onto LB plates (100mm) containing lOmM MgSO . The
4
plates were incubated for 2.5 h with the lid removed for the final 
15 min. Plates were then overlaid with nitrocellulose filters 
presoaked in IPTG and the filters were processed as described in 
Section 2.2.12b). Approximately 10% recombinant phage were observed.
(i) Preparation of lysogens from recombinant phage
o
The cells from a 2ml overnight culture at 37 C of host
Y1089 grown in L Broth, pH7.5, 0.02% (w/v) maltose and lOmM MgSO ,
4
were pelleted before resuspension in 2ml of SM buffer. After a |
repeat washing of the cells, the cells were finally resuspended in
o
2ml of SM buffer and incubated for 1 h at 37 C.
lOOul of these cells were infected with a five fold excess
of viable phage (a multiplicity of infection of 1:5). The samples
were left for 1 h at room temperature before the number of p.f.u.
determined (titred). The lysates were streaked out on LB plates
o
and incubated overnight at 30 C.
(j) Replica plating
An overnight L-Broth agar plate impregnated with lysogens
is rolled onto filter paper. A fresh L-Broth agar plate is placed
o
over the filter paper and the plate stored overnight at 42 C.
The procedure is repeated with a second L-Broth agar plate and this
o
plate is stored at 30 C overnight.
The two plates are compared and temperature sensitive
o
lysogens containing the component X phage will be present at 30 C 
o o
but not 42 C. At 42 C the temperature sensitive phage
o
repressor is non functional. Clones which grow at 30 C but not 
o
at 42 C are assumed to be lysogens. Lysogens arise at a 
frequency of between 10% and 70% under these conditions.
(k) Preparation of crude lysate
After inoculation with a single colony of the Y1089
recombinant lysogen 10ml of L Broth was incubated overnight at
o o
30 C. After incubation for 20 min at 45 C, IPTG was added to a
o
final concentration of lOmM and the cells incubated at 37 C for a 
further 80 min. The lac-Z directed fusion protein production is 
induced by the addition of IPTG to the medium.
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The clear supernatant fraction obtained after
centrifugation at 5000 x g for 10 min was discarded and the pellet
resuspended in lysate buffer. The cells were disrupted by passing
them through a 21 gauge needle and heating them for 3 min at 
o
70 C. After a 10 min high speed spin on a microcentrifuge a very 
viscous solution was obtained. DNase was added to a final
concentration of 0.5yjg/ml and the suspension incubated for 1 h at 
o
37 C.
(1) Permanent storage of lysogens
A single colony from a Y1089 recombinant lysogen grown 
o
overnight at 30 C was used to inoculate 10ml LB medium, pH7.5.
o
After overnight incubation at 30 C, 200^ il was removed and added to
200ul of glycerol. The mixture was rapidly frozen in alcohol/dry
o
ice and stored at -80 C. Cells frozen in the absence of glycerol
are damaged by the formation of ice crystals.
(m) Identification of fusion protein
An aliquot of crude lysate was removed, added to an equal
volume of Laemmli sample buffer and resolved by a 10% SDS-PAGE
before blotting onto nitrocellulose (Section 2.2.9a). The
nitrocellulose was challenged with appropriate antisera and the
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presence of the appropriate protein identified using [ I] 
protein A (Section 2.2.9a).
2.2.13 Preparation of DNA
(a) Preparation of phage DNA (Maniatis et_ al., 1982)
This procedure is based on the method of Yamamoto et al.
1970. A Y1089 recombinant lysogen was grown overnight in LB medium 
o
at 32 C. 4ml of the overnight culture was diluted into 400ml LB
o
medium and aerated at 32 C until the cell density was = 0.4.
o
The phage were induced by shaking the flasks at 42 C for
o
20 min and then aerated for a further 3 h at 37 C. Cells were 
harvested by centrifugation at 8000 x g for 10 min and resuspended 
in 40ml SM buffer. Following centrifugation at 10000 x g for 
10 min, the resultant pellet was resuspended in phage buffer.
o
Cells were lysed by freeze thawing in dry ice/alcohol and a 37 C
water bath respectively. This was repeated three times. DNase I
and RNase I (heat treated) were added to a final concentration of
0.5yug/ml to digest chromosomal DNA and the mixture allowed to stand
overnight on the bench.
Solid sodium chloride 0.5M followed by PEG 8000 [to a final
concentration of 10% (w/v)] were added and the solution left for 1 h 
o
at 4 C. Following a spin at 6000 x g for 30 min, the resultant
pellet was resuspended in 5ml SM buffer, the mixture vortexed for
o
30 sec and then centrifuged at 1600 x g for 15 min at 4 C. The
-1
aqueous layer (top) was removed and added to 0.5g ml of solid 
caesium chloride.
Caesium Chloride Gradient
Table 2.1 Caesium Chloride solutions for step gradients 
prepared in SM (100ml)
Density CsCl SM Refractive
(P) (g) (ml) (?)
1.45 60 85 1.3768
1.50 67 82 1.3815
1.70 95 75 1.3990
The step gradients were made by carefully and sequentially layering 
solutions of decreasing density on top of one another.
The aqueous layer was added to the gra<3ient an<3
samples were centrifuged at 50000 x g for 80 min. The DNA was 
visualised in the middle of the p 1.5 band. A needle was inserted
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below the DNA and the DNA was extracted into a sterile Eppendorf
tube. Caesium chloride was removed by overnight dialysis against
o
SM buffer. The DNA was incubated at 70 C for 30 min at 0.2 vol 
lysis buffer followed by 30 min incubation on ice with 0.25 vol 8M 
potassium acetate. The precipitate was spun at 10,000 x g for 20 
min and the DNA precipitated from the supernatant by the addition of 
3M Na acetate, pH6.0, followed by 2.5 vol of 80% (v/v) ethanol.
DNA was dissolved finally in TE buffer.
(b) Alternative preparation of bacteriophage DNA
It was found that preparation of DNA through a caesium 
chloride gradient resulted in pure DNA but with reduced yields. An 
alternative hybrid preparation based on the method of Yamamoto 
(1970) resulted in improved yields.
The original method was followed as in the preparation of 
phage DNA up to and including the extraction of phage with 
chloroform.
Bacteriophage particles were then collected by
centrifugation at 50,000 x g for 2 h in a Beckmann SW27 rotor. 2ml
of SM buffer was added to the glassy pellet which was left to
solubilise overnight. The pellet may be pipetted gently to ensure
the bacteriophage particles have resuspended.
Proteinase K was added to a final concentration of 50ug/ml
followed by SDS to 0.5% (w/v) and the bacteriophage particles
o
incubated for 1 h at 65 C. An equal volume of TE-equilibrated 
phenol was added and the tube inverted several times to ensure 
thorough mixing. After a brief spin, the aqueous layer was removed 
and extracted with 1:1 phenol/chloroform. The aqueous layer was 
dialysed against TE buffer overnight.
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(c) Separation of DNA fragments by agarose gel electrophoresis
Agarose gel electrophoresis was the standard procedure used
to separate, identify and purify DNA fragments.
o
Agarose gels were prepared by heating at 100 C, under
pressure for 7 min, the required amount of agarose in
electrophoresis buffer (Section 2.1.9). This was usually enough
time to completely melt the agarose. When the agarose had cooled 
o
to around 50 C, ethidium bromide was added (to 0.5^ug/ul) before 
quickly casting the gel, concentrations of between 0.75% (w/v) 
agarose and 2% (w/v) agarose were routinely used, depending on the 
size of the DNA fragments. Electrophoresis was performed in a 
horizontal mini gel apparatus.
The gel was immersed in electrophoresis buffer containing 
ethidium bromide (O.^ug/ml) and electrophoresis was performed at 50 
or 100 V until the dye front 1 had almost reached the end of the 
gel. DNA was visualised by ethidium bromide fluorescence on a U.V. 
trans-illuminator. The gels were photographed with a polaroid CU-5 
camera. The size of fragments were estimated by comparison with 
DNA Hind III marker fragments derived from Xcl857 DNA digested to 
completion by Hind III.
(d) Restriction Digests
Restriction enzymes were used as recommended by the
supliers.
Buffers
Table 2.2 10 x Stock restriction enzyme buffers (>ul)
Salt conc. H O 
2
4MNaCl 1M Tris lmMgCl^ 1M DTT
Low 790 0 100 100 10
Medium 640 50 200 100 10
High 300 100 500 100 0
Figure 2.2 The multiple cloning sites of (a) the plasmid vector
pUC18, and (b) the double-stranded replicative form of 
bacteriophage M13mpl8
Maps of plasmid vector pUC18 (a) and the replicative form
of bacteriophage M13 (b) are shown. The plasmid vector pUC18 is
derived from a fragment of pBR322 by insertion of a fragment of the
lac gene at Haell sites; the multiple cloning sites interrupt the
R
lacz* (truncated -galactosidase) gene. Ap ; ampicillin
resistance gene. The same lac fragment including the multiple
cloning sites has also been inserted into phage M13. I-X: the
genes of bacteriophage M13.
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(e) Restriction enzymes
One unit of enzyme activity is defined as the amount of 
enzyme required to digest lug of DNA to completion in 60 min. 
Typically, 1/ig of DNA was digested with a slight excess of 
restriction enzyme. The DNA was mixed with 0.1 vol of the 
appropriate ten fold stock buffer (see Table 2.2) and twice the 
recommended quantity of restriction enzyme. Sterile water was 
added to the required volume. The reaction mixture was incubated 
for 60 min at the required temperature.
2.2.14 Subcloning into M13 (M13mpl8)
M13 is a specific filamentous bacteriophage of E_^  coli.
The virus particles contain single stranded, circular DNA which 
following infection, serves as a template for the synthesis of the 
complementary strand. The double-stranded form of the viral DNA 
present in infected cells is called the replicative form (RF 
form). Several modifications were introduced into the phage and 
host cells to engineer an efficient vector/host system on the basis 
of these bacteriophage (Messing, 1983), making it an ideal source 
for producing single stranded DNA for sequencing by the dideoxy 
method (Sanger, 1981). The double stranded RF-form was modified to 
serve as an efficient cloning vector, by introducing the same 
multiple cloning region and colour selection system for the 
identification of recombinants (on the basis of yS -galactosidase 
activity) (Fig. 2.2).
All procedures used for cloning were according to the M13 
cloning and sequencing handbook (Amersham International).
(a) DNA sequencing
All DNA sequencing was carried out using the M13/dideoxy 
method (Sanger, 1981; Messing, 1983). Initially the components
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were purchased in kit form; latterly, individual components were 
purchased and substituted. All the protocols for cloning and 
sequencing were supplied with the kits in the form of the "M13 
cloning and sequencing handbook" (Amersham International pic). In 
the following sections, page numbers in the format (Handbook pi) 
refer to the Amersham Handbook.
(b) Restriction Digest of RF DNA
RF-form of M13mpl8 (lyug) was digested with 4 units of EcoRl
o
at 37 C for 40 min and then placed on ice. After checking that 
all the vector had been cut (by running a small aliquot on an 
agarose gel), the vector was purified by phenol extraction and 
ethanol precipitation.
(c) Phenol extraction
TE buffer (50/jl) was added to the digested vector and 
extracted with an equal volume of phenol. After a brief vortex 
(20 s) the sample was microfuged and the upper aqueous layer removed 
and saved. Another 50ul of phenol was added to the aqueous phase 
and the process repeated. Care was taken to avoid material at the 
interface. After the phenol extractions, 500/ul of diethyl ether 
was added to the aqueous layer and the sample vortexed briefly.
The aqueous phase (lower) was saved and the process repeated twice 
more.
(d) Ethanol precipitation
To the phenol/ether extracted DNA 0.1 vol 3M Na acetate
o
pH6.0 was added followed by 2.5 vol of (-20 C) ethanol. After an
o
overnight incubation at -20 C the sample was microfuged for 5 min
and the supernatant removed and discarded. The pellet was washed 
o
in 750jj1 of (-20 C) ethanol, care being taken not to disturb the 
pellet, and, after a brief spin (30 s), the ethanol was discarded.
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The pellet was vacuum-dried and the DNA dissolved in TE buffer to
give a final concentration of approx. lOng/ml. The samples were
o
stored in small aliquots at -20 C.
(e) Ligation of RF DNA to insert DNA (Handbook p24)
Ligation mixes for ligation of RF DNA to insert DNA were as
follows:
RF DNA ( 20ng) 2jil
Insert DNA (lOOng) 5/il
10 x ligase reaction buffer l/il
ATP lOmM lp 1
Dithiothreitol ]/il
T4 DNA ligase lpl
o
Incubation was for 4-6 h at 14 C.
The final volume was varied from 10-20jul, depending on the 
volume of buffer in which the insert DNA was resuspended.
(f) Transformation of E. coli JM1Q1 (Handbook p25)
E. coli JM101 was streaked out on minimal medium plates 
and, after overnight growth, the plate was stored at 4°C (for 
approx.
1 month before re-streaking). A single colony was innoculated into
o
2 x TY medium (10ml) and shaken overnight at 37 C. 40ml 2 x TY
o
was inoculated with 2ml fresh overnight culture and shaken (37 C)
for 3 h. 10ml 2 x TY was also inoculated with a drop of overnight
culture to provide fresh cells. Cells from the 40ml 2 x TY culture
were harvested (5000 x g, 5 min) resuspended in 20ml 50mM C a C ^2
and left on ice for 20 min before re-harvesting (5000 x g, 5min) and
resuspending in 4ml 50mM CaCl^. 0.3ml of competent cells were
added to 5ul of DNA ligation mix and kept on ice for 40 min. Cells
o
were then heat shocked at 42 for 3 min and returned to ice.
The following were added to each tube:
lOOmM IPTG 40/il
2%(w/v)-X-gal 40/il
Fresh cells 200/il
Molten top agar 3ml
and the mix poured onto H plates prewarmed at 37 C.
(g) Preparation of single stranded template DNA (Handbook p27)
A single plaque was mixed (using a sterile Eppendorf
pipette tip) into fresh 2 x TY (1.5ml) containing lml/lOOml medium
of an overnight culture of E. coli JM101. This culture was shaken 
o
for 5 h at 37 C and the cells harvested by spinning in a microfuge
for 5 min. The supernatant fluid was carefully transferred to a
sterile Eppendorf and microfuged for 5 min to ensure all the cells
were removed. The supernatant fraction was added to 200yil PEG/NaCl
[20% (w/v) polyethyleneglycol 8000/2.5M-NaCl], shaken and left for ^
15 min; then centrifuged for 5 min and the supernatant discarded.
Following a further 2 min spin, all remaining traces of PEG were
removed using a drawn out Pasteur pipette. lOO/il TE buffer and
50ul of phenol saturated with TE buffer were added to the viral
pellet and vortexed for 15 sec. After 15 min at room temperature
the contents were again vortexed for 15 sec and microfuged for 3
min. The upper layer was transferrred to a fresh Eppendorf tube
and 1ml of chloroform added. The chloroform was mixed by vortexing
for 15 sec and separated after a 1 min microfuge spin. The aqueous
(upper) layer was transferred to a sterile Eppendorf tube. 3M-Na
acetate, pH6.0 (10/il) and ethanol (250^ il) were added and DNA
o
precipitated by standing overnight at -20 C or by placing the tube 
o
at -70 C (dry ice/methanol) for 15 min. The DNA was recovered by
o
centrifugation for 10 min and washed with 1ml of -20 C, ethanol.
Figure 2.3 Sequence and annealing site of 17-mer primer
The sequences of the multiple cloning sites in the 
single-stranded templates of M13mpl8 and M13mpl9 and the restriction 
sites are indicated. The sequence and the position of annealing of 
the universal sequencing primer, 17 bases (A) long, is shown.
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The ethanol was discarded and the tube left to dry. The DNA pellet
o
was redissolved in TE buffer (50ul) and stored at -20 C.
(h) Annealing of primer and template (Handbook p33)
For each clone, the following were placed in a 1.5ml
microfuge tube:
single stranded template DNA 5yul
primer l/il
10 x Klenow reaction buffer 1.5^ il
(lOmM-Tris pH8.5, lOOmM MgC^)
Distilled water 2.5yul
The primer used is a 17-mer, its sequence and its annealing
site in M13mpl8 can be observed in Figure 2.3.
(i) The sequencing reactions (Handbook p34)
To the annealed primer/template mix 1.5pl (l^ jucia) of
, 3 5
( S) dATP ©C S at ^ 600 Ci/mmol (Amersham SJ304) and ljil
(lu/ul) of Klenow fragment of E. coli DNA polymerase I. 2.5/il of 
the mixture was placed on the rim of each of four tubes, marked A,
C, G or T in a microfuge rotor. 2jjl1 of the relevant dNTP/ddNTP mix
(see below) was placed inside the rim of each tube and a brief spin
mixed the contents. After 20 min, 2pl of chase mixture (0.5mM 
uniform mixture of dATP, dCTP, dGTP and dTTP) was placed on the rim 
of the tube and mixed in with a brief spin. After a further 15 min 
chase reaction, Apl of formamide dye mix was added. Formamide dye 
mix was prepared as follows: 100ml of formamide was deionised by
stirring with 5g Amberlite (BDH) for 20 min, then filtered to remove 
the resin, to this was added 0.03g xylene cyanol FF, 0.03g 
bromophenol blue and 4ml 0.5mM-EDTA.
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(j) Reaction mixes (Handbook p32)
The final concentration of each reagent in a sequencing 
reaction mix is listed in Table 2.3.
A reaction C reaction 
mix mix
16.6
G reaction
mix
dATP
dCTP
dGTP
dTTP
ddATP
ddCTP
ddGTP
ddTTP
16.6 
28 
28 
28 
22. 2
0.3
28
28
22.6
16.6
28
0.3
28
T reaction 
mix 
16.6 
28 
28 
0.3
66.6
111
Final concentration of reagents in sequencing reaction mixes. All 
concentrations are ^ tiM.
(k) Polyacrylamide gel electrophoresis (Handbook pp36 and 45)
The DNA fragments in the sequencing reaction mixes were 
resolved by electrophoresis on polyacrylamide gels (20 x 40 x
0.4cm). The notched plate was siliconised before use with 
Repelcote.
Two types of gel were employed, linear and buffer 
gradient. The quantities of reagents necessary to pour a 6% (w/v) 
acrylamide, 8M-urea tris borate gel are shown in Table 2.4.
Before loading, the wells were flushed out with running 
buffer ( 1 x tris-borate) to remove unpolymerised acrylamide and 
urea, which leaches into the gel slots, preventing the samples from 
forming a precise layer.
o
The samples were heated to 95 C for 3 min, then loaded 
immediately onto the gel. Gels were run at 28mA for 2 to 4 h.
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Gels were fixed after removing the notched plate by soaking 
in a 2:1 bath of 10% (v/v)acetic acid, 10% (v/v) methanol for 30 sec 
to remove the urea. The gel was removed from the bath and a sheet 
of Whatman 3MM paper laid on top. The gel was peeled off with the 
paper backing, placed on a Bio-rad Model 1125 gel dryer and covered 
in saran wrap. Sixty minutes under vacuum was usually sufficient 
to dry the gel.
Table 2.4 Quantities of reagents necessary to pour a single
polyacrylamide gel for DNA sequence analysis
Linear buffer gradient
Top Bottom
Urea (g) 21 19.2 3.8
acrylamide stock (ml) 7.5 6 1.125
10 x tris-borate (ml) 5.0 2 1.875
sucrose (g) 0.75
bromophenol blue (ml) 0.075
water (ml) 50 40 7.5
TEMED (/i 1 ) 50 80 15
AMPS (cone) (/il) 300 80 15
Acrylamide stock 40% (w/v) 38:2 acrylamide : NN'methylene 
bisacrylamide deionised by stirring with 5g Amberlite MBl and 
filtered through a scintered glass funnel.
(1) Autoradiography
The dried gel was placed in a light proof cassette and 
covered by a sheet of Kodak X-Omat X-ray film. The film was 
exposed overnight at room temperature before developing.
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2.2.15 Plasmid preparations
(a) Plasmid preparation of PTZ18
Plasmid PTZ in host HB101 was used to inoculate a 10ml
-1
culture,;of L broth containing 50/ig ml of ampicillin. After
o
overnight growth at 37 C, 500^ ul was removed and used to inoculate
o
a second 10ml LB + ampicilll.n medium and incubated at 37 C until
the A _ was 0.6. At this time chloroamphenical was added to a
620
final concentration of 170^1/ml and the culture incubated for a 
further 20 h at 37°C.
The culture was pelleted by centrifugation at 5000 x g for
-1
10 min, the supernatant was discarded and 2.5mg ml lysosyme
added. After 5 min at room temperature, the cells were lysed by
the addition of 200/il 0.1% (w/v) SDS, 0.2M NaOH. 0.5M potassium
acetate pH4.8 followed and after 15 min in ice the cells were
transferred to sterile Eppendorf tubes and pelleted at 16000 g for
15 min. The supernatant fluid was phenol extracted followed by
extraction with equal volumes of chloroform isoamyl alcohol (24:1
v/v). Chloroform denatures the proteins while the isoamyl alcohol
reduces foaming during the extraction phase and facilitates the
separation of the aqueous and organic phases. DNA was precipitated
by the addition of 3M Na acetate followed by 4 vol of ethanol and
o
storage overnight at -20 C. The DNA was pelleted in a microfuge 
and washed 3 times in 80% (v/v) ice cold ethanol before being dried 
under vacuum. The DNA was solubilised in an appropriate volume of 
TE buffer and RNA was removed by the addition of heat-treated RNase 
I (0.5jug/ml final).
(b) Ligation of insert DNA into plasmid PTZ 18R
PTZ 18R and PTZ 19R are specially designed plasmids which 
permit DNA cloning, dideoxy DNA sequencing, iri vitro mutagenesis and
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in vitro transcription in one system. The size of PTZ 18R is
approximately 2880 base pairs and a 300bp insert ligated .into the
vector would constitute 10% of the plasmid. Therefore greater
Li amounts of insert can be produced when ligated with PTZ 18R and
amplified by a plasmid preparation.
Ligation of insert was carried out essentially as described
in Section 2.2.14e. A single colony from E. coli host TGI was
o
inoculated into 2 x TY medium (10ml) and grown overnight at 37 C 
and processed as described in Section 2.2.14f. Selection of 
recombinant was slightly different. IPTG and X-gal were spread 
onto H plates and allowed to dry before lOOyul of ligation mixture 
was spread on to the plate. Clear colonies were assumed to be 
successfully ligated plasmid and insert. Purified plasmid and 
insert was prepared as described above.
CHAPTER THREE
ACETYLATION REACTIONS OF COMPONENT X OF 
MAMMALIAN PYRUVATE DEHYDROGENASE COMPLEX
82
3. Acetylation reactions of component X of mammalian pyruvate
dehydrogenase complex
3.1 Introduction
A recently recognised subunit of mammalian PDC, M 51000
r
forms a close physical and functional union with the E2 core
assembly (De Marcucci et al., 1986; Jilka et al., 1986). In
addition, the E2 assembly, isolated from PDC of Saccharomyces
cerevisiae, contains a tightly-bound polypeptide M 48000 which ----------  r
exhibits similar properties to mammalian protein or component X
(Kresze and Ronft, 1981). While the distinctive nature of this
subunit in eukaryotic PDC has been confirmed recently (De Marcucci
and Lindsay, 1985), it was originally thought to be a degradation
product of E2 or possibly the intrinsic kinase (Bliele et al.,
1981). However, by employing refined immunological techniques and
protein chemical criteria it has been possible to establish that
component X is a specific polypeptide distinct from the other major
components of the complex (De Marcucci and Lindsay, 1985; Jilka
et al., 1986).
In similar manner to E2, component X is reductively
acetylated by El in the absence of CoASH (De Marcucci et al.,
1986). Acetylation of E2 and component X requires an active El
subunit and rapid deacetylation occurs on the addition of CoASH.
The site of acetyl group incorporation on E2 polypeptides is the
lipoic acid prosthetic group which is covalently attached via an
6
amide bond to the N -amino group of specific lysine residues in 
the polypeptide chain. Recently the site of acetylation on
component X has also been established to be lipoic acid (Hodgson 
et al., 1986). Comparison of the deduced amino acid sequences of 
yeast protein X and E2 reveals that the amino terminal part of 
protein X resembles E2, but the carboxyl-terminal is completely 
different (Behai et al., 1989). Protein X lacks the
Figure 3.1 Substrate protection against NEM modification and
inactivation of PDC
The diagram indicates only the site of chemical attack by 
NEM not the exact product formed after modification of the reduced 
thiol on the dithiolane ring.
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carboxy-terminal segment of E2 that contains a highly conserved
sequence which is thought to be part of the putative catalytic site
of all dihydrolipoamide acyltransferases (Miles and Guest, 1987).
This finding suggests that yeast protein X, in contrast to E2, is
unable to catalyse an acetyl transfer between the protein-bound
S-acetyldihydrolipoyl moiety and CoASH.
A unique feature of eukaryotic PDC is its ability to
diacetylate the lipoic acid moieties on E2 (Fig. 3.1). Treatment
of PDC with N-ethylmaleimide (NEM) results in a substrate or
product-dependent inhibition of complex activity owing to the
generation of a free thiol on the S-acetyldihydrolipoamide
intermediate. However, prolonged incubation of PDC with pyruvate
or NADH plus acetyl CoA prior to the addition of N-ethylmaleimide
diminishes the inhibition of the complex activity by NEM and also
14
reduces incorporation of N-ethyl [2,3- C] maleimide into both E2
and component X. The increase in protection against inhibition by
NEM occurs in parallel with a second, slow phase of incorporation of
acetyl groups into both E2 and protein X which is in agreement with
a previous report (Cate et al., 1980). It has been suggested that
prolonged incubation with acetylating substrate under these
6 8
conditions produces a n S  S (diacetyl) lipoyl group
6 8
(Fig. 3.1). The formation of S S (diacetyl) lipoamide by
13
mammalian PDC has been detected previously by C-nmr spectroscopy 
using high concentrations of exogenous dihydrolipoamide as substrate 
(O’Connor et al., 1982). The physiological significance of 
diacetylation is discussed more fully in Chapter 7.
Preparation of PDC free from component X employing standard 
biochemical separation techniques would greatly facilitate studies 
on the precise function of component X in the complex. It is 
possible to dissociate El, E2 and E3 in active form with relative 
ease (Linn et al., 1972). Unfortunately under these conditions
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component X remains tightly bound to E2. However, in a recent 
report it has been claimed that an active E2 oligomer can be 
prepared which is devoid of component X (Powers-Greenwood et al., 
1989). By employing severe dissociating c'onditions i.e. 5.2M urea, 
0.35M NaCl and 0.2M EDTA, it has proved possible to separate an 
oligomeric form of E2 by gel filtration. The isolated E2 oligomer 
apparently retains its acetyltransferase activity and capacity to 
bind El. The E2 oligomers have a greatly diminished ability to 
bind the E3 component leading the authors to suggest that protein X 
is responsible for binding E3 to the core structure. Such data 
must be viewed with caution as the integrity of the E2 core and 
damage to the outerdomains under such severe dissociating conditions 
has not been fully assessed.
In view of the close physical and functional relationship
between E2 and protein X within the E2 core structure, it has been
difficult to determine the precise function of this polypeptide in
the multienzyme complex. Does component X mediate directly in the
catalytic mechanism for the transfer of two carbon units from El to
the final acceptor CoASH or is component X in equilibrium with E2
with which it interacts strongly, perhaps promoting acetyl group
transfer to an unknown physiological acceptor? It is also
important to establish if E2 and X polypeptides can interact
independently of each other with pyruvate dehydrogenase (El) or is
there a defined sequence of acetyl group transfer between these
polypeptides (Fig. 1.7). Similarly while both polypeptides can be
deacetylated by the addition of CoASH, it is not known if both can
interact independently with this cofactor with X providing an
alternative pathway for the transfer of acetyl groups and electrons 
+
into CoASH and NAD respectively.
A number of approaches were employed in this chapter in an 
attempt to delineate the route of acetyl group transfer within the
PDC complex and the involvement of protein X.
Figure 3.2 Acetylation of E2 and component X during normal
turnover of the complex
250/ig of PDC was made to lOO^ il with 20mM potassium
phosphate buffer pH7.4 containing 2.5mM NAD , ImM MgCl^ ^ndO.lmH
TPP. CoASH was added to a final concentration of 0.2mM and the
14
mixture incubated for 10 min. 5,uCi of [2- C] pyruvate was added 
and 5/ig of enzyme withdrawn and assayed (A). After 6 s, 12s,
30s, 1 min, 1.5 min, 2min and 5 min, 25pg aliquots were withdrawn 
and added directly to Laemmli sample buffer. The samples were
resolved by SDS-PAGE on a 10% (w/v) gel and processed for
/ \ 14
fluorography (B). Lane A, 25/ig of PDC labelled with [2- C] pyruvate
14
in the absence of CoASH? lane B, PDC labelled with [2- C]
pyruvate in the presence of NEM, final concentration 0.5mM
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3.2 Results
3.2.1 Acetylation of E2 and component X during normal turnover of 
PDC
As indicated previously to test the possibility that
rl4 i[ CJ acetylation of protein X was a non physiological side
14
reaction promoted by conditions required to trap the [ C] acetyl 
dihydrolipoamide intermediate, samples were removed for analysis of 
the extent of acetylation of E2 and component X at various stages 
during the time course of the standard enzyme reaction, resolved by 
SDS-PAGE and processed for fluorography as described in Section 
2 .2 .4f.
Clearly component X is not observed in Figure 3.2 although 
it is the easily detectable original in the fluorograph. Therefore 
the conclusions drawn are based on the data obtained from the 
fluorograph. In the presence of CoASH low levels of acetylating 
substrate are incorporated into both E2 and protein X during the 
initial stages of the enzyme reaction (Fig. 3.2). As the reaction 
rate declines and the reaction reaches equilibrium, increased 
labelling of both E2 and component X is observed until at 
equilibrium the degree of incorporation of radio-label remains 
constant. Thus it appears that E2 and X equally participate in the 
kinetics of acetylation during normal turnover of the enzyme, and 
acetylation of protein X does not appear to represent a non- 
physiological side reaction of the acetyltransferase and is 
compatible with it acting as an normal catalytic intermediate.
3.2.2 Low temperature labelling of E2 and component X with
14
[2- C ] pyruvate
In operational terms both E2 and X can be acetylated at 
similar rates and to similar extents at room temperature by El in a
Figure 3.3 Low temperature labelling of E2 and component X with
_ 14
[2- C] pyruvate
o
A sample of PDC (250yug) was incubated at -20 C overnight
in 50mM potassium phosphate buffer, pH7.2 containing ImM MgCl^,
+ 14
TPP, NAD and 50% (w/v) glycerol. On the addition of [2- C]
pyruvate (O.lmM) samples (30yug) were withdrawn and added immediately 
to boiling Laemmli sample buffer before resolution on a 10% (w/v)
SDS/polyacrylamide gel and processing for fluorography. Lanes 1-6
14 o
PDC incubated with [2- C] pyruvate at -20 C for 6 s, 5s, 30s,
45s, 60s and 120s.
As a control lane (7), PDC (30ug) in 50% (w/v) glycerol was 
14
incubated in [2- C] pyruvate at room temperature for 5s before 
treatment as above.
1 2  3 4 5 6 7
TPP-dependent reaction which is also affected by the phosphorylation 
state of El. The El-mediated transfer of reducing equivalents and 
acetyl group in E2 and X is reported to be the rate-limiting step in 
overall complex activity (Cate and Roche, 1979). In an attempt to
determine a defined sequence of acetyl group migration between these
14 o
components loading of [2- C] pyruvate was performed at -20 C.
It was hoped that the temperature-dependence of the individual steps
was sufficiently altered such that the sequence of acetyl group
transfer between El and E2/X would no longer be rate limiting and
the route of acetyl group transfer between E2 and X could be
elucidated.
o
At -20 C in 50% (w/v) glycerol PDC was incubated with
14
[2- C] pyruvate and samples were withdrawn at different time 
intervals from the incubation mixture. These were added 
immediately to boiling Laemmli sample buffer before analysis by SDS 
polyacrylamide gel electrophoresis and processing for fluorography 
(Section 2.2.4).
14
The extent of [2- C] pyruvate incorporation into E2 and 
o
component X at -20 C can be visualised in Figure 3.3. It is
apparent that the rate of loading of the enzyme has been
significantly reduced, as throughout the length of the time course,
o
at -20 C, compared to incubation at room temperature for 5 s (lane 
7), the rate of acetyl group incorporation into E2 and component X 
was increased slowly. E2 and component X undergo reductive 
acetylation almost immediately and throughout the time course with 
increased labelling of the subunits occurring in a time-dependent 
manner. However, at all times labelling of E2 and X occurred in 
parallel and therefore the sequence of acetyl group transfer under
these conditions could not be elucidated.
Table 3.1 Overall enzyme activity using substrate analogues
Substrate analogue 
(20mM)
1 Pyruvic acid
2 -bromopyruvate
3 o< -oxamate
4 glyoxalate
5 -fluoropyruvate
6 acetylcarnitine
7 0 < -ketoisovalerate
8 oxaloacetic acid
9 0 <-keto-^S-methyl-N-valerate
10 ©(-keto-isocaproic acid
11 o/- ketobutyrate
12 ©(-ketoglutarate
13 D^-ketovalerate
14 p  -hydroxyphenylpyruvic acid
15 -hydroxypyruvic acid
PDC activity 
using substrate 
analogues
100
_ *
40
PDC activity with pyruvate 
30 min preincubation in 
substrate analogue
100%
0
96
91
0
91
92 
0
94
99
50
99
90
0
0
* See text for explanation of recorded oxaloacetic activity
Each determination is the result of two assays which differed 
by less than 10%..
Structure of substrates
Name Structure
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Structure of substrates
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0
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0
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3.2.3 Overall PDC activity with various substrate analogues 
In a separate approach, a series of substrate analogues
were employed with a view to assessing their potential as inhibitors
of acetyl group transfer between El and E2 or X. This idea stemmed
14
from an earlier observation that [2- C] pyruvate can be 
transferred onto the lipoic acid on E2 of the 2-oxoglutarate 
dehydrogenase complex, although it cannot be released subsequently 
by CoASH addition. The 2-oxoglutarate dehydrogenase is therefore 
able to utilise a substrate analogue of 2-oxoglutarate, pyruvate 
(J.A. Hodgson, unpublished results). By adapting a similar 
approach with substrate analogues of pyruvate^ an attempt was made to 
disrupt the interaction between El and E2/X and therefore inhibit 
the transfer of substrate analogue between E2 and X or X and E2.
In preliminary experiments a variety of possible analogues were 
tested for their efficiency as substrates for pyruvate dehydrogenase 
complex (Table 3.1). The structures of the substrate analogues can 
be seen in Figure 3.4.
With the notable exceptions of oxaloacetate and 
^ “ketobutyrate the remaining analogues were inactive as substrates 
for the pyruvate dehydrogenase complex. It was found that with 
freshly prepared oxaloacetate no PDC activity could be detected but 
that an increase of activity was observed with time resulting from 
the rapid decomposition of oxaloacetate to pyruvate and
3.2.4 HPLC analysis of c< ketobutyrate
The possibility that the activity recorded using 
o< -ketobutyrate as substrate was a result of contaminating pyruvate 
was investigated. Samples assayed from freshly prepared
-ketobutyrate over a time period revealed no increase in activity 
suggesting that unlike oxaloacetate, D^-ketobutyrate was not 
decomposing to pyruvate.
Figure 3.5 HPLC analysis of 2-oxobutyrate and pyruvate
(a) Elution profile from 20yil of ImM O^-ketobutyrate passed
through a fast organic acid HPLC column at a flow rate of Iml/min f 
and detected by UV absorbance at 210nm.
(b) Elution profile from 20jil of equilmolar mixture of C < “
ketobutyrate and pyruvate passed through a fast organic acid HPLC 
column at a flow rate of lml/min and detected by UV absorbance at 
210nm
(c) Elution profile from 20yjl of ImM pyruvate passed through a
fast organic acid HPLC column at a flow rate of lml/min and detected 
by UV absorbance at 210nm.
a-
ke
to
bu
ty
ra
te
 
a-
ke
to
bu
ty
 r
at
e/
py
ru
va
te
 
py
ru
va
te i C\JSo
CO -r—
I—  CO CO
cc ^  cvi
J CO CO N  r  03 ^  CVJ< uo
. O  CO 
I—  CO CD 
CC CM CM
CO CO 
CO -*3; 
O  CD 
CO
CM
88
To eliminate the possibility that the overall complex 
activity observed with o<~ketobutyrate was caused by contamination 
with pyruvate, CX-ketobutyrate and pyruvate were subjected to HPLC 
analysis. HPLC analysis of C><-ketobutyrate detected no pyruvate (
(Fig. 3.5). C><-ketobutyrate is therefore a genuine substrate
producing a rate of reaction approximately 50% of that obtained with 
pyruvate. During the course of this worko^-ketobutyrate was 
confirmed as a substrate for pyruvate dehydrogenase (Paxton et al.,
1986).
Although with the exception ofketobutyrate, the 
substrate analogues failed to promote PDC activity, the possibility 
exists that several of these compounds are trapped on the lipoic 
acid sites on E2 and component X and are unable to be transferred to 
a suitable physiological acceptor. Alternatively the substrate 
analogues may inhibit El activity by binding to the active site or 
reacting with TPP in such a way that the substrate cannot be 
transferred onto the E2 core assembly. To investigate the
possibility that the substrate analogues could inhibit 
pyruvate-dependent enzyme activity, PDC was preincubated in 
substrate analogue (final concentration 0.4mM) for 1 min before 
pyruvate dependent enzyme activity was measured (Table 3.1). The 
assay was repeated at time intervals of 15 min and 30 min.
Prolonged incubation of PDC in bromopyruvate, fluoropyruvate, 
hydroxypyruvate and hydroxyphenylpyruvate resulted in a 
time-dependent inactivation of pyruvate-dependent complex 
activity. No such effect was recorded with the remaining 
substrates. Incubation in ketobutyrate resulted in a 50% 
decrease in overall enzyme activity.
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3.2.5 Substrate analogue protection of E2 and component X from 
NEM incorporation
Prolonged incubation of PDC in substrate or NADH plus
acetyl CoA prior to the addition of NEM protects the complex from
,14 ,NEM inhibition and also reduces the incorporation of [ C] NEM 
into E2 and X. As radiolabelled substrate analogues were
,14 ,unavailable this offered a means of visualising, by [ C] NEM
incorporation, the degree of substrate analogue incorporation into
E2 and X and the possibility of observing any lack of catalytic
exchange of substrate between E2 and X by means of preferential 
14
labelling with [ C] NEM of E2 or X.
Radiolabelled NEM and substrate analogue were added
simultaneously to PDC to test if there was immediate activation of
the dithiolane rings. Alternative!,/ PDC, was preincubated for 120
min with substrate analogue to examine the level of protection on E2
and X. The reaction was terminated by addition of
2-mercaptoethanol and the products resolved on SDS-PAGE before
 processing for fluorography. The results of—the experiment are .
visualised in Figure 3.6. The substrate analogues listed in Table
3.1 were employed as possible substrates for pyruvate dehydrogenase ‘
(El) in the absence of CoASH. Several of the substrate analogues
were ineffective in activating the dithiolane ring, (lanes 4,5; 8,9;
10,11; 12,13; 25,26; 29, 30) i.e. j2> -bromopyruvate, glyoxalate
-fluoropyruvate, acetyl carnitine, cC-ketoglutarate and p ~
-hydroxphenylpyruvate. All revealed on simultaneous addition with 
14
[ C] NEM, little incorporation of radio label into E2 and X, 
results which are in agreement with the measurement of overall 
enzyme activity using these analogues as substrates. It is 
observed in (lanes 14,15; 16,17; 27,28), o^-ketoisovalerate, 
oxaloacetate, P<^-ketovalerate, reveal little increase in NEM
Figure 3.6 Substrate analogue protection of E2 and component X
from NEM incorporation
2mg of PDC was incubated in 20mM potassium phosphate pH7.4 
+
containing 2.5mM NAD , ImM MgCl^ on O.lmM TPP. NEM was added 
to a final concentration of 0.5mM. After 120 min excess NEM was 
removed by centrifugal gel filtration through a 1ml Sephadex G25 
column equilibrated in the buffer detailed above (Penefsky, 1977).
60pg of NEM modified PDC was aliquoted into 30 tubes and 
the tubes separated into 15 pairs. A different substrate was added 
to one of each pair of tubes to a final concentration of 4mM.
After incubation of substrate for 120 min at RT lyuCi of N-ethyl 
14
[2,3- C] maleimide was added to each of the 30 tubes followed 
immediately by the appropriate substrate to the second tube.
After 20 min the reaction was quenched by the addition of 
2-mercaptoethanol to 45mm. The samples were then added to Laemmli
sample buffer boiled briefly before resolving on a 1 0% 
SDS/polyacrylamide gel and processed for fluorography (Section 
2 .2.4.5).
• 1 2 5  
(lane M) I M Markers
r 14
(lanes 1, 18) Simultaneous addition of luCi N-ethyl [2,3- C]
maleimide and pyruvate (final concentration 4mM) to 30ug of PDC.
(lanes 2, 3) pyruvic acid, (lanes 4, 5); Bromopyruvate, (lanes 6 ,
7) oxamate, (lanes 8 , 9) glyoxglate, (lanes 10, 11)
fluoropyruvate, (lanes 12, 13) acetyl carnitine, (lane 14, 15)
Keto isovalerate, (lanes 16, 17) oxaloacetic acid, (lanes 19, 20)
Keto-yj -methylvalerate, (lanes 21, 22) cK, Keto isocaproic acid,
(lanes 23, 24) ketobutyrate, (lanes 25, 26) 2-ketoglutarate,
(lanes 27, 28) Ketovalerate, (lanes 29, 30) P  -hydroxyphenylpyruvic
acid, (lanes 31, 32) yS-hydroxypyruvic acid. The first lane of
each pair is the simultaneous addition of substrate analogue and
radiolabel. The second lane of each pair is the addition of
radiolabel after 120 min incubation in substrate analogue.
*Each substrate was prepared immediately before use.
r -^ 
(X 10 3)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1516 17
200 —
E1 (3
M 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
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incorporation with time in substrate indicating that this group of 
substrate analogues are transferred onto E2 and X but subsequently 
are unable to incorporate substrate induced modification of the 
second reduced sulphydryl group. This result suggests that these 
analogues are possible substrates for El but jr- subsequently may be 
trapped on E2 and component X. Of the remaining substrates 
analogues (lanes 6,7; 19,20; 21,22) o(.-oxamate,
cK-keto -methyl-n-valerate, CK-ketoisocaproate reveal increased 
NEM incorporation with time in substrate indicating that this group 
of substrate analogues are transferred very slowly onto E2 and X.
An interesting observation was that JS -hydroxypyruvic acid 
as well as the standard substrates pyruvate and -ketobutyrate 
were observed to protect E2 and component X after prolonged 
incubation in substrate. In all cases, both E2 and X were labelled 
in parallel with no preferential labelling of either E2 or X (lanes 
2,3; 23, 24; 31 and 32). Unloading of the substrate analogues in
the presence of CoASH was not attempted
14
3.2.6 N-ethyl [2,3- C] maleimide incorporation into NADH
reduced PDC incubated in various acyl CoAs
The rate limiting step in pyruvate dehydrogenase complex is 
the reductive acetylation of the core components of the complex 
(Cate and Roche, 1980). Failure to disrupt any interaction between 
E2 and X in the forward reaction may possibly be a result of E2 and
component X being equally effective as substrate for El. -T^ n-------
alternative approach which does not rely on El, is to incubate NADH 
reduced PDC with acetyl CoA this protects E2 and component X from 
NEM incorporation. Thds acetylation may be observed in the reverse 
reaction which depends on the specifpity of the E2 component. 
Therefore it may be possible to preferentially label E2 or component 
X with a suitable CoASH derivative.
Figure 3.7 N-ethyl [2,3- C] maleimide incorporation into 
NADH reduced PDC 
250 i^g of PDC was made to 100ji,l in f^HPO^ buffer 
pH7.0. NADH was added to a final concentration of 0.5mM. After
lOmin^to 30ug of NADH reduced PDC^the appropriate acyl CoA 
derivative was added to a final concentration of 0.4mM. After a 
further 20 min l^ lCi of NEM was added to each tube. The reaction 
was stopped by the addition of 2-mercaptoethanol to a final 
concentration of 45mM.
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(M) I Marker, (lane 1) malonyl CoA, (lane 2) acetyl CoA, (lane 
3) Succinyl CoA, (lane 5) acetoacetyl CoA, (lane 6) S-palmitoyl CoA, 
(lane 7) NADH reduced PDC.
M f -3 ( x 10 3)
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A limited number of CoASH derivatives were employed in this 
study due to expense and availability. The acyl CoA derivatives
were incubated in NADH reduced PDC for 20 min before the addition of 
14
[ C] NEM.
The reaction was stopped on the addition of 
2-mercaptoethanol and the samples were added to Laemmli sample 
buffer before resolving by SDS-PAGE and processing for fluorography 
(Section 2.2.4f).
As expected (lane 2) acetyl groups protect the complex from 
NEM incorporation (Fig. 3.7). Malonyl and succinyl CoA (lanes I 
and 3) revealed little protection of E2 and X indicating that these 
groups were probably not transferred onto E2 and X (lanes I and 3 
!). Acetoacetyl CoA and S-palmitoyl CoA (lanes 5 and 6 ) offered 
partial protection of E2 and X. The results obtained from 
acetoacetyl CoA and s-palmitoyl CoA need to be treated with 
caution. Reduced labelling of the El oC subunit in both cases is 
observed and this may be a consequence of variable loading of the 
gel sample.
3.3 Discussion
In this chapter we have shown that in the presence of
CoASH, component X is involved in acetyl group transfer reactions
during the normal catalytic cycle. If in the absence of CoASH the 
14
[ C 3 acetylation of component X was a side reaction promoted by
14 ,conditions required to trap [ CJ acetyl groups as acetyl
14
dihydrolipoamide, incorporation of [ C] acetyl groups into 
component X would not be expected to occur during normal turnover of 
the enzyme.
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As normal turnover number of PDC is approximately 1800 per 
s, the normal loading occurred* in the millisecond time scale.
Although we were successful in reducing the turnover of
pyruvate dehydrogenase complex by low temperature labelling we were
unable to observe preferential loading of E2 or component X under
these conditions. The rate limiting step in pyruvate dehydrogenase
complex is the reductive acetylation of E2 and component X by El
(Cate and Roche, 1980) and from the data in Figure 3.3 E2 and
component X undergo acetylation almost immediately under these
conditions. It has been demonstrated that purified El from bovine
14
kidney and heart catalysed the incorporation of C-labelled
acetyl groups into isolated E2 component (Linn ejt al., 1972;
Barrera et al., 1972). Similar results were obtained with isolated
lipoyl domains (Bliele et al., 1981). Recently Perham
demonstrated that El of PDC in EL_ coli can incorporate 
14C-labelled acetyl groups, although poorly, into synthetic lipoyl 
peptides of E2 and into free lipoate and has also demonstrated that 
El will label free E2 domains rapidly. It is therefore unlikely 
considering the ability of El to reductively acetylate such poor 
substrates of E2 that slowing the turnover of the intact enzyme 
would disrupt sufficiently the transfer of acetyl group from El to 
E2 and component X. For transfer of acetyl groups between E2 and 
component X to be identified the reductive acetylation of E2 and
component X would need to be disrupted in such a way that it was no
longer the rate limiting step. (Perham and Packman, 1989)
An interesting observation is, in the presence of CoASH, 
ketobutyrate could act as a substrate for pyruvate dehydrogenase 
activity. Investigation of the properties of o(^ ketobutyrate
revealed no contaminating pyruvate. It was also recognised that on
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prolonged incubation of o< ketobutyrate in enzyme complex resulted 
in the protection of lipoic acid residues on E2 and component X from 
NEM incorporation. A similar result was observed with 
hydroxypyruvate. This phenomenonyfirst recognised after prolonged
incubation with acetylating.substrate^was thought to produce
6 8 , .  6 8  
(diacetyl) lipoyl groups, The formation of S S
13(diacetyl) lipoamide has been detected previously by C-NMR 
(O'Connor et al., 1982). The structure of cK ketobutyrate is 
analogous to pyruvate differing in length by one carbon unit, the 
close structural similarity to pyruvate is the probable cause of 
ketobutyrate effectiveness as a substrate for overall enzyme 
activity.
Rigorous kinetic analysis on the types of inhibition of 
complex activity was not attempted. However, it has been reported
that modification of the methyl group in pyruvate produces compounds
that behave initially as strong competitive inhibitors of pyruvate 
dehydrogenase complex of E. coli. (Bisswanger, 1981).
Bromopyruvate, fluoropyruvate, hydroxypyruvate and 
hydroxyphenylpyruvate were found to be ineffective as substrates 
although incubation of these substrate analogues with pyruvate 
resulted in a slow inactivation of the complex. The mode of action
of these substrate analogues on enzyme activity in EL_ coli is known
to be complex (Lowe and Perham, 1984). Using bromopyruvate as an 
example they demonstrated that it was an active site inhibitor of 
free El component and, in the presence of TPP; the substrate analogue 
acts as a competitive inhibitor with pyruvate. It was also 
observed that El catalysed the decomposition of bromopyruvate 
rendering itself inactive. Bromopyruvate is also known to 
inactivate the intact complex in a TPP dependent process probably by 
reductively bromoacetylating the lipoic acid residues in the lipoate 
acetyltransferase.
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Enzyme incubated in substrate analogue and pyruvate results
in a slow inactivation of the complex. This is probably due to the
+
presence of TPP in the NAD reduction assay. With bromopyruvate, 
fluoropyruvate "and hydroxyphenylpyruvate,the slow inactivation of 
the complex was probably related to a substrate analogue event on El 
or TPP as no incorporation of labelled NEM is observed on E2 and 
component X. The inactivation of the complex with hydroxypyruvate 
was a result of lipoic acid residues on the lipoate 
acetyltransferase becoming reductively hydroxyacetylated as 
demonstrated by protection from NEM incorporation.
Observation of the remaining substrate analogues reveals 
greater incorporation of labelled NEM into E2 and X after prolonged 
incubation in substrate. As no overall enzyme activity or 
inactivation in the presence of pyruvate was recorded the substrate 
analogues are obviously poor substrates loading onto E2 and X slowly 
before becoming trapped.
Using the reverse reaction which utilises E2 rather than 
El, with a limited set of acyl CoA derivatives, no preferential 
labelling of E2 or component X was observed.
The activation of PDC kinase activity by a variety of CoA 
esters has been reported (Rahmatullah and Roche, 1985). Activation 
of the kinase occurs as a result of aceylation of specific sites on 
E2 and X. Several short chain CoA esters enhanced kinase activity 
including malonyl CoA, acetoacetyl CoA and propionyl CoA with 
methylmalonyl-CoA and butyryl-CoA inhibiting kinase activity. These 
results are in general agreement with the reductive acetylation of 
E2 observed with 0<. ketobutyrate (propionyl CoA in the reverse 
reaction) and acetoacetyl CoA loading onto E2 and X observed in our 
study. Only the lack of loading utilising malonyl CoA is in 
disagreement with the findings of Rahmatullah and Roche (1985).
CHAPTER FOUR
SELECTIVE PROTEOLYSIS OF MAMMALIAN PYRUVATE DEHYDROGENASE COMPLEX
Part A : Effects of Trypsin Treatment
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4. Selective proteolysis of mammalian pyruvate dehydrogenase
complex - Part A
4.1 Introduction
Selective proteolysis of oligomeric enzymes or multienzyme
complexes in which specific degradation of proteolytically-sensitive 
subunits can be achieved has proved a valuable approach in elucidating 
structural, organisational and functional relationships in a variety of 
complexes e.g. arom complex, PDC kinase and E2 core assembly (Coggins 
et al., 1985; Stepp et al., 1983; Kresze and Steber, 1979).
Previous studies have indicated that mammalian PDC contains an 
oligomeric core structure of defined geometry, consisting of the 
dihydrolipoamide acetyltransferase (E2) to which are bound 20-30 copies 
of pyruvate dehydrogenase (El) and 6 copies of dihydrolipoamide 
dehydrogenase component(E3). The oligomeric E2 assembly of mammalian 
PDC has 60 E2 polypeptides arranged with 532 (icosahedral) symmetry.
The appearance of mammalian PDC-E2 under an electron microscope is that 
of a pentagonal dodecahedron (Reed and Oliver, 1986). The OGDC and 
BCOADC have 24 copies of E2 arranged with 432 (octahedral) symmetry.
The acetyltransferase of the different complexes consists of 
several functional domains (Perham, 1979; Bliele e_t al., 1979, 1981; 
Kresze et al., 1980; Hu et al., 1986). Studies using limited 
proteolysis have shown that E2 consists of an inner domain which, in 
addition to containing the active site, interacts with the other E2 
polypeptides, thereby maintaining the integrity of the central core 
assembly. It is also responsible for binding the El component of the 
complexes. A second outer domain containing the lipoic acid moieties 
interdigitates between the El and E3 components acting as a substrate 
for both these enzymes. The E3 component is apparently bound to a 
distinct conserved region of polypeptide on a folded domain between the 
lipoyl and the catalytic domains of E2.
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In the core assembly of mammalian PDC there is an 
additional polypeptide, component X which co-purifies with, and is
tightly-bound to, the assembled E2 core. One dimensional peptide 
14
maps of the C-labelled enzyme, cleaved with a variety of
specific and non specific proteases, indicates that the M 51000
r
polypeptide of mammalian PDC is not a fragment of the E2 subunit
M 74000 (De Marcucci et al., 1986). It has also been shown that 
r
each component X, M 51000 contains a single lipoyl moiety which
r
can be reductively acetylated (Hodgson et al., 1988).
Proteolysis of PDC from bovine kidney with papain or a
leupeptin sensitive inactivase obtained from rat liver lysosomes,
results in the rapid loss of complex activity (Kresze and Steber,
1979). However, none of the constituent activities of the complex
is destroyed during inactivation of the overall reaction. It has
been demonstrated that treatment of the complex with inactivase
promotes the dissociation of the complex into its individual enzymes
which, though being enzymatically active when assayed separately,
are unable to catalyse the co-ordinated sequence of reactions
required for pyruvate oxidation. The dissociation occurs as a
consequence of limited proteolysis of the lipoate acetyltransferase
core with the appearance of two fragments of M 29000 and M
r r
26000 (Kresze and Steber, 1979). Limited proteolysis of the 
complex by papain results in a similar inactivation of the complex 
activity. In both situations fragmented lipoate acetyltransferase 
retains its intrinsic acetyltransferase activity although it is 
unable to bind the other component enzymes.
Mammalian OGDC and BCOADC have a single lipoyl domain and 
although there is some evidence from early isotope dilution studies 
suggesting that mammalian PDC also has a single lipoate residue per 
E2 (Reed et al., 1980), a more recent report suggests that the E2
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polypeptide has two functional lipoate residues (Hodgson et al., 
1988). It appears, however, that the general organisation of 
mammalian E2 resembles that of the equivalent enzyme from PDC of E. 
coli which contains three highly conserved lipoyl domains, located 
in tandem repeat at the N-terminus of the polypeptide (Stephens et 
al., 1983b). The lipoylated region of each E2 chain is released 
from the PDC complex by limited tryptic cleavage at the flexible 
hinge regions, which are rich in alanine, proline and charged amino 
acids. These hinge regions connect the lipoyl segments to each 
other and to the inner catalytic E2 core and are associated with the 
conformational mobility expected of the lipoyl segments (Graham et 
al., 1986).
An interesting recent development is the observation that
limited proteolysis of the purified dihydrolipoyl acetyltransferase
core by protease argC selectively converts component X into an inner
domain fragment M 35500 and an outer lipoyl bearing fragment M 
r r
15500. The E2 subunit is converted more slowly into an inner
domain fragment M 31000 and an outer domain fragment M 49000 
r r
which have M values at least 3000 and 10000 larger, respectively 
r
than the corresponding E2 fragments generated by trypsin 
(Rahmatullah et al., 1989). Addition of E3 to the argC-treated 
core results in little re-association of dihydrolipoamide 
dehydrogenase (E3) and consequently little or no restoration of 
overall complex activity. Also, addition of E3 to the E2/X core 
prior to treatment with argC resulted in partial protection of 
component X and overall loss of approximately 50% of complex 
activity which closely paralleled the extent of proteolysis of 
protein X under these conditions (Gopalakrishnan et al., 1989).
From these observations, Gopalakrishnan and co-workers claim that 
the role of component X in mammalian PDC is to bind the E3 component 
to the core assembly (Gopalakrishnan et al., 1989).
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This chapter deals with a similar approach. E2 and X are 
known to be more proteolytically sensitive than the other major 
component enzymes, namely El and E3. Therefore the effects of 
selective proteolysis of the E2/X core of PDC with trypsin and of 
component X with protease argC are investigated in detail in order 
to gain a greater insight into the involvement of these subunits in 
the structural and catalytic properties of the complex.
4.1.1 Selective proteolysis of PDC with trypsin
To equate the appearance of proteolytic fragments of E2
and/or X with loss of PDC activity, samples were withdrawn at
14
different times from an incubation mixture containing [ C]
acetylated PDC and trypsin. The samples were added immediately to
soya bean trypsin inhibitor (SBTI), analysed by SDS-PAGE and
processed for fluorography (Section 2.2.4f). It is evident from
Figure 4.1A that the E2 polypeptide M 74000 and component X M
r r
51000 are rapidly degraded during incubation in trypsin. Three
major peptides are observed: a transient M 45000 and stable Mr
38000 and M 15000 species. (The origins of these peptides will 
r
be discussed in Chapter 5.)
No effect on either El or E3 subunits or the individual 
activities was observed, although on prolonged incubation in trypsin 
the ElcKsubunit is slowly degraded (data not shown).
In a parallel study, PDC was incubated with trypsin and at 
the times specified (Fig. 4.IB), samples were removed and assayed 
immediately as described in Section 2.2.11a. Rapid inactivation of 
the complex was observed. After 10 min incubation in trypsin, 
enzyme activity had been reduced to approx. 2 0 % of control values 
and after 40 min no enzyme activity could be detected. PDC was 
also incubated in SBTI prior to the addition of trypsin. No loss 
of enzyme activity was detected throughout the time course.
14
Figure 4.1A Selective release of [ C] acetylated lipoyl domains
from E2 and X polypeptides of native bovine heart PDC
Purified bovine heart PDC (500/ig) was preincubated for 15 
14
min with [2- C] pyruvate (0.2mM) in 20mM potassium phosphate
+
buffer pH7.5 containing ImM MgCl^, 0.2mM TPP and 2.5mM NAD
o
before treatment with 1% (w/w) trypsin at 25 C for the indicated 
times. Samples (30/ig) were removed, immediately treated with 
Laemmli sample buffer and subjected to fluorography following 
resolution on a 12.5% (w/v) SDS/polyacrylamide gel(Section 2.2.4f).
Figure 4.IB Effect of trypsin on overall PDC activity
PDC (100/ig) was incubated in 20mM potassium phosphate
+
buffer pH7.5 containing ImM MgCl^, 0.2mM TPP and 2.5mM NAD at 
o
25 C. Digestion was initiated by the addition of 1% (w/w) 
trypsin. At the times indicated samples (5/ig) were removed and 
assayed for PDC activity (— — □ —  -). Similarly, PDC (lOOug) was
incubated with 2% (w/v) SBTI prior to incubation with 1% (w/v)
trypsin (--------- ). Results are the mean of two determinations
differing by less than 10%.
IN
IT
IA
L 
PD
C 
AC
TI
VI
TY
A
Mr_T
( x 10 5 )
—  H 5  
 38 
 15
Time of trypsin treatment (min)
B
120 n
100
80 -
60 -
40 -
20 -
706030 40 50201 00
0 5 10 25 20 25 30 45 60
TIME IN TRYPSIN (MIN)
99
4.1.2 The effect of tryptic digestion on the acetylation of PDC 
In PDC S-acetylation in the presence of pyruvate generates a
free thiol on the adjacent sulphur atom in the dithiolane ring which
may be specifically modified by NEM (Fig. 3.1). In the absence of
NEM, a slow second phase of acetylation protects against NEM
modification. The best interpretation of this result is that the
diacetylation reaction protects against NEM modification (Fig. 3.1).
To investigate if the peptides generated by tryptic digestion
of PDC can still be acetylated by El and are still capable of
14
diacetylation, the incorporation of [ C] pyruvate into intact PDC
and tryptic peptides was measured. Figure 4.2 compares the extent of 
14
[ C] acetyl group incorporation into intact E2/X and tryptic 
peptides derived from them in the presence and absence of NEM. It is
apparent that NEM pretreatment of the intact complex diminishes the
14
incorporation from [2- C] pyruvate by approximately 50%. However}
in the case of trypsin treated PDC, acetyl group incorporation was
also reduced by approximately 50%. In this case, the presence of NEM
had little effect on the profile of incorporation of acetyl groups
into tryptic peptides.
In the presence of NEM only half of the sites are apparently
available for acetylation; therefore the most probable interpretation
of the result (Fig. 4.2) is that release of E2/X peptides from the
6 8
core leads to loss of the ability to form the S S (diacetyl) 
lipoamide intermediate.
4.1.3 Fluorographic detection of E2/X derived tryptic peptides
14 ,
after incubation with [ CJ pyruvate
It is possible that after digestion with trypsin certain of
the lipoyl peptides generated from E2 and component X are not active
14
substrates for acetylation with [ C] pyrvuate and this results in 
the lower levels of incorporation observed with trypsin treated PDC
Figure 4.2 Time course of acetylation of native or trypsin 
treated PDC
Native PDC (200ug), incubated in the presence (— ---)
or absence (— O ) of NEM (0.5mM), or trypsin treated PDC,
incubated in the presence (— ® —  ) or absence (— O —  ) of NEM?was
14acetylated by the addition of [2- C] pyruvate (0.2mM). On the 
14
addition of (2- C) pyruvate (0.2mM), aliquots (lOul) were 
withdrawn at the indicated times and spotted onto Whatman No. 1 
filter paper discs to estimate the radioactivity incorporated into 
proteins (section 2.2.3a). Results are the mean of two 
determinations differing by less than 10%.
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Figure 4.3 Fluorographic detection of E2/X derived tryptic peptide
Intact PDC (lOOyug) was incubated in 20mM potassium
+
phosphate buffer containing ImM MgCl^, 0.2mM TPP and 2.5mM NAD
14
for 30 min in the presence of [2- C] pyruvate. After 30 min 
14
half of the [ C] acetylated PDC sample was withdrawn and 
incubated in trypsin for 30 min, before the addition of 2% (w/v) 
SBTI to terminate the reaction.
Similarly trypsin treated PDC (50jug) was incubated with
14
[2- C] under the conditions detailed above. Samples were added 
to Laemmli sample buffer before resolution by SDS-PAGE and
processing for fluorography.
125 14 , .
Lane M, I Markers; lane 1, [ C] acetylated intact
14
PDC; lane 2, trypsin-treated, [ -C] acetylated PDC; lane 3
14
[ C] acetylated, trypsin-treated PDC.
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Fig. 4.2). In order to establish if released peptides could be 
acetylated, PDC was incubated with trypsin, after 30 min the reaction
was terminated by addition of SBTI and the trypsin treated sample was
14
incubated with [2- Cj pyruvate (lane 3). Similarly, PDC
14
preincubated in [2- C] pyruvate was treated with trypsin as above 
(lane 2). In Figure 4.3, a similar profile of radiolabelled peptides 
is observed for both sets of conditions i.e. the presence of the M
r
45000, M 38000 species. The M 15000 peptide is not detectable 
r r
on this occasion, but subsequent studies (see Fig. 4.4C) reveal that 
it is acetylated also.
14
4.1.4 Deacetylation of [2- C] pyruvate labelled intact and 
trypsin-treated PDC
Rapid deacetylation of both E2 and component X occurs on the
addition of CoASH, the products being acetyl CoA and NADH. PDC
modified by NEM is not deacetylated in the presence of CoASH, the
acetyl group remaining trapped on the dithiolane ring (Fig. 3.1). To 
14
establish if the C-labelled peptides generated from a tryptic
digest could be deacetylated on the addition of CoASH and in the
presence of NEM, PDC was incubated in trypsin to produce the
recognised tryptic peptides and the reaction stopped by addition of
SBTI. The digest was divided into two and one half incubated in
14
[2- C] pyruvate while the other was incubated in NEM prior to the 
addition of radiolabelled substrate. This procedure was repeated for
untreated PDC and NEM modified PDC and the extent of [ C] 
acetylation incorporated into protein determined (Fig. 4.4A) (Section .
2.2.3). After 30 min CoASH was added and again at the time points
14
specified the release of [ C] acetyl groups was monitored (Fig.
4.4B). At various times samples were also removed from each of the 
incubation mixtures, resolved by SDS-PAGE and processed for 
fluorography (Section 2.2.10f) (Fig. 4.4C).
14
Figure 4.4 Deacetylation of [2- C] pyruvate labelled intact PDC
and trypsin-treated PDC
Native PDC (400ug), incubated in the presence (-—-0— ’') or
absence (•— #*—*) of NEM (0.5mM), or trypsin treated PDC, incubated
in the presence (— — ) or absence (—— O' ^) of NEM was acetylated
14
by the addition of [2- C] pyruvate (0.2mM).
Duplicate aliquots (lO/il) were withdrawn at the times indicated and
spotted onto Whatman No. 1 filter paper discs (Fig. 4.4A).
After 30 min excess N-ethylmaleimide was removed from the
incubation mixtures by passing the samples through a Sephadex G25
column equilibrated in potassium phosphate buffer pH7.2.
CoASH (ImM) was added to the incubation mixture and at the
time indicated samples (lO/il) were withdrawn and treated as detailed
above (Fig. 4.4.B). The data points are the average of duplicate
determinations differing by less than 10%.
Samples (25^ ig) from each stage of the experiment detailed
above were withdrawn, mixed with Laemmli sample buffer and resolved
on a 10% (w/v) SDS/polyacrylamide gel and processed for fluorography
(Section 2.2.4f) (Fig. 4.4.C).
125 14
Lane M, I Markers; lanes 1, 2, [ C] acetylated PDC
14
in the absence and presence of CoASH; lanes 3,4 [ C] acetylated
PDC in the absence or presence of NEM; lanes 5,6 trypsin treated 
14
[ C] acetylated PDC in the absence or presence of CoASH; lane 7 
14
[ C] acetylated trypsin treated PDC incubated in NEM; lane 8 , as 
lane 7 plus the addition of CoASH.
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These results confirm that, in comparison to untreated PDC,
the amount of radiolabel incorporated into the tryptic peptides is
equivalent to that observed for NEM modified PDC. This suggests
that the tryptic peptides are no longer able to incorporate a second
unit of acetylating substrate into the dithiolane ring which are
therefore not protected against NEM modification. On incubation in
14
CoASH, both untreated PDC and [ C] acetylated peptides are
rapidly deacetylated, as observed by the rapid decline in
acid-precipitable radiolabelled material (Fig. 4.4B). Both NEM
modified peptides and PDC remain acetylated on incubation in CoASH
(Fig. 4.4). Confirmation of the results can be observed directly
14
in Figure 4.4C. A reduced level of incorporation of C-label is 
observed in E2 and X and tryptic peptides after incubation in CoASH 
(Fig. 4.4C). In this case the rapid deacetylation of the M
r
15,000 peptide can also be readily observed.
4.1.5 Association of tryptic peptides with E2 core assembly
Since it is now evident that the lipoyl peptides derived 
from E2 and X are capable of participation in the overall catalytic 
cycle of the complex, the association of the peptides with the E2 
core is investigated.
14
After trypsin treatment, C-acetylated PDC high M
core structure are pelleted by ultracentrifugation so that both
14
pellet and supernatant fractions can be investigated for C
14
labelled E2/X peptides as shown in Figure 4.5. In controls [ C] 
acetylated E2/X are observed only in the pellet fraction. In
contrast the major tryptic cleavage products M 38000 and M
r r
15500 are visualised exclusively in the supernatant fractions 
(Fig. 4.5). Therefore the peptides generated from tryptic 
digestion of PDC are not tightly-associated with the core.
Figure 4.5 Association of tryptic peptides with E2 core assembly
PDC (500pg) was incubated in the presence or absence of NEM
14
prior to the addition of [2- C] pyruvate. After 30 min, half of 
the intact PDC and NEM treated PDC was removed and incubated with 
trypsin for 45 min. The digestion was stopped by the addition of 
2% (w/v) SBTI.
Intact PDC and the products of proteolysis were subjected
to ultracentrifugation (150000 x g for 150 min) in a Beckmann Ti70
rotor. The supernatant fractions were precipitated by addition of
10% (w/v) TCA and the resultant pellet solubilised in Laemmli sample
buffer (Section 2.2.4a). The pellets from the ultracentrifuge spin
were solubilised in 20mM potassium phosphate buffer pH7.4 containing
+
ImM MgCl2, 0.2mM TPP and 2.5mM NAD . Samples were resolved on
a 10% (w/v) SDS/polyacrylamide gel and processed for fluorography. 
125
Lane M, I Markers; lane 1,2, supernatant fractions 
from intact PDC and NEM treated PDC respectively; lane 3,4, pellet 
fraction from intact PDC and NEM treated PDC; lane 5,6, supernatant 
fraction from trypsin treated PDC in the absence or presence of 
NEM; lane 7,8, pellet fraction from trypsin treated PDC in the 
absence or presence of NEM respectively.
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Figure 4.6 Incorporation of N-ethyl [2,3- C] maleimide into
tryptic peptides of PDC
Native PDC (250jug);? in 20mM phosphate buffer pH7.4
+
containing ImM MgCl^/ 0.2mM TPP and 2.5mM NAD was incubated in
1% (w/v) trypsin. At the times indicated aliquots OO^ug) were
removed and added to 2% (w/v) soya bean trypsin inhibitor. The
samples were reduced by addition of NADH (0.5mM) and after 10 min
the samples were acetylated in the presence of 0.5mM acetyl CoA.
After a further 15 min, the samples were radiolabelled for 10 min on
14
the addition of N,-ethyl[2,3- C] maleimide and excess N-ethyl 
maleimide was reacted with 45mM 2-mercaptonethanol. Laemmli sample 
buffer was added to the samples which were then resolved on a 10% 
(w/v) SDS/polyacrylamide gel and processed for fluorography (Section 
2.2.4f).
As control, lane A, native PDC (30/ig) was incubated in
14
[ C] NEM, lane B, incubated in NADH prior to the addition of 
14
[ C] NEM; lane C, incubated in NADH prior to the simultaneous 
14
addition of [ C] NEM and acetyl CoA; lane D, and NADH reduced
PDC was incubated in acetyl CoA for 15 min prior to the addition of 
. 14 ,
[ C] NEM.
Time course: PDC treated with 1% (w/v) trypsin for 5, 10, 20, 40
min. Samples from the time course were processed as lane 4 and can 
be compared directly with laneD .
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4.1.6 Incorporation of N-ethyl [2/3- C] maleimide into tryptic 
peptides of PDC
In intact PDC the rate limiting step is the reductive
acetylation of E2 by El. An alternative procedure for loading onto
lipoyl groups using NADH and acetyl CoA involves the interaction of
E3 and acetyl group transfer onto E2 or X which is completely
independent of El.
Preincubation of PDC in NADH followed by acetyl CoA results
in a time dependent diminution of incorporation of radiolabelled NEM
into component X and E2. Similar to PDC preincubated in pyruvate,
PDC is protected from NEM modification (Cate et al., 1980).
To visualise the peptides generated from a tryptic digest,
samples were removed and reduced by NADH. Acetyl CoA was added
14
prior to the addition of [ C] NEM and the samples resolved by
SDS-PAGE. Proteolysis of the E2, X and the El <pCsubunit is
observed (Fig. 4.6).
After 20 min the normal tryptic cleavage pattern is
observed with the formation of two peptides M 45000 on M 38000
r r
which are not protected by acetyl groups from NEM incorporation. 
Therefore with the formation of peptides from E2 and component X,
PDC loses the ability to diacetylate the lipoic acid sites on E2 and 
consequently, on prolonged incubation in acetylating substrate, to 
protect from NEM modification.
Discussion
The loss of enzyme activity on incubation with trypsin 
parallels the release of lipoyl peptides from the E2 core. This is 
in contrast to the findings of Packman and Perham (1989), where 
similar treatment of PDC from E. coli released one or two lipoyl
I
domains (of three) per E2 chain without affecting catalytic
103
activity. Recent evidence from our laboratory confirms the finding 
of Kresze, 1980, that, on incubation with trypsin, El and E3 are 
released from the core. Cleavage of the lipoyl peptides apparently
occurs within the domains responsible for binding El and E3 and, thus
kj
%■
leads to dissociation of the complex. However, prolonged 
incubation with trypsin can destroy El activity (Kresze et al.,
1980).
A consequence of the removal of the lipoyl peptides from
E2/X was the inability of the enzyme to protect against NEM
modification. This observation is best explained by the loss of the
diacetylation reaction. E2 and X peptides generated from trypsin
14
treatment are observed to incorporate greater levels of [ C] NEM
than similarly protected intact E2 and X which indicates lack of
protection on the lipoyl peptides. It seems likely, as the
peptides are no longer associated with the core, the interaction
between E2/X peptides or/between the peptides and the high M core
r
assembly has been reduced sufficiently to prevent diacetylation of 
the peptides. Although the peptides can participate in the overall 
catalytic cycle of the enzyme, their release from the core 
effectively decreases the effective concentration of the peptides by 
several orders of magnitude. A single turnover of the enzyme now 
occurs so slowly that enzyme activity cannot be recorded.
As preferential digestion of component X was not observed 
after trypsin treatment, possible functions of component X including 
its participation in diacetylation could not be elucidated in these 
studies.
SELECTIVE PROTEOLYSIS OF MAMMALIAN PYRUVATE DEHYDROGENASE COMPLEX
Part B : Effects of ArgC Treatment
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4.2 Part B
During the course of this work Roche and co-workers
reported their findings on limited proteolysis of PDC with protease
argC (Rahmatullah et al., 1989;o Gopalakrishnan _et^ al., 1989; 
Powers-Greenwood et al., 1989). Their main conclusions are as 
follows:
a) With isolated E2/X core assembly, component X is 
preferentially degraded by argC
b) The E3 component fails to bind effectively to argC treated 
E2 core
c) The E3 component protects component X from proteolysis
d) A marked reduction of PDC activity is observed on re­
addition of the El and E3 components to argC treated core
in comparison to untreated controls.
As detailed in the previous section, similar experiments 
using trypsin were being carried out, and as Roche and co-workers 
reported that argC exhibited a high specificity for component X, it 
was decided to investigate further the claims of this group using 
protease argC and to elucidate a possible role for component X in 
the complex.
14
4.2.1 Limited proteolysis of [ C] acetylated PDC by argC and
its effect on overall complex activity
As with trypsin, it was initially decided to determine the
effect of protease argC on structure, organisation and catalytic
function of PDC. Samples were withdrawn from an incubation mixture
14
containing PDC preincubated with [2- C] pyruvate prior to 
degradation with protease argC. Figure 4.7A illustrates the slow 
degradation of component X while E2 remains virtually intact.
In a parallel experiment, PDC was incubated with protease 
argC, samples withdrawn at the times indicated (Fig. 4.7B) and
1 4Figure 4.7A Limited proteolysis of [ C] acetylated PDC with argC
Purified bovine heart PDC (20(tyig) was incubated with
14
[2- C] pyruvate (0.2mM) in 20mM potassium phosphate buffer
+
pH7.4 containing ImM MgCl^ 0.2mM TPP, 2.5mM NAD . After 30 min 
3% (w/v) argC was added and at the times indicated samples (30^) 
were removed, added to Laemmli sample buffer and subjected to 
fluorography following resolution on a 10% (w/v) SDS/polyacrylamide 
gel.
Figure 4.7B Effect of protease argC on overall complex activity
PDC (lOOug) was incubated with 3% (w/v) argC in 20mM
potassium phosphate buffer containing ImM MgCl^, 0.2mM TPP and 2.5 
+
NAD . At the times indicated samples (5pg) were removed and 
assayed immediately for PDC activity. The data observed in the 
figure are the average of two determinations of activity differing by 
less than 10%.
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Figure 4.7C Extent of degradation of E2 and component X after
limited proteolysis with argC
14
As detailed previoulsy [ C] acetylatecif PDC ( 500;ig) in
20mM potassium phosphate buffer pH7.4 containing ImM MgCl^, 0.2mM 
+
TPP and 2.5mM NAD , in 3% (w/v) was incubated in argC and at the
times indicated duplicate samples (30^ ig) were removed, added to
Laemmli sample buffer and resolved on a 12.5% (w/v)
SDS/polyacrylamide gel. The proteins were stained with Coomassie
blue before the gel was dried. The radiolabelled bands
corresponding to E2 and X were excised from the gel and counted on a
14
liquid scintillation counter (Section 2.2.3b). [ C] acetylated
14
E2 ( Q  ) [ C] acetylated protein X ( B  )
Similarly PDC (50^g) was incubated with 3% (w/v) argC and
at the indicated times samples (5jig) were removed and added
immediately to Laemmli sample buffer. Samples (lpg) were resolved
on an 12.5% (w/v) SDS polyacrylamide gel and subjected to
immunoblotting analysis with anti-E2 and anti-X sera. The bands
corresponding to E2 and X were cut from the nitrocellulose and added
125
to 5ml liquid scintillant before counting. I-labelled E2
125
(--- ^  ) I-labelled protein X (---0 ----).
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assayed for PDC activity (Section 2.2.7a). A small 10-25%
decrease in complex activity is observed after 60 min incubation
with protease argC.
The extent of degradation of E2 and X was determined by two
separate approaches:- (a) the determination of radioactivity in gel
slices from Figure 4.7A was performed as described in Section 2.2.3b
and (b) the polypeptides from a similar incubation of
non-radiolabelled PDC with argC were electrophoretically transferred
onto nitrocellulose and challenged with the appropriate antisera 
125
followed by I-labelled protein A. The polypeptides, which 
were located by autoradiography, were cut from the nitrocellulose 
for estimation of radioactivity by scintillation counting. The 
results indicate that component X is slowly degraded,to 
approximately 10% of its original value with the PDC activity 
remaining at approximately 80% of its original value. The slight 
inactivation (10-20%) of PDC closely parallels the minor degradation 
of E2 detected under these conditions.
4.2.2 Immunological detection of proteolytic fragments from E2
and component X on incubation with protease argC 
14
Digestion of [ C ] acetylated PDC with argC generates
three major lipoyl peptides which can be detected by fluorography
(Fig. 4.8A). Identification of those peptides derived from E2 and
X respectively was achieved by immunoblotting with subunit specific
antisera with samples obtained from a parallel digestion of
non-radioactive labelled PDC (Fig. 4.8B and C). The pattern of E2
and X cleavage indicates that component X is preferentially digested
with protease argC although limited proteolysis of E2 is also
apparent. A single immunoreactive peptide from component X
15500 is observed while two peptides are generated from E2 with
M values 45000 and 35000. 
r
Figure 4.8 Immunological detection of proteolytic fragments from
E2 and component X on incubation with protease argC
14
Native PDC (lOO^g) was incubated with [2- C] pyruvate 
(0.2mM) prior to the addition of 3% (w/v) argC. At the times 
indicated, samples (30ug) were removed and added to Laemmli sample 
buffer and subjected to fluorography after resolution qn a 1 2 .5% 
SDS/polyacrylamide gel (Panel A).
Similarly native PDC (50^ ig) was incubated with 3% (w/v) 
argC and at the times indicated samples (5jug) removed and added 
directly to Laemmli sample buffer. The digested proteins (lug) 
were resolved on a 12.5% (w/v) SDS/polyacrylamide gel. Gels were 
used for immunoblotting analysis (Section 2.2.9a) with antibody 
raised against E2 subunit (Panel B) and protein X (Panel C). PDC 
was also incubated in the absence of argC for 60 min (lane 60') as a 
control.
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4.2.3 The effect of high salt concentration on PDC activity
Treatment of intact PDC with argC results in preferential 
(approx. 90%) removal of the lipoyl domains of component X with 
minimal release (10-20%) of lipoyl peptides derived from E2. 
Gopalakrishnan et al. (1989) reported that removal of E3 from the 
core assembly is necessary for preferential digestion of component X 
by protease argC. These conclusions were based on examination of 
silver stained gels and no effort was made to quantitate the extent 
of degradation of E2 in relation to component X. This group also 
observed that re-addition of E3 and El to argC digested core 
assembly failed to restore overall enzyme activity. They do not 
discuss the possibility of limited proteolysis of the other subunits 
or detail the percentage recovery of activity on reconstitution of 
the El and E3 subunits with the intact E2 core assembly.
An alternative method of releasing E3 and El from the core 
assembly without the necessity of preparing E2/X core and employing 
reconstitution analysis is to incubate PDC in 0.25M MgCl^ or 1M 
NaCl (Kresze and Steber, 1979).
The effects of high salt concentrations on PDC structure
and activity were therefore examined. PDC preincubated in 0.25M
MgCl^ or 1M NaCl was resolved on a gel filtration column and the
products observed, as shown in Figure 4.9A. On incubation in high
salt El and E3 are readily dissociated from the high M core
r
structure.
Surprisingly, however, the data in Figure 4.9B also 
indicate that treatment of the enzyme with 0.25M MgCl or 1M NaCl 
does not result in rapid inactivation of the complex.
Although high salt treatment of PDC appears to lower the
affinity of El and E3 for the core (Fig. 4.9A) resulting in
separation during gel filtration, interactions between El, E3 and
the core assembly must be maintained to a sufficient degree to 
promote normal complex activity.
Figure 4.9A SDS-PAGE analysis of constituent enzymes of PDC, after
treatment in high salt followed by resolution on a gel 
filtration column
Native PDC (250ug) was incubated in 20mM potassium 
phosphate buffer, pH7.4 containing 2.5mM NAD , ImM M g C ^  0.2mM 
TPP. Solid (0*25 ,-M) was added and the sample incubated for
30 min at room temperature.
The PDC sample was resolved on a Superose 12 column (10 x 
300mm) and peak fractions were precipitated on the addition of 10% 
(w/v) TCA.. The resultant pellets were solubilised in Laemmli 
sample buffer, resolved on 12.5% SDS/polyacrylamide gel and stained 
with Coomassie blue.
Lane M, M standards; lane 1, untreated PDC (lOug) 
r
resolved by gel filtration; lane 2 , void volume peak from high salt 
treated PDC (lOug) resolved by gel filtration; lane 3, 2nd peak 
obtained from gel filtration column (lOug) after high salt treatment.
Figure 4.9B The effect of high salt concentration on PDC activity
PDC (lOOug) was incubated in the presence ( O  ) or
absence (---- •---- ) of solid MgCl^ (0.25M) or NaCl and incubated
in the buffer detailed above. At the time points indicated, 
samples (5ug) were removed and assayed for PDC activity. Results 
are the average of duplicate determinations differing less than 10%.
A similar result was obtained with PDC (lOOug) incubated 
in 1M NaCl. Data not shown.
% 
IN
IT
IA
L 
PD
C 
AC
TI
VI
TY
A
M f - 3  (x 10
67 —  
4 3  —
30 —
M 1
—  E2
—  E3
^  X
—  Eia
—  E13
B
120 H
100
— a- —
80 -
60 -
40
20
1 0080604020
TIME COURSE OF HIGH SALT TREATMENT (MIN)
Figure 4.10 The effect of high salt and argC on PDC activity
Native PDC (lOOug) was incubated in 20mM potassium
+
phosphate buffer, pH7.4 containing 2.5mM NAD , ImM MgC^ and 
0.2mM TPP. On the addition of 3% (w/v) argC samples (5ug) were 
removed and assayed immediately for PDC activity. At the times 
indicated by the arrow MgCl^ was added to a final concentration of 
0.25M and samples (5ug) removed at the times indicated and assayed 
for activity ( d  ).
As controls PDC was incubated in 3% (w/v) argC ( ft-----)
and 0.25M MgCl (-----O ) respectively for the duration of the
experiment and at the times indicated samples (5ug) removed and 
assayed.
PDC (lOOpg) incubated in the buffer detailed above before 
the addition of solid 0.25M MgCl^. After 60 min 3% (w/v) argC 
was added and at the indicated times samples assayed for activity
(.— a ----- ). Each value represents the means of two separate
determinations differing by less than +_ 1 0%.
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4.2.4 The effect of high salt and argC on PDC activity
The surprising observation that MgCl^ or NaCl, although 
known to dissociate PDC complex into its constituent enzymes, had 
little effect on enzyme activity was investigated further.
As component X is preferentially degraded by argC, it was 
decided to examine the effect of high salt on argC-treated 
complex. PDC was incubated with argC under conditions which were 
known to digest approx. 90% of component X. This was achieved by 
monitoring overall complex activity until it had reached 80-90% of 
its original value (Fig. 4.10). On the addition of MgCl^ samples 
were withdrawn and assayed for PDC activity (Fig. 4.10).
Similarly, PDC preincubated in 0.25M MgCl^ or 1M NaCl was treated 
with protease argC and again samples were removed and assayed at 
various time intervals thereafter.
On the addition of high salt to argC treated complex, a 
rapid decline in PDC activity was observed. This result was also 
seen on addition of argC to high salt treated complex. Thus a 
combination of high salt and argC treatment leads to rapid and 
complete inactivation of the complex. In contrast, PDC activity is 
not markedly affected by individual treatment with either high salt 
or argC as shown in control incubations.
4.2.5 Relationship between decline in PDC activity and extent of 
degradation of component X in PDC treated with argC in the 
presence or absence of high salt
In an experiment designed to examine the relationship
between the activity of the complex and the levels of proteolysis
undergone by component X in the absence or presence of high salt,
14samples were removed from incubation mixtures containing [ C]
Figure 4.11 Relationship between enzymatic activity of PDC and
degradation of component X in PDC treated with argC in 
the presence or absence of high salt
14
Native PDC (200pg) was incubated with [2- C] pyruvate in
20mM potassium phosphate buffer, pH7.4 containing 0.25M MgCl^,
2.5mM NAD+ and 0.2mM TPP. On the addition of 3% (w/v), argC in
the presence ( C> ) or absence (*----^ --- ) of MgCl^ (0.25M),
samplfes (30^ ig) were removed at the indicated times and added
immediately to Laemmli sample buffer resolved in a 10% (w/v)
SDS/polyacrylamide gel and processed for fluorography (Panel A).
E2 and X bands were then densiometrically scanned. The photograph
of proteolysis of component X in the absence of MgCl^ is not shown.
In a parallel experiment PDC (lOOpg) was incubated in 20mM
potassium phosphate buffer, pH7.4 containing 0.25M MgCl^, 2.5mM 
+
NAD and 0.2mM TPP. On addition of 3% (w/v) argC samples (5/ig) 
were removed and immediately assayed for PDC activity (Panel B).
( Q  ) As a control untreated PDC was assayed for the 
duration of the time course ( O  ).
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acetylated PDC and protease argC, in the absence or presence of high 
salt, and added to Laemmli sample buffer (Figs. 4.11A; 4.7). In a
parallel experiment the inactivation of PDC with argC and high salt 
was monitored (Fig. 4.11B) where rapid and cpmplete inactivation of 
the complex is observed after 45 min.
The rates of degradation of component X by argC in the presence or 
absence of MgCl2 proceeds at similar rates to each other.
However, the rate of degradation of protein X is more rapid than the 
inactivation of the complex when incubated in argC.and high salt 
concentrations. As high salt treatment of argC treated complex 
does not result in a more rapid degradation of protein X, 
inactivation of the complex under these conditions may be a result 
of lowering the affinity of El and E3 for the core assembly.
4.2.6 Release of E3 from E2/X core on incubation with argC
It has been observed that limited proteolysis of E2/X core 
by protease argC preferentially digested component X and as a 
consequence of the removal of the lipoyl domains of component X the 
E3 component failed to bind effectively to argC-treated E2 core 
(Gopalakrishnan et al., 1989).
In an attempt to study the release of E3 from argC treated 
PDC, intact complex was incubated in argC prior to resolution on a 
gel filtration column. Untreated PDC and high salt/argC-treated 
PDC samples were resolved in a similar manner. Samples were 
removed from the column fractions, assayed for complex activity 
(Fig.4.12C') and the remainder of the column fractions were analysed 
by SDS-PAGE. The finding that argC promotes release of E3 from the 
complex was confirmed both by Coomassie staining (Fig. 4.12A') and 
immunoblotting analysis (Fig. 4.12B') using anti-E3 specific 
serum. The separation of E3 from E2/X core assembly results in
Figure 4.12 Release of E3 from E2/X core on incubation with argC
Native PDC (200jug) was incubated in 20mM potassium 
phosphate buffer, pH7.4 containing ImM MgCl^, 2.5mM TPP and 0.2mM 
TPP (A) plus 3% (w/v) argC (B) or plus 0.25M MgCl^ and 3% (w/v) 
argC (C) and after 60 min each sample was passed through a 5ml 
Sepharose CL 4B column equilibrated in 20mM potassium phosphate 
buffer, pH7.4. 1ml fractions were collected and samples (lOOul) 
removed and assayed for PDC activity (C'). The remaining samples
(900ul) were precipitated on the addition of TCA [10% (w/v)]. The
resultant pellets were solubilised in Laemmli sample buffer and 
resolved on a 10% (w/v) SDS/polyacrylamide gel and either stained 
with Coomassie blue (Fig. 4.12A') or immediately subjected to
immunoblotting analysis with anti E3 serum (Fig. 4.12B').
Untreated PDC («— — o-— ) argC treated PDC (---• ---- ) and MgCl
and argC treated PDC ( O  ).
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a diminished yield of active complex compared to control enzyme.
As discussed previously argC preferentially degrades component X in 
intact PDC, indicating that the lowered affinity of E3 is probably 
facilitated by proteolysis of component X
No release of El oCor 3^ subunits from the core was 
observed. under these conditions. ,
4.2.7 Study of the integrity of the E2/X core assembly after
inactivation of the complex with argC and high salt
The rapid inactivation of PDC by a combination of high salt
and protease argC treatment may occur as a result of disruption of
the E2/X core assembly. Alternatively, as on incubation of PDC
with papain (Kresze and Steber, 1979), inactivation may occur as a
result of dissociation of the component enzymes, El and/or E3. The
release of El 0<, M 42000, El/2 M 36000 and E3 M 55000 from
r / r r
the intact core allows separation of the high intact core 
assembly, from the released polypeptides, by ultracentrifugation.
In an attempt to understand the inactivation of the complex 
on treatment with argC and high salt, PDC was incubated under the 
conditions described in Figure 4.13 and the E2/X core assembly 
pelleted by ultracentrifugation. Identification of the subunits 
was by immune replica analysis using subunit specific antisera 
(Fig. 4.13).
It is apparent from Figure 4.13 that E3 is released into 
the supernatant after treatment with argC or argC/high salt. Also, 
E2 is not observed in the supernatant of these samples but is 
detected in the pellet, which indicates that the integrity of the 
core is preserved after the release of E3 from both protease treated 
samples. Only minor degradation products of E2 are detected in the 
supernatant samples. El (A.and El subunits are present in 
supernatant and pellet fractions from both intact and argC treated 
PDC samples.
Figure 4.13 Study of the integrity of the E2/X core assembly after
inactivation of the complex with argC and high salt 
Native PDC (500pg) was incubated in 20mM potassium
+
phosphate buffer, pH7.4, ImM MgCl^/ 0.2mM TPP and 2.5mM NAD 
(lanes 1A, IB and 1C); in the presence of 0.25M MgCl^ (lanes 2A,
2B and 2C); with 3% (w/v) argC (lanes 3A, 3B and 3C); and with 
0.25M and 3% (w/v) argC (lanes 4A, 4B and 4C).
After 60 min benzamidine (ImM) was added and each sample 
diluted to 1ml with 20mM potassium phosphate buffer pH7.4. The
samples were centrifuged at 150,000 x g for 2.5 hr. The 
supernatant fractions were precipitated by addition of TCA (Section 
2.2.3a) and the resultant pellets solubilised in Laemmli sample 
buffer. Samples (lpg) were resolved on a 10% (w/v) 
SDS/polyacrylamide gel and immediately subjected to immunoblotting 
analysis with anti-E2 serum (Panel A), anti-E3 serum (Panel B) or 
anti-El serum (Panel C). Lane M, intact PDC (0.5ug)
(x 10’ * )
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As the E2 core is pelleted after proteolysis and high salt 
treatment, it indicates that a gross disruption of the core assembly 
is not responsible for the loss of enzymatic activity although a 
structural re-arrangement of the core resulting in overall loss of 
complex activity cannot be ruled out at this stage.
14
4.2.8 Labelling of PDC with [ C] NEM after proteolysis with 
a.r9c
On prolonged incubation in acetylating substrate E2 and
I4 ,component X become increasingly resistant to N-ethyl [2,3- CJ 
maleimide (NEM) modification of the reduced thiols on E2 and X. This 
offers an alternative method of visualising the products of 
proteolysis of E2 and component X and the ability of argC-treated 
PDC on prolonged incubation in acetylating substrate to protect 
against NEM modification.
To examine the peptides generated by proteolysis with argC 
and their ability to be protected against NEM modification, samples 
were removed at various times from an incubation mixture containing 
PDC and argC and processed as described in Figure 4.14.
Under the conditions described in Figure 4.14, component X 
cannot be visualised. Reduced incorporation of radiolabel into E2 
is observed over the time course which can be compared to the 
protection of the E2/X subunits shown in lane C. This indicates 
that E2 can still be protected from NEM modification. No peptides 
from E2 or component X are observed suggesting that they are also 
protected.
An interesting observation is that the M 55000
r
polypeptide (E3) incorporates NEM after proteolysis with argC (Fig.
4.14). This observation was repeated on incubation of PDC with
14
high salt prior to the addition of NADH and [ C] NEM (data not 
shown).
14
Figure 4.14 Enhanced susceptibility of E3 to [ C ] NEM
modification after limited proteolysis of PDC with argC
Native PDC (50Ctyig) was incubated in 20mM potassium
phosphate buffer pH7.4 containing ImM MgCl^, 0.2mM TPP and 2.5mM 
+
NAD . On the addition of 3% (w/v) argC samples (50jig) were
removed and at the times indicated added to benzamidine. NADH
(0.5mM) was added and after 10 min samples were acetylated in the
presence of acetyl CoA (0.5mM). The proteins were labelled by the
14
addition of _N-ethyl [2,3- C] maleimide (approximate final
concentration of ImM) and excess NEM removed by the addition of
2-mercaptoethanol. Laemmli sample buffer (X2) was added to each of
the samples which were (50;ig) resolved on a 10% (w/v)
SDS/polyacrylamide gel and processed for fluorography.
125
Lane M I-labelled M standards
r
14
Lane A NADH reduced PDC (50ug) labelled with [ C] NEM
14 ,
Lane B Simultaneous addition of acetyl CoA and [ C] NEM 
to NADH reduced PDC
14
Lane C NADH reduced PDC incubated with [ C] NEM, after 
incubation in acetyl CoA for 15 min.
Samples from the time course 5, 10, 30 min can be compared 
directly with lane C.
Enhanced susceptibility of E3 to [1 ^ C1 NEM modification 
after limited proteolysis of PDC with ARG C.
M A B C 5 15 30
Time (min)
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4.2.9 Enhanced labelling of E3 may be at the active site
As discussed previously, proteolysis of PDC by argC and 
argC/high salt results in dissociation of the E3 component from the
E2/X core. Also, under these conditions, an increased 
14
incorporation of [ C] NEM into E3 is observed. The E3 component 
may be shielded in the intact complex and only rendered susceptible 
to NEM modification after release from the core assembly and 
treatment with NADH. The active site on E3 consists of a reactive 
cysteine disulphide which functions in catalysis. Substitution of 
the active site cysteine, by a serine residue using oligonucleotide- 
directed mutagenesis, abolished E3 activity, confirming the critical 
role of the redox-active disulphide in catalysis (Russell et al., 
1989).
To test the hypothesis that modification of dissociated E3 
is at the active site and is NADH dependent, PDC was incubated in 
argC and at various time points samples removed, processed as
described in Figure 4.15 and the E3 activity of each determined. 
Similarly, PDC incubated in high salt was treated as above. Excess 
NADH was removed by dilution in centricon tubes (Section 2.2.2) 
prior to measurement of E3 activity (Fig. 4.15).
As E3 inactivation is not observed in intact PDC the 
inactivation seen in argC or high salt treated complex appears to 
result from the release of E3 from the core assembly. Furthermore, 
the inactivation following release of E3 is NADH dependent. On 
release the active site may be exposed making it, in the presence of 
NADH, susceptible to NEM incorporation and inactivation. The NADH 
dependent inactivation was confirmed by substituting NEM with other 
sulphydryl group reagents (oxidised glutathione and oxidised DTT) 
and a similar profile as in Figure 4.15 was obtained (data not 
shown). In intact PDC component X may be involved in protection 
of the active site on E3.
Figure 4.15 NADH dependent inactivation of E3 by NEM
Native PDC (lOOpg) was incubated in 20mM potassium 
phosphate buffer pH7.4 (Panel A). Similarly native PDC (lOCtyig) was 
incubated in the above buffer plus 3% (w/v) argC (Panel C) and PDC 
(lOO^ ig) was incubated in potassium phosphate buffer plus 0.25M 
m9c12 (Panel fi). After 60 min, NADH was added to a final 
concentration of 0.5mM followed by incubation for 10 min in 0.5mM 
N-ethylmaleimide. The reaction was stopped by the addition of 
2-mercaptoethanol to 45mM.
Excess NADH was removed by dilution (1:100) with potassium 
phosphate buffer pH7.4 followed by a (5000 x g) centrifuge spin for 
15 min in a centricon 30 tube (Section 2.2.2). The above process 
was repeated once more.
The samples (lOpg) were assayed for E3 activity (Section 
2.2.7a). Results are means of duplicate determinations which 
varied by less than 1Q°o.
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4.2.10 Effect of protease argC on PDC kinase
It has been argued that the catalytic reduction and 
acetylation of protein X is sufficient to stimulate the intrinsic 
kinase activity of pyruvate dehydrogenase and therefore component X 
has a regulatory role in mediating the activation of pyruvate 
dehydrogenase kinase by changes in the state of acetylation of the 
complex (Rahmatullah and Roche, 1987).
Rapid and complete inactivation of PDC as measured by the
+
NAD reduction assay, occurs on incubation of the enzyme in ATP.
To study the effect of component X on the regulation of the kinase 
and subsequently the rate of inactivation of the complex PDC was 
digested with argC under conditions which were known to degrade the 
lipoyl domains of component X. On the addition of ATP, to the argC 
treated complex, samples were removed and assayed for PDC activity 
(Fig. 4.16A). Untreated PDC was inactivated by ATP in a similar 
manner (Fig. 4.16A). From the data it is apparent that a more 
rapid rate of inactivation of protease treated PDC occurs on the
addition of ATP. This result is confirmed from the measurement of
32 . incorporation of P into the El subunit of PDC (Fig. 4.16B).
4.2.11 Proteolysis of PDC by argC in various buffer systems 
During this study on PDC kinase, it was observed that the
E l s u b u n i t  was susceptible to proteolysis by argC in Tris-HCl 
buffer pH8.0. Therefore in an attempt to protect ElCK. from 
proteolysis by argC the incubation conditions were varied.
Proteolysis of PDC by argC in 50mM Tris/HCl, pH8.0
2+ . 
containing TPP and Mg resulted in protection of the El os.
subunit from degradation (Fig. 4.17D). The effect of TPP and 
2+
Mg on the ElOssubunit is confirmed (Fig. 4.17) from the
Figure 4.16A Effect of protease argC on PDC kinase
PDC (lOO^ ig) was incubated with 3% (w/v) argC in 50mM Tris 
HC1 pH8.0 for 60 min. At the times indicated samples (5jjg) were 
removed and assayed for PDC activity. The reaction was stopped by 
the addition of benzamidine to ImM. After 60 min untreated PDC
(---- ^ ----- ) and argC treated (-------  ) were incubated in
0.5mM ATP and at the times indicated samples (5^ ug) removed and 
assayed for PDC activity. As a control non-phosphorylated PDC
( V  ) was also assayed. Results are means of duplicate
determinations which varied by less than +_ 5%.
The values of 100% activity for argC treated and untreated 
samples represent the maximum activity recorded before the addition 
of ATP.
Figure 4.16B Incorporation of P into E l s u b u n i t  of PDC
PDC (lOOjug) was incubated in 50mM Tris HC1 pH8.0.
y 32
Reactions were initiated by the addition of [ 0 ~ P]ATP (0.2mM; 
lOOOOOdpm/nmol). Aliquots of lOul were applied to filter papers to 
estimate the time course of incorporation into TCA-precipitable 
material. Similarly PDC incubated with 3% (w/v) argC for 60 min
was treated as above and the time course of incorporation of 
V  32[ /) - P] ATP into TCA-precipitable material determined for
PDC (- ED ) an<3 argC treated PDC (--- ^ --- ) (Section 2.2.3a).
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Figure 4.17 Proteolysis of PDC by argC in various buffer systems
Native PDC (50ug) incubated with 3% (w/v) argC in 20mM 
potassium phosphate buffer containing lmM MgCl^, 0.2mM TPP (Panel 
A). ATP-inactivated PDC (50^ ig) incubated with 3% (w/v) argC in 
20mM potassium phosphate buffer (Panel B). Native PDC incubated 
with 3% (w/v) argC in 50mM Tris-HCl pH8.0 (Panel C). Native PDC 
incubated with 3% (w/v) argC in 50mM-Tris HC1 pH8.0 containing lmM 
MgCl^f 0.2mM TPP (Panel D).
At the times indicated, samples (10/ig) were removed and 
added to Laemmli sample buffer and resolved on a 10% (w/v) 
SDS/polyacrylamide gel. Proteins were visualised by staining in 
Coomassie blue.
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observation of PDC incubated in 20mM phosphate buffer pH7.4
2+
containing TPP and Mg (Fig. 4.17A). PDC incubated in Tris
2+
buffer pH8.0 and in the absence of TPP and Mg results in 
significant degradation of the El <X subunit by protease argC 
(Panel C).
An interesting observation is the phosphorylated El
subunit may also be partially protected against degradation by argC
(Fig. 4.17, Panel B)
Further investigation into the effect of argC on the kinase
confirmed the observations in Figure 4.16. Limited proteolysis of
2+
PDC with argC [1% (w/v)] in the presence of Mg and TPP resulted
in little degradation of component X or the El <X subunit. A more
32
rapid rate of incorporation of P and inactivation of the complex 
compared to untreated PDC was observed. During the course of this 
work, Rahmatullah et al. (1989) confirmed the effect of argC 
treatment on the kinase.
Discussion
Summary
The reports of Roche and his group in relation to 
proteolysis of PDC with argC (Gopalakrishnan et al., 1989) have been 
evaluated in detail. Their findings, based essentially on visual 
inspection of silver stained gels and enzymatic assays following 
reconstitution -of PDC have indicated that E3 protects component X 
from proteolysis by argC and that the argC treated core, on the 
addition of El and E3, can no longer interact with the E3 subunit. 
These claims need to be treated with caution.
In our study, it has been demonstrated quantitatively and 
immunologically that it is possible to degrade 90% of component X in 
intact PDC with argC with no significant effects on overall complex
114
activity. In support of our findings that E3 does not protect 
component X, it has been possible to release E3 from the intact core 
after limited proteolysis with argC. In addition, Roche and 
co-workers have not demonstrated the effect of argC on E l ^  or 
considered the consequences for overall enzyme activity.
A major new discovery described in this chapter is that 
release of E3 from the core assembly exposes the active site on E3, 
which, in the presence of NADH, is susceptible to inactivation by 
NEM, oxidised DTT or glutathione. Therefore a possible function 
for component X is to protect the active site of lipoamide 
dehydrogenase.
Discussion
Incubation of PDC with protease argC results in the release 
of most of the lipoyl domains from component X without affecting the 
overall enzyme activity of the complex. This observation is at 
variance with Roche’s group who found that limited proteolysis of 
PDC with argC resulted in a loss of activity which paralleled the 
release of the lipoyl domains from component X (Gopalakrishnan 
et al., 1989). However, complete release of the lipoyl domains of 
component X cannot be achieved without minor (10-20%) cleavage of E2 
lipoyl domains, causing a slight reduction in overall complex 
activity. Proteolysis of PDC by argC releases two peptides from 
E2, M^_ 35000 and M 45000, as confirmed by immunoblotting with 
monospecific E2 antiserum and a single immunoreactive peptide from 
component X, M^ 15000. Under certain conditions the El subunit 
of PDC also undergoes limited proteolysis.
A surprising observation was that incubation of complex in 
high salt, under conditions which were known to dissociate El and E3 
from the E2/X core, did not affect the overall enzyme activity.
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However, the complex was more susceptible to inactivation by high 
salt after protease argC treatment. Inactivation of the complex 
incubated in high salt and argC did not parallel the degradation of 
component X. In both the absence or presence of high salt, 
cleavage of component X proceeds at a more rapid rate than the loss 
of enzyme activity, suggesting that if intact protein X is essential 
for complex activity it does not become rate limiting until less 
than 10% is remaining although it may have an important function 
related to the acetylation of E2. Support for these findings has 
been obtained by analysis of PDC activity from patients lacking 
protein X. These patients show significant levels of PDC activity 
(see general discussion for greater detail).
A possible explanation for the inactivation of the complex 
with argC and high salt is that in the presence of either argC, or 
high salt, the affinity of E3 for the core has been lowered without 
affecting overall enzyme activity, whereas a combination of high 
salt and argC decreases the affinity of E3 for the core to a level 
where the complex is rendered inactive.
Examination of pellet and supernatant fractions following 
ultracentrifugation of argC treated PDC reveals that the pelleted 
core assembly remains intact while E3 and small peptides from the E2 
core are released into the supernatant fractions. This theory is 
in agreement with the observation of Kresze et al. (1980) who show 
that complex incubated with papain dissociates with loss of overall 
enzyme activity while each subunit maintains its own activity.
Release of the E3 component from the intact complex after 
proteolysis with argC has been demonstrated. Proteolysis of the 
lipoyl domains of component X results in the E3 component 
dissociating from the core. This result is in contrast to the
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findings of Roche and co-workers who report that the E3 component 
protects component X selectively (Gopalakrishnan et al., .1989). An 
E3 binding site at the C-terminus of E2 has been identified 
(Thekkumkara et al., 1988) and recent investigations have revealed 
an E3 binding site on component X from S. cerevisiae (Behai et al., 
1990). Direct interaction between component X and E3 has also been 
claimed (Powers-Greenwood et al., 1989). An E2 oligomer (lacking 
protein X and fully retaining acetyltransferase activity) exhibited 
significantly reduced binding of the E3 component and a component X 
fraction (lacking E2 subunits) bound a significant amount of E3. 
Therefore it is probable that component X participates in the 
binding of E3 to the core assembly.
Release of E3 from the core assembly either by proteolysis
with argC or treatment with high salt exposes a sulphydryl group on
14
E3 which in the presence of NADH is modified with [ C]NEM. 
Inactivation studies on argC treated complex indicated that 
modification of E3 with oxidised DTT, oxidised glutathione or NEM, 
was NADH dependent and resulted in inactivation of E3. The active 
site on E3 is a short 4 residue sequence containing a disulphide 
bond which functions in catalysis. This disulphide bond is readily 
reduced in the presence of NADH and consequently can be inactivated 
by an appropriate inhibitor (Williams et al., 1989). In the intact 
complex E3 remains tightly associated with the core and is fully 
active, therefore, component X may interact with the active site of 
E3 rendering inaccessible to modification by a variety sulphydryl 
group reagents.
Incubation of PDC in trypsin resulted in the loss of 
overall enzyme activity, and loss of the ability of the complex on 
prolonged incubation in acetylating substrate to protect the
S-acetyltransferase from NEM incorporation. Removal of 90% of the 
lipoyl domains of component X from the complex^with protease argC^
did not effect the overall enzyme activity or the ability of the 
complex on prolonged incubation in acetylating substrate to protect 
from NEM modification and inactivation. Unfortunately the 
remaining 10% of the lipoyl domains of component X still associated 
with the core may be sufficient for component X to function in the 
diacetylation and protection of the complex from NEM modification.
It has been reported that removal of over 90% of the El component of 
E. coli PDC does not affect the ability of El component to 
reductively acetylate E2 (Packman and Perham, 1986). A similar 
situation may apply with component X.
An interesting observation was that in the absence of TPP
2+
and Mg argC promoted significant degradation the El C< subunit of
2+
PDC. The effect of TPP and Mg in protecting the El oC subunit 
is unclear. Either binding of TPP to El o< subunit occurs at a
proteolytically susceptible site, thus preventing proteolysis by 
2+
argC or TPP and Mg induce about a conformational change on the
El subunit with similar results. A similar effect may be observed
with ATP inactivated complex where phosphorylated ElcXmay be
partially protected from protease degradation. Garland and Nimmo
(1984) have reported that isocitrate dehydrogenase in the presence 
+
of NADP can be protected against proteolysis. The binding of 
+
NADP to, or phosphorylation of active isocitrate dehydrogenase 
induces a major conformational change, thus preventing proteolytic 
cleavage of the enzyme.
Roche and co-workers have reported that binding of E3 and 
El to argC degraded core assembly results in little restoration of 
the original complex activity and they conclude that the loss of
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activity is caused by reduced E3 binding in the absence of component 
X. Any preparation of core assembly will have significant levels 
of El associated with the core [however, the data presented by this 
group (Gopalakrishnan et al., 1989) does not show the endogenous 
level of El oC and present in the E2 core assembly preparation] and 
therefore limited proteolysis of the core assembly will degrade the 
endogenous El present. Therefore subsequent reconstitution 
studies performed on argC treated core assembly may result in 
reduced levels of activity due to the degradation of E1<X present in 
the core assembly.
In reconstitution studies, in the absence of TPP and
2+
Mg , Gopalikrishnan et. al., 1989, observed with reconstituted PDC 
that the loss of activity^50%, closely parallels the degradation of 
component X. Their finding did not consider the effect of argC on 
the Elo< subunit.
2+
Recent studies, in the absence of TPP and Mg , have
shown that the loss of activity also parallels the degradation of
the El subunit and therefore this effect has to be considered
when assessing the involvement of protein X in overall activity of
the complex (data not shown).
In preliminary reconstitution studies, recovery of activity
after high salt or argC treatment has not occurred. It is possible
that the effect on PDC of high salt or argC causes a conformational
change on the E2 core with resultant loss of E3 binding. If this
>
is the case then our findings are in general agreement with Roches: 
group.
A more rapid rate of inactivation of protease treated
2+
complex by ATP was recorded. In the presence of TPP and Mg the 
greater rates of inactivation and incorporation of % ATP into the
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complex is probably due to a protease effect on the kinase. The
kinase consists of two subunits o< and fc M 48000 and M 450000
/ r r
respectively. It has been reported that kinase activity resides in
the subunit and proteolysis of the small subunit with trypsin
resulted in a slight increase in kinase activity (Stepp et al.,
1983). It is thought they3 subunit plays a structural role through
favourable topographical positioning of the catalytic <X subunit.
Similarly limited proteolysis of the complex by argC may result in a
32
more rapid inactivation and incorporation of P into the complex 
which may be due to limited proteolysis of the kinase yS subunit 
allowing the catalytic subunit to operate without regulation.
CHAPTER FIVE
STRUCTURAL AND FUNCTIONAL RELATIONSHIP OF COMPONENT X 
TO THE LIPOATE ACETYLTRANSFERASES (E2) COMPONENT
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5. Structural and functional relationship of component X to
the lipoate acetyltransferases (E2) component
5.1 Introduction
The lipoate acetyltransferase and protein X subunits of the 
bovine PDC core assembly are antigenically distinct polypeptides 
(De Marcucci and Lindsay, 1985; Jilka et al., 1986).
Recent cloning and sequence analysis of the human lipoate 
acetyltransferase (E2) gene (Coppel et al., 1988; Thekkumkara 
et al., 1988) in conjunction with earlier protein-chemical studies 
(Hodgson et al., 1988) have demonstrated the presence of two 
tandemly-repeated lipoyl domains of approximately 125 amino acids in 
length, located at the N-terminus of the polypeptide. A short, 
highly conserved E3 binding sequence is found distal to the second 
lipoyl domain followed by a C-terminal inter-subunit binding domain 
which also houses the acetyltransferase activity. The general 
structure for E2 was first elucidated for PDC from E. coli (Guest 
et al., 1985; Graham et al., 1986) which, however, contains 
3 homologous lipoyl domains while the equivalent Sj_ cerevisiae 
enzyme has only a single lipoyl domain (Niu et al., 1988). The 
exact number of lipoyl groups on component X is unknown although 
recent evidence suggests that it contains only one. Specific 
cross-linking studies on E2 and X with phenylene-o-bismaleimide via 
substrate generated thiols or lipoic acid groups has provided 
evidence for the presence of two lipoyl groups per E2 chain and only 
a single lipoate domain per protein X (Hodgson et al., 1988).
This chapter describes the immunological approach employed
to investigate the possible number of lipoyl domains on component
X. The monospecificity of high titre antisera raised against gel
purified lipoate acetyltransferase and component X is demonstrated
and the location of component X and E2 in various cell extracts is 
determined.
Figure 5.1 Immunoblotting analysis of lipoamide acetyltransferase
(E2) and protein X in various cellular extracts
Purified PDC and various cellular extracts were resolved by 
electrophoresis on 10% (w/v) SDS/polyacrylamide gels. Gels were 
used for immunoblotting analysis (see Methods section for details) 
with antibody raised against the E2 subunit (Panel A) or protein X 
subunit (Panel B).
Panel A :
Lane 1 (and 5) 0.]^ ug PDC; lane 2, SDS extract of BRL cells,
80 jag; lane 3, BRL mitochondria, 40jig; lane 4, rat liver
mitochondria, 40jag; lane 6 , ox heart mitochondria, 15jjg; lane 7,
SDS extract of NBL-1 cells, 80jag; lane 8 , SDS-extract of PK-15
cells, 80^ ig; lane 9, PK-15 mitochondria, 20/ag; lane 10, PK-15
125
post-mitochondrial supernate, 60jag; lane 5, I-labelled M 
marker, bovine serum albumin.
Panel B :
Lane 1, 0.5^ug purified PDC; lane 2, SDS extract of BRL
cells; lanes 3 and 4, post-nuclear supernate, 50 and 60jjg; lane 5,
BRL mitohondria, 40jag; lane 6 , nuclear fraction, 40jjg; lane S,
125
I-labelled M markers.
I
O
CD I
121
Conclusive evidence that component X is different, but 
homologous to E2 is presented and the location of the lipoyl domain 
on component X determined.
5.2 Results
The monospecificity and high titre of antiserum raised to
the gel purified lipoate acetyltransferase (E2) subunit of bovine
heart PDC is demonstrated in Figure 5.1, where immune replica
analysis (Panel A) is conducted against purified PDC and several
cellular and mitochondrial extracts. Variations in the M values
r
of the E2 subunit are evident in different cell lines. In 
particular, the E2 polypeptide in BRL cells (lanes 2-4) has a lower 
apparent value of 68000 compared to 70000-72000 in bovine and 
porcine tissues. This finding is in agreement with the subunit 
molecular masses reported for lipoate acetyltransferase in purified 
rat liver (Matuda et al., 1983), and bovine heart PDC (De Marcucci 
and Lindsay, 1985). No cross reaction of the E2 antiserum with 
protein X was observed.
In Figure 5.1, Panel B, the reactivity of X antiserum is 
illustrated against bovine heart PDC (lane 1), whole cell (lane 2), 
mitochondrial (lane 5), post nuclear supernatant (lane 3 and 4) and 
nuclear fractions (lane 6 ) derived from BRL cells. It is evident 
that the antibody to component X shows a strong positive cross 
reaction with an unidentified 48kDa species which is not present in 
either nuclear or mitochondrial fractions. Its exact subcellular 
location has not been determined. In mitochondrial extracts, 
however, this antibody reacts exclusively with the 52kDa component 
corresponding to protein X. Once again, anti X-IgG failed to 
recognise the E2 component in these cell cultures.
Figure 5.2 Selective tryptic release of C acetylated lipoyl
domains from E2 and X polypeptides of native bovine 
heart PDC
Purified PDC (500ug) was preincubated for 15 min with
14
non-radioactive (panels B and C) or [2- C] pyruvate (panel A) in
the presence of NEM (0.5mM). Excess NEM was reacted with
2-mercaptoethanol (45mM) before treatment of radiolabelled enzyme
with 1% (w/w) trypsin at 25°C for the indicated times. Samples
(30ug) were removed, immediately treated with Laemmli sample buffer
(2x) and subjected to fluorography following resolution on 12.5%
(w/v) SDS-polyacrylamide gels.
14
(panel A) [ C] acetylated peptide; panels (B and C) 
immunoblots of parallel samples with anti E2 and anti X sera, 
respectively.
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In Figure 5.2, Panel A, pure bovine heart PDC, preincubated
14 14
with [2- C] pyruvate in the absence of CoASH to promote [ C]
acetylation of lipoyl groups on the proteolytically- sensitive E2
and X subunits, was then subjected to tryptic digestion for the
14
mdiiated times to promote selective release of C-labelied lipoyl
14
domains. Specific proteolysis of the [ C] acetylated domains is 
observed with protein X degrading rapidly to produce a unique, 
stable, radiolabelled 15kDa peptide (Panel B) as confirmed by immune 
replica analysis (Panel C).
In contrast, E2 is cleaved more slowly via a transient
14
C-labelled 45kDa species, finally generating a stable 38kDa 
lipoyl peptide (Panel A). Verification that these polypeptides 
were tryptic fragments of E2 and X, respectively, was again achieved 
by immunoblotting with subunit specific antisera (Panel B). A 
similar pattern of E2 and X-derived cleavage products could be 
obtained with several specific (e.g. V-8 protease) or non specific 
(e.g. papain, elastase) proteases (data not shown).
N-terminal amino acid sequence and quantitation of recovery 
obtained from bovine heart E2 and component X is detailed in 
Table 5.1.
Table 5.2 compares the N-terminal amino acid sequences of 
bovine heart E2 and protein X polypeptides with the equivalent 
primary structuresof the human (Coppel et^  al., 1988; Thekkumkara 
et al., 1988) rat (Gershwin et al., 1987) and S. cerevisiae (Niu 
et al., 1988), lipoate acetyltransferases derived from determinations 
of the nucleotide sequences of the cloned genes. Protein X 
exhibits significant homology with all eukaryotic lipoate 
acetyltransferases examined to date, particularly evident in a 
highly conserved PS/ALSPTM sequence commencing at residues 9-12 from 
the N-terminus or at equivalent positions in the internally repeated
Table 5.1 N-terminal amino acid sequence of ox heart E2 and 
component X
Sequence No. PTH X umoles E2 u moles
Amino Acid recovered amino acid recovered
1 ALA 28.1 SER 25
2 ASP 11.4 LEU 47.5
3 PRO 13.6 PRO 46.3
4 ILE 13.5 PRO 44.0
5 LYS 11.0 HIS 8.5
6 ILE 13.7 GLN 28.3
7 LEU 12.1 LYS 29.3
8 MET 11.45 VAL 36.2
9 PRO 10.3 PRO 30.0
10 SER 4.0 LEU 31.7
11 LEU 9.5 PRO 28.3
12 SER 3.8 SER x 6.7
13 GLY/PRO 3.0/4.5 LEU 24.0
14 THR 3.7 SER 4.1
15 MET 3.2 PRO 17.0
16 GLU 2.8 THR 5.0
17 GLU 3.1 MET 9.0
18 GLY 6.2 GLN 10.5
19 ASN 1.8 ALA 7.5
20 ILE 1.3 GLY 5.0
21 (VAL) x 1.0 THR x 3.1
22 (LYS) 1.0 ILE 4.0
23 ALA 4.0
24 -
25 -
26 -
27 LYS 4.2
28 LYS 4.8
29 -
30 GLU 1.5
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lipoyl domains of the human and rat enzymes. There are two 
additional positions in which complete identity is retained in all 
cases involving an invariant proline near the N-terminus and a 
glycine located in the C-terminal region of this peptide sequence. 
Interestingly, a conserved histidine at positions 3 or 4, present in 
all these lipoate acetyltransferases including the yeast enzyme is 
absent in protein X as is a conserved N-terminal serine (residue 
1 or 2). The N-terminal sequence from protein X was subsequently 
confirmed by sequencing of peptides generated from limited 
proteolysis.
The corresponding amino acid sequence from the N-terminal 
and internally repeated lipoyl domains of human E2 reveals sequence 
identity in 15 out of 24 residues while protein X exhibits lower 
homology (10 out of 22 residues) with the equivalent N-terminal 
region from bovine heart E2. The N-terminal primary structures of 
human and bovine heart E2 are identical over the first 22 residues. 
Heterogeneity was also observed at residue 13 in the protein X 
sequence where both proline and glycine were found in comparable 
yields. During the course of this work, a similar, but not 
identical sequence was published for the N-terminal region of 
protein X from bovine kidney (Powers-Greenwood et al., 1989). 
Considerable sequence variability was noted amongst this group of 
enzymes in areas outwith the highly conserved regions as evidenced 
by alterations in sequence length and the presence of many 
conservative and non-conservative substitutions, notably in protein 
X which has several unique features e.g. two consecutive glutamic 
acid residues at positions 16 and 17.
Internal amino acid sequence from protein X was also 
obtained (Table 5.3). Limited proteolysis of gel purified protein 
X with protease V 8 generated three major peptides of M 48000,
Table 5.2 Comparison of N-terminal amino acid sequences of
protein X and various lipoate acetyltransferase (E2) 
from eukaryotic sources
Bovine heart E2 and protein X amino acid sequences were 
determined directly while the N-terminal human liver, E2(a), rat 
liver and yeast sequences were derived from the corresponding 
nucleotide sequences in the indicated publications. Primary 
structures of bovine heart E2 and protein X are continuous with 
blank positions present only to optimise sequence alignment. For 
human and rat liver enzymes the corresponding internal repeat 
sequences E2(b), at the start of the second lipoyl domain are 
included for comparison. Regions of complete or near complete 
sequence identity are highlighted as shown. Bracketed amino acids 
have been identified only tentatively.
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Table 5.3 Internal amino acid sequence of component X
Gel purified protein X (20ug) (Section 2.2.4c) was incubated
in 0.01% (w/v) V8 proteinase for 30 min. On the addition of Laemmli
sample buffer the sample was resolved on a 10% SDS/polyacrlymade gel
and then electrophoretically transferred to nitrocellulose. The
nitrocellulose was stained with Coomassie blue and a band M 22000
r
cut out and sequenced.
Table 5.3: Internal Amino Acid Sequences of Component X
20kDa Component X Peptide
Sequence No.
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
PTH amino acid
D,G,A,P,V,F,I
ALA
ASN
ILE
LEU
ALA
LEU
ILE
GLY
LEU
(LEU)
VAL
GLU
TYR
ILE
THR
ASP
pmoles recovered
4.2
4.2
2.4
7.6
3.0
3.3
1.5
4.0 
1.9
1.0 
1.0
2.7 
0.6 
0.6
3.2
0.2 
0.6
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M 35000 and M 30000. Amino acid sequencing of each of these 
r r
peptides revealed that they were N-terminal fragments confirming the 
sequence of component X in Table 5.1 and indicating that the carboxy 
terminus end of protein X is more proteolytically sensitive.
Internal amino acid sequence was determined from a fragment M
r
20000 (Table 5.3) from a digest with V8 protease on gel purified 
protein. Comparison of internal component X sequence revealed 
little homology with the primary structures of lipoate 
acetyltransferases derived from nucleotide sequence listed.
5.3 Discussion
Immunology of protein X and lipoate acetyltransferase (E2)
In view of the striking homology (45% identity) in the 
N-terminal sequences of the bovine heart E2 and X polypeptides, it 
may seem surprising that no immunological cross-reactivity is 
apparent employing antisera raised to the individual subunits. In
one case, an anti-X serum has been reported to recognise the E2 
enzyme also (Jilka jet al., 1986). Conflicting observations occur 
frequently with polyclonal sera where the characteristics of the IgG 
population depend on multiple factors, e.g. the method of antigen 
presentation the immunisation regime and individual animal responses.
Immunological studies have been widely used to demonstrate 
homologies within families of isoenzymes where a linear relationship 
has been established between the degree of cross-reaction and the 
extent of sequence divergence. However, systematic analysis of a 
selection of purified lysozymes revealed that enzymes exhibiting 
less than 60% homology did not usually show an immunological 
cross-reaction in precipitation assays or by microcomplement 
fixation (Prager and Wilson, 1971a & b).
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Antibodies to native proteins are primarily against 
non-contiguous epitopes (three dimensional determinants) on the 
surface of the polypeptide while, for denatured antigen, linear 
elements of sequence (5-8 amino acids) are responsible for eliciting 
the major antibody response. If the common sequences are highly
conserved e.g. the PS/ALSPTM sequence in E2 and X they may be very
weak immunogens accounting for the lack of cross-reactivity between 
these two homologous proteins (De Marcucci et al., 1985). The 
absence of cross reaction may suggest that the E2 and X polypeptides 
are encoded by separate genes rather than products arising from
alternate exon splicing of a single genomic copy. In the latter
case the presence of long identical sequences in common exon 
segments should lead to immunological cross recognition by anti-E2 
or anti-X sera. This argument has been confirmed recently (Behai 
et al., 1989), where extensive homology observed between E2 and X 
indicates that they evolved from a common ancestor.
Organisation, origins and functions of protein X
Limited amino acid sequence data on bovine heart protein X 
indicates that this protein contains a lipoyl domain located at its 
N-terminus and belongs to a family of homologous enzymes, all the 
other members of which possess lipoate acetyltransferase activity. 
The heterogeneity at position 13 in the protein X sequence where 
both proline and glycine were present, probably represents separate 
allelic forms of the enzyme as the PDC was purified from a single 
beef heart.
There are several reasons for suggesting that, in contrast 
to bovine E2, protein X contains only a single lipoyl domain:
(i) selective release of lipoyl domains from E2 and X by limited 
proteolysis with a variety of specific and non specific proteases
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producing stable peptides, containing all the [ C] acetylation 
sites, in the 35-42kDa range for E2 and 15-20kDA range for 
protein X (ii) the subunit molecular mass of protein X, 51kDa as 
opposed to 70kDa for E2 is best accounted for by the absence of a 
second lipoyl domain on protein X. These domains are known to 
migrate anomalously on SDS/polyacrylamide gels owing to the 
presence of Ala-Pro-rich linker regions (Graham et al., 1986) and 
(iii) specific cross-linking studies on E2 and X with 
phenylene-o-bismaleimide via substrate-generated thiols on lipoic 
acid groups has provided evidence for the presence of two lipoyl 
groups per E2 chain and only a single lipoate on protein X 
(Hodgson et al., 1988).
Both E2 and protein X participate in the acetylation 
reactions of the complex (De Marcucci et al., 1986) and 
apparently acts as independent substrates for reductive 
acetylation by pyruvate dehydrogenase (El) (Rahmatullah and 
Roche, 1987). The inability to dissociate protein X from the E2 
core assembly except under denaturing conditions also highlights 
the close physical and functional integration of these two 
components (De Marcucci and Lindsay, 1985). Indeed protein X 
contains a C-terminal domain, equivalent to the intersubunit 
binding domain of E2 and may be an effective replacement for E2 
within the core structure. A recent report (Powers-Greenwood et 
al., 1989) also claims that protein X is involved in binding 
dihydrolipoyl dehydrogenase (E3) and thus may also possess an E3 
binding region which is highly conserved in both prokaryotic and 
eukaryotic PDCs (Thekkumkara et al., 1988). An intriguing 
question, therefore, currently under investigation, relates to
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the precise role of component X: is it a variant of E2
performing an essential structural or mechanistic role within the 
multimeric core assembly? Cloning and sequence analysis of the 
protein X gene will be an important first step in endeavouring to 
answer these questions (see Chapter 6 for details).
*
CHAPTER SIX
CLONING AND SEQUENCE ANALYSIS OP A cDNA
ENCODING PROTEIN X
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6. Cloning and sequence analysis of acDNA encoding protein X
6.1 Introduction
In all eukaryotic pyruvate dehydrogenase complexes studied
to date, a structural core of high is formed by 60 E2 subunits
organised into a pentagonal dodecahedron to which El and E3
polypeptides are bound to produce a large multienzyme array of 
6
M^ 8.5 x 10 . The cellular location of the pyruvate
dehydrogenase complex is considered to be the mitochondrial matrix
although there are indications that in plants the complex exists in
both mitochondria and chloroplasts (Mierynk et al., 1988).
Eukaryotic PDC preparations also contain a prominent
M 51000 species (M 48000 in yeast), component X, which is 
r r
associated with the E2 core (De Marcucci and Lindsay, 1985). The
presence of component X in mammalian PDC has been confirmed (Jilka
et al., 1986; Behai et al., 1989) and like E2, this component is
14 ,
reductively acetylated in the absence of CoASH, with [2- C] 
pyruvate.
On incubation with CoASH, component X and E2 are rapidly 
deacetylated. The site of acetylation on the component X 
polypeptide, like E2 is reported to be lipoic acid (Hodgson et^  al., 
1986). In earlier studies component X was considered to be a 
proteolytic fragment of E2; however no common peptides were 
produced when isolated E2 or component X were digested with a 
variety of specific and non-specific proteinases (De Marcucci 
et al., 1986).
Deoxyribonucleotide sequencing of a cDNA for the 
dihydrolipoamide acetyltransferase (E2) of human pyruvate 
dehydrogenase complex and examination of the deduced amino acid 
sequence (Thekkumkara et al., 1988) revealed that E2 shows the
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presence of the amino terminal lipoyl bearing domain and the carboxy 
terminal catalytic domain. Both domains had been demonstrated to 
be present in E2 of PDC based on proteolytic cleavage of mammalian 
E2 (Bleile et al., 1979) and the sequencing of E. coli E2 (PDC) 
(Stephens et al., 1983b). The deduced amino acid sequence of human 
PDC-E2 also indicated the presence of two lipoyl binding sites in 
the lipoyl bearing domain. The second lipoyl-binding site shows 
approximately 80% homology with the first and the differences that 
exist between the two lipoyl-binding sites are conservative.
A dihydrolipoamide dehydrogenase (E3) binding site has been 
identified from E2 based on sequence homology between the E2 
components of the three 2-oxo acid dehydrogenase complexes (Hummel 
et al., 1988). A sequence of 32 amino acids which is highly 
homologous to the E3-binding site, is also present in human PDC 
E2. Overall, there is approximately 90% homology in the E3-binding 
region between human and rat liver PDC E2 (Gershwin et al., 1987) 
and 53% homology between human and E. coli PDC E2 (Stephens et^  al., 
1983). Further comparison of the amino acid sequences of the 
catalytic domains of human liver E2 and coli E2 revealed a 
segment of 14 amino acids near the carboxy-terminal with 
approximately 79% homology. A histidine residue is conserved in 
both sequences which may serve as the active site residue for 
catalysis.
Sequence analysis of a cDNA encoding component X would, 
hopefully, allow us to identify possible subunit binding sites 
(e.g. E3-binding site) on component X and identify through deduced 
amino acid sequence comparison with eukaryotic and prokaryotic 
acetyl transferase any region of sequence which may have a specific 
function (e.g. acetyltransferase activity).
There are several strategies which could be employed to 
clone the desired gene.
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6.1.1 Nucleic acid hybridisation
This is the most commonly used method of screening cDNA 
libraries for clones of interest.
6.1.2 Homologous probes
Homologous probes contain at least part of the exact 
nucleic acid sequence of the desired cDNA clone. They are used in 
a variety of circumstances, for example, when a partial clone of an 
existing cDNA is used to isolate a full length clone from a cDNA 
library. Usually, a fragment derived from the existing clone is 
isolated, radiolabelled in vitro and used to probe the new library. 
Hybridisation with a homologous probe is always carried out under 
stringent conditions.
6.1.3 Partially homologous probes
Partially homologous probes are used to detect cDNA clones 
that are related, but not identical, to the probe sequences. If
the same gene has already been cloned from another species or if a
related gene has been cloned from the same species, it is possible 
that there is sufficient conservation of nucleic acid sequence to 
allow the screening of a cDNA library by hybridisation.
6.1.4 Synthetic oligonucleotide probes
Three types of oligonucleotide probes are in common use:
a) Single oligonucleotides of defined sequence
b) Pools of short oligonucleotides whose sequences are highly
degenerate 17 bases long)
c) Pools of longer oligonucleotide of lesser degeneracy ( ^  17
bases long) .
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Degenerate oligonucleotide probes are used to screen 
libraries by hybridisation to take account of the degeneracy of the 
genetic code. There are 64 possible codons for only 20 amino 
acids; most amino acids are represented by more than one codon. 
Thus a certain sequence of amino acids can be encoded by a number of 
different oligonucleotides. A completely degenerate pool of 
oligonucleotides contains all DNA sequences that can code for a 
given sequence of amino acids. A pool of limited degeneracy 
consists of a selected subset of oligonucleotides that can code for 
a given sequence of amino acids.
a) Single oligonucleotides of defined sequence
Probes consisting of a single oligonucleotide of defined
sequence usually correspond to part of the sequence of a previously
cloned segment of DNA. In general, such oligonucleotides match
with their target sequence perfectly, or nearly perfectly, and they
are sufficiently long (19-40 nucleotides) to allow the use of
hybridisation conditions which can guarantee discrimination between
the target sequence and other closely related sequences. Single
oligonucleotides of defined sequence are used to screen cDNA,
genomic DNA libraries, or subclones derived from them by employing
Southern, Northern and dot blot hybridisation to identify and detect
the sequence of specific genes. Oligonucleotide probes used for
these purposes are usually labelled by phosphorylation of 5(or 3)'
SJ 32
termini with [0(- P]ATP.
b) Pools of short oligonucleotides whose sequences are highly
degenerate
Degenerate pools of short oligonucleotides containing all 
possible sequences that can code for a given tract of amino acids 
have been used as hybridisation probes to isolate both cDNA and 
genomic DNA clones (Maniatas et al., 1989). The sequences of these
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oligonucleotides are typically chosen, using the genetic code, from 
short tracts of amino acid sequence determined by the sequencing of 
small quantities of highly purified proteins (Kent et al., 1987; 
Maniatas et al., 1989).  ^ As a consequence of the degeneracy of the 
genetic code several oligonucleotides must usually be synthesised to 
represent all possible combinations to code for a given short 
sequence of amino acids. Thus, if hybridisation conditions can be 
found under which only perfectly matched sequences form stable 
duplexes, cloned copies of the gene of interest can readily be 
isolated from cDNA or genomic DNA libraries. However, it is 
important to realise that not all strongly hybridising clones will 
necessarily contain sequences of the gene of interest.
There may be other oligonucleotides in the pool that, by 
chance, match perfectly with the sequence of other cloned genes. 
Furthermore hybridisation conditions cannot always be established 
that allow only perfectly matched hybrids to form, which leads to 
the isolation of other clones containing sequences which are closely 
related. Pools of degenerate oligonucleotides are used not to 
identify target clones unambiguously, but to select a series of 
candidate clones that can be tested further.
6.1.5 In vitro amplification of DNA by the polymerase chain
reaction (PCR)
The polymerase chain reaction (PCR) is used to amplify a 
segment of DNA that lies between two regions of known sequence.
Two oligonucleotides are used as primers for a series of synthetic 
reactions that are catalysed by DNA polymerase. These 
oligonucleotides lie on the opposite strands of the template DNA and 
flank the segment of DNA that is to be amplified. The template DNA 
is first denatured by heating in the presence of a large molar
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excess of each of the two oligonucleotides and the four dNTPs. The 
reaction mixture is then cooled to a temperature that allows the 
oligonucleotide primers to anneal to their target sequences, after 
which the annealed primers are extended with DNA polymerase. The 
cycle of denaturation, annealing and DNA synthesis is then repeated 
many times. Because the products of one round of amplification 
serve as templates for the next, each successive cycle essentially 
doubles the amount of desired DNA product.
Although a relatively new technique, PCR amplification has 
already found extensive application in the diagnosis of genetic 
disorders, the detection of nucleic acid sequences of pathogenic 
organisms in clinical samples and the genetic identification of 
forensic samples from individual hairs or single sperm. In 
addition PCR is being used for the generation of specific sequences 
of cloned double stranded DNA, generation of probes specific for 
uncloned genes by selective amplication of particular segments of 
cDNA and generation of large amounts of DNA for sequencing.
6.1.6 Antibody screening
A cDNA copy of a eukaryotic transcript can be expressed as 
a fusion protein with a large proportion of the -galactosidase 
enzyme (in vector ^gtll). The eukaryotic portion of the fusion 
protein may be sufficiently antigenic to be detected by appropriate 
antibody probes (Young and Davis, 1983). Expression of the 
recombinant gene from the vector gal Z promotor is by treatment of 
actively replicating phage in a suitable E_^  coli host with isopropyl- 
yS -D-thiogalactopyranoside followed by adsorption of proteins, from 
plaques, onto nitrocellulose paper. The method of antigen 
visualisation involves using specific IgG followed either by a 
second antibody directed against the species-specific epitopes of
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the first antibody and colour development with 4-chloro-naphthol
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plus (De Wet, 1984) or by I-radiolabelled protein A.
An equivalent approach has already been successful in isolating gene 
sequences. For example, the E2 component of human BCOADC was 
isolated and sequenced from a human cDNA library housed in Agtll 
(Litwer and Danner, 1985) and similarly the full cDNA clone from
human El oC of PDC has been isolated.(De Meirleir et al., 1988).
As subunit specific antisera to each component of mammalian 
PDC was available it was decided to screen a human hepatoma cDNA 
library housed in the gene expression vector ^\gtll (De Wet, 1984) 
using subunit specific antisera raised against the individual 
components of denatured and intact PDC. Recombinant A  gtll phage 
isolated by immunological screening would be investigated to confirm 
that sequences coding for PDC subunits were present.
6 .2 Results
6.2.1 Reactivity of antisera with denatured PDC on a Western blot
The key to success with antibody screening lies in the 
quality of the antisera. It is essential that the antibody 
specifically recognises the denatured protein. Therefore to test 
the antibody signal produced from a Western blot, ox heart PDC was 
purified as described in Section 2.2.5a, resolved by SDS-PAGE on a 
1 0% (w/v) slab gel and electrophoretically transferred to 
nitrocellulose paper (Section 2.2.9a), before challenging with 
purified IgG or antisera. Small amounts, lug and 0.5ug;of PDC. 
subunits ore readily detected by antisera to E2 and component X (Fig. 
6.1). lyug and 0.5pg of PDC is also detected by anti E2 IgG and 
component X IgG but at reduced intensities. Similar observations 
were made for PDC IgG and PDC antisera.
Figure 6.1 Immunological detection of PDC and PDC subunits with
IgG prepared from antisera raised against PDC, E2 and 
component x
Samples of purified pyrvuate dehydrogenase complex were 
electrophoresed on a 10% (w/v) polyacrylamide slab gel and analysed 
by immunoblotting with antiserum and IgG raised against E2 (A). A 
similar blot was processed with antisera and IgG to component X (B) 
and antisera to PDC and IgG (C).
(A, B and C) lanes 1, 3 ljig of PDC lanes 2,4 0.5/ig of PDC
(A) lanes 1,2 challenged with 1:100 dilution of E2 antiserum
lanes 3,4 challenged withl:100 dilution of E2 IgG
(B) lanes 1,2 challenged and 1:100 dilution of component X
antiserum
lanes 3,4 challenged with 1:100 dilution of component 
X IgG
(C) lanes 1,2 challenged with 1:100 dilution of pyruvate
dehydrogenase antiserum
lanes 3,4 challenged with 1:100 dilution of pyruvate 
dehydrogenase IgG
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Denatured proteins transferred from an SDS-polyacrylamide gel 
are likely to display many of the same epitopes as the cognate fusion 
protein synthesised in bacteria. The foreign polypeptide sequences 
of most fusion proteins are unlikely to fold into completely native 
structures and after transfer to nitrocellulose, as in the screening 
process, may undergo further denaturation. Therefore it is likely 
that proteins detected by Western blot analysis (Fig. 6.1) will be 
recognised by the appropriate antisera, IgG when synthesised in 
bacteria as a fusion protein.
6.2.2 Dot blot analysis (Levels of antigen detected by antisera)
Ideally, the antibody should be capable of detecting as 
little as 50-100pg of antigen in an area the size of a small bacterial 
colony. The amount of antigen present in colonies and plaques 
expressing fusion proteins varies widely depending on the toxicity of 
the fusion protein, its rate of degradation and physical state. 
However, an antibody capable of detecting as little as lOOpg of 
denatured antigen should allow all but the most labile of fusion 
proteins to be recognised.
In order to determine the levels of antigen which could be 
detected by antisera, native PDC (O.lng to 50ng) was spotted onto 
nitrocellulose and challenged with the appropriate IgG or antiserum 
(Section 2.2.9c) followed by incubation with donkey-anti rabbit IgG 
conjugated with peroxidase. Colour development was initiated on the 
addition of 4-chloronaphthol plus H 2° 2 (Fig. 6.2).
Levels of O.lng of antigen were detected by E2 antiserum, 
component X antiserum and PDC antiserum. Only E2 IgG could detect 
levels of antigen approaching O.lng, component X IgG and PDC IgG could 
detect levels of 5ng of antigen (Fig. 6.2). As the most sensitive 
limit?; of detection possible was necessary it was decided to screen 
the human hepatoma cDNA Agtll gene expression library with E2 IgG and 
antisera to component X and-antisera to PDC.
Figure 6.2 Dot blot analysis
Native PDC, (50ng, 10ng,, 5ng, lng and O.lng) were spotted onto
strips of nitrocellulose.
Panel A lane 1 PDC challenged with 1:100 dilution of X IgG
lane 2 PDC challenged with 1:100 dilution of X antiserum
Panel B lane 1 PDC challenged with 1:100 dilution of E2
lane 2 PDC challenged with 1:100 dilution of E2 antiserum
Panel C lane 1 PDC challenged with 1:100 dilution of PDC antiserum 
lane 2 PDC challenged with 1:100 dilution of PDC IgG
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6.2.3 Screening of Xgtll gene expression library
In simple terms the screening of a Xgtll gene expression
library involves the detection of a fusion protein by an antibody
followed by the isolation anrd purification of the plaque expressing
the appropriate fusion protein. Xgtll libraries are screened with
antibody probes as plaques on a confluent plate of E. coli Y1090
(Section 2.2.12a). Strain Y1090 contains several important
features which make it a suitable host. It contains a lac fusion 
q
repressor, lac I , which prevents the lac Z-directed gene 
expression i.e. prevents the formation of fusion protein. This
repression is overcome by the addition of IPTG when required.
Fusion proteins are alien to host cells and therefore often
toxic to the host cell. To overcome this toxicity .proteases will
act to prevent formation of a fusion protein. In this situation 
two problems have to be overcome; firstly the stability of the 
fusion protein must be ensured and secondly, it must not adversely 
affect its host cell. Host Y1090 has a deficiency in Ion protease, 
which increase the stability of the recombinant fusion protein and 
the formation of the fusion protein will not occur until the 
addition of IPTG which supresses the function of the lac 
repressor. Y1090 also has a supF gene to suppress the phage 
mutation causing defective lysis (S100).
As described in Materials and Methods (Section 2.2.12)
5 x J'V million phage were screened at 500,000 per 150mm plate.
Each plate was overlaid with up to three different IPTG impregnated 
nitrocellulose filters and each filter processed and challenged with 
either anti E2 IgG, anti PDC or antisera to component X (Section 
2.2.12d). Several positive clones were detected by all three 
probes after the primary screening. Subsequent rescreening of the 
isolated "positives" from E2 or PDC antisera probes failed to
Figure 6.3 Specificity of component X antisera for recombinant
Phage
An equal number of non recombinant phage were mixed with
(A) approximately lOOPfu from the recombinant clone and plated 
onto an LB plate and transferred to nitrocellulose. The 
nitrocellulose was challenged with 1:100 dilution of 
antisera to component X and processed as described in 
Section 2.2.12d.
(B) approximately lOOOPfu from the recombinant clone plated 
onto an LB plate and transferred to nitrocellulose. The 
nitrocellulose was cut into three pieces and (1 ) challenged 
with 1:100 dilution of antisera to component X, (2) 
challenged with 1:100 dilution of E2 antisera and (3) 
challenged with 1:100 dilution of PDC antisera and 
processed as described in Section 2.2.12d.
Specificity of component X anti serum 
for purified recombinant phage.
A
Anti E2
• • •
• . *•
Anti X
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confirm the original identification elicited from the plaque. Only 
a positive plaque to component X antisera survived the isolation and 
purification process until 100% positives to component X antiserum 
were identified.
The positive nature of the clone was confirmed in two ways: 
firstly, by rescreening with a 50:50 mixture of non-recombinant and 
recombinant component X phage (Fig. 6.3A), approximately 50% of the 
phage show a greater immune response to component X antisera 
confirming that the fusion protein of the recombinant phage is 
recognised by antibody to component X.
Secondly, 100% recombinant X phage were rescreened and 
challenged with component X antisera, E2 antisera and PDC antisera 
(Fig. 6.3B). A strong signal is elicited from component X 
antiserum and a weaker signal from PDC antisersum (an immune 
response to PDC antiserum is to be expected as component X is a 
component enzyme of PDC). E2 antiserum failed to detect the 
antigen produced by the phage. Therefore the specificity of the 
phage for component X antiserum was confirmed.
6.2.4 Preparation of lysogens
It is often useful to have sufficient amounts of 
polypeptide specified by the cloned segment of DNA. A crude lysate 
containing a particular recombinant antigen can be prepared by 
expressing a Agtll recombinant as a lysogen in E. coli Y1089.
Host Y1089 like Y1090 contains a repressor and a deficiency in Ion 
protease. Where it differs from Y1090 is that it contains a 
mutation which enhances the frequency of phage lysogeny (Hfla 150). 
For production of a recombinant fusion protein, Y1089 is lysogenised 
with recombinant Agtll containing the putative protein X DNA, the 
lysogens are grown to a high cell density, and the lac Z-directed
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fusion protein induced by the addition of IPTG. Using replica
o o
plating, colonies which had grown at 32 C and not 42 C were
o
isolated and purified. At 32 C the temperature-sensitive phage
repressor (cl857) is functional. Four single colonies from an LB
o o
plate which had grown at 32 C and not at 42 C were used to
o
inoculate 10ml LB and the phage grown overnight at 3 0 C.
Occasionally the Y1089 lysogen will lyse even though Y1089 does not
suppress the mutation causing defective lysis (S10 0) in Xgtll.
This is a consequence of the "leakiness" of the (S100) amber
mutation, and secondly the accumulation of foreign protein in E.
coli often renders it susceptible to lysis.
The overnight culture (10O/il) was used to inoculate 
o
prewarmed (30 C) LB medium and the incubation continued until the
OD =0.45 (approx. 3 h). The cultures were transferred for 
600
o
15 min to a water bath at 44 C followed by the addition of IPTG to 
a final concentration of lOmM. After 1 h the induced lysogenic 
cultures were pelleted and the pellets resuspended in 500^1 of 
lysate buffer and 30/il of each of the positive lysogens resolved on 
a 10% (w/v) SDS polyacrylamide gel, transferred electrophoretically 
to nitrocellulose and the nitrocellulose challenged with antiserum 
to component X. The nitrocellulose was processed as described in 
Section 2.2.9a.
An immune response to component X antiserum is observed 
from the fusion protein of four recombinant lysogens selected, 
appearing above the 69K marker (Fig. 6.4). No immune response is 
observed from non recombinant Y1089 lysogens prepared in a similar 
manner. The recombinant lysogens were also challenged with PDC and 
a weak immune response was detected from all but one of the 
recombinant lysogens. This recombinant was not processed further.
Figure 6.4 Identification of fusion protein of component X by 
iimnunob lotting
Crude lysates were prepared as described in Section 2.2.12k
and resolved on a 10% (w/v) SDS/polyacrylamide slab gel.
Polypeptides were transferred onto nitrocellulose and subsequently
analysed by immunoblotting technique and challenged with 1:100
dilution of antisera to component X. lanes 7-4 30pl of positive
lysogens. lanes 3,2 30;il of non recombinant lysogens. laneM,*
M marker 69000. 
r
Identification of a (3- galactosidase fusion 
protein with component X anti serum
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6.2.5 Preparation of DNA that encodes for protein X
In order to study the structure and function of the gene 
encoding the fusion protein recognised by component X antiserum DNA 
was prepared from 3 lysogens which gave a positive immune response 
(Section 2.2.13a). From the yields of DNA of the three recombinant 
lysogens only one recombinant X1A, produced amounts of DNA 
equivalent to that produced by non recombinant Agtll (Fig. 6.5.).
In view of the difficulties in preparing sufficient amounts of DNA 
from all three lysogens our work focussed on the DNA prepared from 
recombinant X1A.
6.2.6 Restriction endonuclease digestion of DNA
DNA (ljLig) prepared from each of the three recombinants and 
the non-recombinant control were digested with the restriction 
enzyme EcoRI. As discussed in Section 6.2.5 the relative amounts 
of DNA prepared can be compared and only DNA from X1A approaches the 
levels of non-recombinant DNA (Fig. 6.5). On one side of the EcoRI 
insertion site (Fig. 2.1) there is an SstI and on the other a Kpnl 
site, and the recombinant DNA was digested with SstI amd Kpnl 
restriction enzymes. DNA fragments from the restriction enzyme 
digests were electrophoresed on a 1.5% (w/v) agarose and the results 
are visualised in Figure 6.2.6. EcoRI digestion of X1A releases a 
fragment of approximately 300 base pairs. The insert is confirmed 
in the double digest involving SstI and Kpnl which produces a 
fragment of approximately 2.3kb. A 2kb size fragment is released 
from non recombinant DNA confirming the size of the insert (Fig. 6.5).
Figure 6.5 Restriction endonuclease digestion of recombinant
Agtll
Agarose gel analysis.
lane 1 EcoRI digest of recombinant Agtll XI
lane 2 EcoRI digest of recombinant Agtll X1A
lane 3 EcoRI digest of recombinant Agtll X16
lane 4 EcoRI digest of non recombinant Agtll
lane 5 SstI + Kpnl digest of non recombinant Agtll
lane 6 SstI + Kpnl digest of recombinant Agtll XI
lane 7 SstI + Kpnl digest of recombinant Agtll X1A
lane 8 SstI + Kpnl digest of recombinant Agtll X6
lane 9 EcoRI + SstI + Kpnl digest of non recombinant Agtll
lane 10 EcoRI + SstI + Kpnl digest of recombinant Agtll XI
lane 11 EcoRI + SstI + Kpnl digest of recombinant Agtll X 1A
lane 12 EcoRI + Sst + Kpnl digest of recombinant Agtll X6
lane M Hindlll digest of DNA
—  4361
r^ -2322
^ 2 0 2 7
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6.2.7 DNA sequencing
M13 is a single stranded filamentous phage. The phage 
enters a suitable host cell by way of the F pilus. On entering the 
cell, the virus is stripped of its protein coat and the single 
stranded viral DNA is converted to a double-stranded replicative 
form (RF). This stage is followed by DNA replication to give 
100 + progeny RF molecules from which new single stranded viral DNA 
is synthesised. This is then packaged into viral coat proteins and 
extruded from the host cell without lysis. In this way, some 
100 phage particles are produced per cell, per generation. The M13 
life cycle can be exploited for the preparation of pure single 
stranded recombinant DNA by using the double stranded RF DNA as a 
cloning vector. Fragments of foreign DNA can be inserted into a 
suitable restriction enzyme site on the vector. M13 RF DNA 
carrying such a double stranded insert can be introduced into a 
suitable host by a transformation step. The resultant phage growth 
will lead to production of the hybrid molecules in both double 
stranded (RF) and single stranded (mature virus) forms, thus 
offering both an amplification step and a means of producing the 
insert DNA in single stranded form.
Although M13 does not lyse its host cell, the growth of the 
cell is retarded as a consequence of supporting phage growth. Thus 
when plated out those cells infected with M13 will show up as areas 
of slower growth, which look like turbid plaques on a lawn of 
uninfected cells.
Alternatively, under appropriate conditions the cells 
containing the M13 vector will grow to form a blue plaque, but this 
process is disrupted by the introduction of a fragment of foreign 
DNA within the M13 insertion site. As a result cells containing
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recombinant phage will give colourless opaque plaques. This 
discrimination is based on the presence or absence of the enzyme 
/8 -galactosidase. JE^_ coli host cells infected with M13 vector 
strains will, in the presence of the lac operon-inducer IPTG, 
produce a functional /S -galactosidase. Such cells will hydrolyse
the substrate X-gal to give a blue dye. Insertion of foreign DNA
into an appropriate site in the DNA vector interferes with the 
production of -galactosidase. Thus cells containing recombinant 
M13 give colourless plaques on an E^ _ coli lawn in contrast to the 
blue plaques formed by cells containing the intact vector.
6.2.8 Preparation of competent cells
In order to introduce vector DNA into host E^ _ coli cells
o
the host cells are treated with CaCl  ^at 4 C (Section
2.2.14f). It is necessary to use these competent cells for the
transformation of coli strains by recombinant M13.
Host E. coli K12 (E. coli JM103) were grown overnight in 
o
10ml of 2 x TY medium at 37 C. 2ml of the overnight culture was 
then used to inoculate fresh 2 x TY medium (40ml) and the cells were 
processed as described in Section 2.2.14f.
6.2.9 Transformation of competent cells
The ability to transfer plasmids into E^ _ coli cells is
brought about by the interaction of DNA and divalent cations at low 
o
temperatures (4 C). The frequency of transformation may be
improved by treating the cell/DNA mixture at elevated temperatures
o
for a short period of time (heat shock) (42 C).
Half of the ligated DNA prepared was added to 0.3ml of 
o
competent cells at 4 C. After 40 min the cells were heat shocked
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o
at 42 C for 3 min and returned to ice. Fresh cells, IPTG and
X-gal were added to the heat shocked cells followed by 3ml of molten 
o
H top agar at 42 C. The mixture was then poured onto H plates
o
and incubated overnight at 37 C (Section 2.2.14f). !{
The following morning ten colourless plaques were selected.
6.2.10 Preparation of single stranded DNA
After overnight growth, transformed cells will have formed 
plaques. Cells infected with recombinant DNA form colourless 
plaques and cells infected with non recombinant DNA should form blue 
plaques. Infected cells from recombinant, colourless plaques are 
grown up to produce single stranded template for the sequencing 
reaction. Recombinants should not be stored as plaques but may be 
stored as purified single stranded DNA. Single stranded DNA was 
prepared from 10 colourless plaques as described in Materials and 
Methods (Section 2.2.14g).
6.2.11 Nucleotide sequencing of insert DNA
Single stranded DNA prepared from colourless plaques was 
primed with Amersham Universal primer. The M13 primer is a single 
stranded synthetic oligonucleotide complementary to a region of 
vector DNA which flanks the insertion site.
The sequence reaction was performed as described in the 
Amersham M13 cloning and sequencing handbook and the samples 
resolved by gel electrophoresis (Section 2.2.14k).
The gel autoradiograph from DNA for 2 colourless plaques is 
shown in Figure 6.6. The sequence from the recombinant DNA is 
different from Ml3 vector run as a control therefore it has been 
assumed that the insert has been successfully ligated into M13
Figure 6.6 Example of a polyacrylamide sequencing gel
DNA fragments synthesised in the presence of 
dideoxynucleotides were separated on a high resolution thin 
polyacrylamide gel (buffer gradient). Chain elongation was 
carried out with Klenow polymerase and the electrophoresis was 
terminated when the bromophenol blue had reached the bottom of 
the gel (2.5 h). Better resolution of larger fragments was 
obtained by performing electrophoresis for up to 5 h.
Clone
A C G T A C 6 T
Figure 6.7 Nucleotide sequence and predicted amino acid sequence 
determined from cDNA encoding protein X
Figure 6.8 Comparison of nucleotide sequence coding for mammalian 
protein X gene with the nucleotide sequence coding for 
yeast protein X gene
The nucleotide sequence for the mammalian protein X gene 
is indicated by upper case letters and that encoding for yeast 
protein X gene in the lower case letters. In regions of similarity 
the nucleotides encoding mammalian protein X gene which are 
identical to the encoding yeast protein X gene sequence are 
indicated by vertical lines.
1 GGTTACTTTCTTGGTGTAACGAACTAATAGCGCATTTCTGGAATTTGTACTCTCCAAGCT 60 
V T F L V Y R T N S A F L E F V L S K L -
61 GCTCAAAAAGCTCACAATTTTGTTTGATGAAATTCTGAGGCTCTTCCACAAGAAGTTTAA 120 
L K K L T I L F D R I L R L F H K R F K -
121 ATTGATCGAACACTTTGGCATAGCATTCATGAGGATCTGCAGCGGCACAGCACTTCTCTA 180 
F I E H F G I A F M R I C S G T A L L Y -
181 CAGTGGTTTCATATGTCTTGGCAAGTCTCAGCAGCAGCACGACAGAGTATCAGGTGCCTT 240 
S G F I C L G K S Q Q Q H D R V S G A F
241 CTTGG 245 
L
62 CTCAAAAAGCTCACAATTTTGTTTGATTGAATTCTGAGGCTCTTCCACAA 111 
I I I I II I I III I III II I ill II I I I I I
1467 ctgaaaaaaacgaatatatactagcgttgaat.gttagcgtcaacaacaa 1515
112 GAAGTTTAAATTCATCGAACACTTTGGCATAGCATTCAT 150 
I I I I I I I I I I II I I I I  I I I I 1
1516 gaagtttaatgacgcggaggccaaggcaaaaagattcct 1553
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vector. Another noticeable feature seen in Figure 6.6 is that 
clone 2 appears to be different from clone 4 and the other 8 clones 
(data not shown). It is possible that, during ligation, the DNA 
fragment has been inserted into the vector in the opposite 
orientation. This allowed the reading of the sequence in the 
opposite direction and thus confirm the sequence. The nucleotide
sequence and the predicted amino acid is determined in Figure 6.7.
6.2.12 Ligation of insert into vector PTZ 18
RF recombinant M13 vector was digested with EcoRI and 
ligated into EcoRI digested PTZ (Section 2.2.14e). After 
transformation into a suitable host, TGI, selection for ligated 
insert into PTZ 18 was by identification of colourless colonies on 
an IPTG, X-gal impregnated H + ampicillin plates.
6.2.13 Preparation of recombinant plasmid PTZ 18
Clear colonies from H plates were selected and spread onto
o
H + ampicillin plates and grown overnight at 37 C. The colonies
were further purified by replica plating and grown overnight at 
o
37 C. No blue colonies were observed. Colonies were then 
selected and used to inoculate lOul culture of L-broth containing 
ampicillin (50/ig/ml) and recombinant plasmid prepared as in Section 
2. 2.15a.
6.2.14 Restriction digest of recombinant plasmid PTZ 
Recombinant plasmid prepared (Section 2.2.15a) was digested
with EcoRI releasing an approximate 300 base pair fragment (Fig.
6.9. ).
Figure 6.9 EcoRI digest of recombinant PTZ 18
Agarose gel analysis of EcoRI digested plasmid PTZ 18R 
containing ligated insert from recombinant DNA X1A 
lane 1 EcoRI digested vector PTZ containing inert X1A
lane 2 EcoRI digested vector PTZ containing insert X1A
lane 3 uncut vector PTZ 18R
The samples were electrophoresed in 1.5% (w/v) agarose gel.
P T Z 1 8
E Co RI  d i g e s t e d  P T Z 1 8
I n s e r t
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6.3 Discussion
Most strategies used to isolate genes from recombinant DNA 
libraries have employed nucleic acid probes (Davis et al., 1980; 
Maniatas et al., 1989). Genes can also be identified and isolated 
through the use of antibody probes of the antigen expressed by 
specific genes (Young and Davis, 1983). The phage expression 
vector was constructed to permit insertion of foreign DNA into the 
-galactosidase structural gene lacZ under the control of the lac 
operator (Fig. 2.1). The recombinant DNA can be propagated 
lytically, and the expression of the foreign DNA is repressed by the 
lacl gene product. Production of the foreign antigen fused to 
ft -galactosidase can rapidly be induced by the addition of IPTG to 
the culture medium. The presence of the Ion mutation appears to 
permit accumulation of otherwise unstable novel proteins to levels 
which facilitate detection by immunological analysis.
In our studies we found that using the "dot blot" antigen 
detection method (Fig. 6.2) E2 IgG could detect levels of O.lng of 
PDC, component X IgG and PDC IgG could detect levels of 5ng of 
PDC. Antisera to component X and PDC could detect levels of O.lng 
of PDC. These values were compatible with the levels suggested by 
Young and Davis (1983) for cloning genes.
Although other methods of detection of antigen may be as
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sensitive as the "dot blot" (Section 2.2.9c) e.g. T-protein
A. The dot blot method has the distinct advantage of producing
signals directly onto nitrocellulose filters, thereby exactly
reproducing the pattern of plaques on the plate. This allows the
precise location of a single plaque producing the signal to be
determined X. Moreover, the frequency of false positives is very
125
low (Young and Davis, 1983). While the I-protein A protocol 
has the advantage of being sensitive and allowing controlled films 
exposure to maximise signal to noise ratio, it is useful only in the
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detection of IgG and is prone to producing false positives. It was 
also felt the use of radiolabelled isotopes should be avoided 
wherever possible.
In order to maximise the detection of fusion proteins the 
most sensitive antibody/antigen combination was selected i.e. the 
library was screened with E2 IgG, antisera to component X and 
antisera to PDC.
Screening of the library
With each screen of the library several positives were 
detected by each of the antibodies. Subsequent rescreening of the 
initial positives failed to show any replication of the positive 
plaque. The maximum size of insert which can successful ligated 
into a A g t l l  gene expression library is approximately 7kb. The 
complete E2 gene and PDC genes are approximately 1.8kb and 4.5kb 
respectively therefore they should not be unstable in the A g t l l  
vector. Another problem is that unusual polypeptides are 
efficiently degraded in E. coli (Edman et al., 1981) and it may be 
that the fusion product of -galactosidase and eukaryotic antigen 
is degraded by certain proteases. A third major problem with 
foreign antigen synthesis in E. coli is the presence of these 
unusual proteins is occasionally harmful to the cells. One of 
these factors or a combination could be responsible for the failure 
to reproduce the initial positive to E2 IgG and PDC antiserum.
Identification of component X clone
A plaque positive to component X antiserum survived the 
isolation and purification process, 100% positives being obtained 
(Fig. 6.3). It was also observed that preparative amounts of 
polypeptide specified by the component X clone, when subjected to 
immunoblotting (Section 6.4) gave an immune response to component X 
antiserum and a weaker response to PDC antiserum. These results 
confirmed that a clone of component X had been isolated and purified.
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Restriction digest of DNA encoding protein X
Restriction digest of recombinant DNA revealed a 250-300 
base pair fragment. The complete cDNA for protein X is expected to 
be approximately 1500 base pairs. Therefore in view of the strong 
immune response elicited by the fusion protein to component X 
antiserum the particular region of cDNA must encode for a highly 
immunogenic region protein X.
Sequence analysis of the DNA encoding protein X
The nucleotide sequence and the deduced amino acid of the 
protein X clone are shown in Figure 6.7. The open reading frame of 
243 nucleotides encodes for 81 amino acids residues. It was 
expected as component X and E2 have a close relationship both 
physically and functionally a degree of homology would exist between 
the nucleotide sequences. Comparison of the mammalian E2 
nucleotide sequence (Gershwin et al., 1987) and the nucleotide 
sequence obtained from the component X clone revealed little 
homology. Assuming that the component X clone is genuine this may 
suggest that component X has a unique function in mammalian pyruvate 
dehydrogenase.
During the course of this work the nucleotide sequence of 
component X from Saccharomyces cerevisiae was published (Behai 
et al., 1989). Comparison of the nucleotide sequence from yeast 
component X and the nucleotide sequence from mammalian component X 
clone revealed 70% homology between the two sequences at the carboxy 
terminal of yeast protein X. An area of high homology extending 
over 30 nucleotides is observed between^gg pairs [ 81-110) of the 
mammalian component X clone. A further region of homology exists 
between base '-pa'lrs( 62-70) this homology was achieved without any 
sequence addition or deletion to optimise the alignment (Fig. 6 . 8 ).
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Comparison of the deduced amino acid sequences of yeast 
protein X and yeast E2 (Nui et al., 1988 and Behai et al,, 1989) 
reveals that the amino terminal part of protein X resembles E2, but 
the carboxy-terminal part is quite different. The two proteins 
exhibit 50% sequence identity in the amino terminal that corresponds 
to the putative lipoyl bearing domain on E2. This extensive 
homology indicates that protein X and E2 evolved from a common 
ancestor. Protein X also lacks the carboxy terminal segment of E2 
that contains the highly conserved sequence which is thought to be 
part of the putative catalytic site of all dihydrolipoamide 
acyltransferases (Guest, 1987). This finding suggests that yeast 
protein X, in contrast to E2, is not able to catalyse the transfer 
between the protein bound S-acetyldihydrolipoyl moiety and 
coenzyme A.
Evidence has been presented that in mammalian pyruvate 
dehydrogenase complex from bovine kidney, protein X contributes to 
the binding of the E3 component, perhaps by facilitating the
transfer of reducing equivalents to E3 (Powers-Greenwood et al.,
1989; Gopalakrishnan et al., 1989). We have observed, by studying 
the predicted amino acid sequence of yeast protein X, a possible E3
\ I. _ . l i................ ..... . ... . . .. . . .
binding domain between residues (145-176) (Behai et al., 1989) shown below.
Lc lov‘'-v
The amino acid sequence of the 32 residue E3 binding domain of veast 
protein X.
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CHAPTER SEVEN 
GENERAL DISCUSSION
7. General Discussion
Mammalian PDC has been studied extensively over the last 
twenty years. In particular its enzymatic and physiochemical 
characteristics have been the subject of detailed examination 
following its isolation from several tissues (Koike and Koike, 1976).
The regulation of this multienzyme complex by 
phosphorylation/dephosphorylation has also received considerable 
attention, as a result of its importance in the conservation of 
glucose in starvation and diabetes (Reed et al., 1980; Denton et 
al., 1981; Weiland, 1983; Reed and Yeaman, 1987).
The discovery of an extra polypeptide of the complex, M^ 
51000 of unknown function (component X) has resulted in intensive 
investigation into the properties and function of this unique protein 
of mammalian PDC (De Marcucci and Lindsay, 1985; Hodgson et al., 
1986; Jilka et al., 1986; Gopalakrishnan et al., 1989; Behai et 
al., 1989). These authors have shown that component X undergoes 
reductive acetylation on a lipoic acid site and in the presence of 
CoASH is also rapidly deacetylated. In addition, component X 
preferentially binds the E3 component to the core assembly. 
Consequently component X depleted core is unable to bind the E3 
component or recover overall complex activity on reconstitution of 
the enzyme and this suggests that this polypeptide is essential for 
overall complex activity. It was also observed that component X 
does not contain a recognised acetyltransferase site. This putative 
catalytic site is thought to include the highly conserved 
His-Xaa-Xaa-Xaa-Asp-Gly segment near the carboxyl terminus (Guest, 
1987).
7.1 Role of component X
Component X has been shown to participate in the normal 
turnover of the enzyme. It was demonstrated the component X was
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involved in the catalytic cycle of the enzyme and was not reductively 
acetylated as a consequence of a side reaction promoted by conditions 
which trap acetyl groups on E2.
Inactivation of the complex by phosphorylation by the 
intrinsic protein kinase, causes a parallel decrease in the 
acetylation on E2 and X indicating that the latter protein can 
participate in acetylation/deacetylation reactions of the complex. 
This result suggests that loading of protein X must proceed through 
the formation of a TPP intermediate associated with El.
Although the turnover of the enzyme was successfully slowed, 
as observed from low temperature radiolabelling of the complex 
elucidating the sequence of acetyl group transfer from El or between 
E2 and X, under these conditions, was unsuccessful.
In a separate approach to determine the sequence of acetyl 
group transfer within the complex, various substrate analogues were 
employed as potential substrates for PDC. Only o<-ketobutyrate 
could substitute as a substrate for PDC and it was also recognised 
that 2-oxobutyrate could protect lipoic acid residues on E2 and X 
from NEM incorporation. This phenomenon, unique to eukaryotic PDC, 
was first observed with pyruvate as substrate and may offer an 
explanation as to the role of component X in the complex. The 
physiological basis for this phenomenon is unknown and it is possible 
it may be promoted by component X. In cases of starvation and 
diabetes not all the acetyl CoA generated can be metabolised by the 
tricarboxylic acid cycle and alternatively excess acetyl CoA is 
accumulated and converted to produce ketone bodies etc. By assuming 
that there are two active lipoyl domains per E2 chain and 60 E2 
subunits, then it is possible the E2 core assembly can act as a 
reservoir for acetyl groups by incorporating 240 acetyl groups, thus 
preventing production of excess acetyl CoA. Investigation of the
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levels of acetylation on E2 and X of the ratio of NADH/NAD in 
patients with diabetes or malnutrition could provide a clue to the 
possible role of protein X in the complex.
7.2 Limited proteolysis of component X
Incubation of PDC with trypsin resulted in limited 
proteolysis of E2 and X with resultant loss of overall enzyme 
activity. The loss of activity was a result of cleavage of lipoyl 
domains from the E2 core assembly. As a consequence of the cleavage 
of the lipoyl domains the enzyme complex lost its ability to promote 
diacetylation of the lipoic acid residues on E2 and X and therefore 
its ability to protect against NEM modification. As E2 and X 
undergo similar degrees of proteolysis with trypsin it was not 
possible to determine the role of component X in the complex. An 
interesting observation was that limited protelysis of PDC with argC 
preferentially digested component X and released the E3 component 
from the E2 core assembly, supporting the observations of Roche’s 
group that X was involved in E3 binding (Gopalakrishnan et al♦ ,
1989; Powers-Greenwood et al., 1989). However our evidence differs 
in several important respects from the observations reported by the 
above authors. E3 does not protect X from proteolysis by argC and 
extensive proteolysis of component X does not result in loss of 
overall complex activity although it could be argued 1 0% was 
sufficient to promote activity. On incubation of complex in high 
salt, the activity of the complex remained unaltered although, as 
with argC treatment the E3 component was released from the core 
assembly on resolution on a gel filtration column.
Incubation of PDC in argC and high salt leads to rapid 
inactivation of the complex. This result is best explained by 
incubation of PDC in argC or high salt lowers the affinity of E3 for
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the core assembly without affecting overall enzymatic activity. It 
is only a combination of high salt and argC which lowers the affinity 
of the E3 compared for the core assembly sufficiently to effect the 
enzyme activity. These observations are supported by Kresze (1980) 
who observed that limited proteolysis of PDC with papain released the 
El and E3 components from the core assembly rendering the complex 
inactive although each of the components maintained their individual 
catalytic properties.
The binding of E3 to component X is further confirmed by 
binding studies on an E2 oligomer prepared free from component X 
(Powers-Greenwood et al., 1989). These authors observed reduced 
binding of E3 to the E2 oligomer and significant binding of E3 to the 
component X fragment although they fail to define the term 
significant.
The structural role of component X in the complex has not 
been fully considered. Component X may not directly bind E3 to the 
core assembly. Instead, it may position E3 in the correct 
orientation to ensure efficient binding to the core assembly (E2), 
or, component X may position E2 to effect efficient binding of E3. 
Therefore, limited proteolysis, and inactivation of the complex as 
reported by Roche and co-workers and lack of activity recorded by a 
yeast mutant lacking component X (Reed et al., 1990) could be caused 
by disruption to the core assembly. In support of the argument, 
removal of the subunit 3 of cytochrome e oxidase does not render the 
complex inactive. However, investigation into a yeast mutant 
lacking subunit 3 reveals that proper assembly of the complex is not 
completed when this subunit is missing and therefore the complex 
lacks overall enzymatic activity.
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In recent weeks, investigation of cells taken from two 
French children (brothers) were characterised by a complete absence 
of protein X subunit on examination of the polypeptide profile of 
their PDC by immune replica analysis of mitochondrial £ind cellular 
extracts. Measurement of overall PDC activity revealed 20% to 30% 
of normal activity. However, preparation of cellular extracts was 
carried out in 0.15M KC1 and 0.1M Tris/HCl pH8.0 and the level of
J
activity recorded may be caused by the enzymes sensitivity to high 
salt concentration. Repeating the experiment in low levels of salt 
may give an accurate level of enzymatic activity in the absence of 
protein X. Hopefully, by examining the enzymology and regulation of 
the mutant PDCs we will determine how their properties differ from 
wild-type enzyme.
Several authors have reported that E2 of mammalian PDC 
possess an E3 binding domain located near the inner catalytic domain 
on E2 (Thekummkara et al., 1988; Coppel et al., 1989). Therefore, 
why should eukaryotic PDC possess an additional polypeptide which 
serves this function? It may simply be that PDC, as the most 
important enzyme of the 2-oxo acid dehydrogenase complexes, is 
ensuring priority in binding E3 over OGDC and BCOADC or it may be 
that component X serves an additional function.
Radiolabelling of argC or high salt treated NADH reduced 
14
complex with [ C] NEM results in the enhanced labelling of the E3 
component. Subsequent studies on the E3 enzyme revealed that 
inactivation by NEM on treated enzyme was NADH dependent leading to 
the conclusion that component X binds the E3 component at its active 
site, possibly protecting the active site on E3 from inactivation. 
Protecting the active site on E3 has physiological significance. In 
the cell glutathione is a potential inhibitor of E3 function and 
protection of the active site by component X may protect the complex
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from the sulphydryl group inhibitor. Confirmation that the 
incorporation of NEM into the reduced active site of E3 may be 
achieved by limited proteolysis of radiolabelled E3 followed by amino 
acid sequencing of the radiolabelled fragment to determine if it has 
been incorporated into the active site. This would confirm 
cooperation between components of multienzyme complexes in substrate 
channelling and organisation.
E2 of E^ coli has three tandomly repeated lipoyl domains per 
E2 chain while mammalian E2 has two lipoyl domains and a third lipoyl 
domain if component X is considered. Now that various constructs of 
E2 from E. coli are available lacking one or more lipoyl domains 
(Graham et al., 1986) an interesting investigation would be to 
determine the efficiency of E3 binding to each of the constructs and 
possibly assign a role to one or more of the lipoyl domains of E2 of 
E. coli.
7.3 Structural and functional relationship of component X to the
E2 core assembly
Component X is associated with the other components of the 
complex in reproducible amounts. Based on quantitative scanning of 
Coomassie blue-stained bands of the complex in SDS-PAGE gels, it 
appears that 6% of the total absorbance is represented by this 
component. On the other hand, component X retains 14-16% of the 
total radioactivity associated with the complex after labelling in
I4the presence of [2- C] pyruvate (De Marcucci et al., 1986).
Assuming one "acetylatable" group per molecule of X, an estimated 
8-10 molecules of polypeptide per core is obtained which agrees with 
the value calculated on the basis of densitometric scan of 8-12 
molecules of component x per core. This provisional conclusion 
requires confirmation by employing more reliable stoichiometric 
analysis.
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Selective release of the lipoyl domains from E2 and X by 
limited proteolysis with a variety of specific and non specific
proteases produced stable peptides M 32000-42000 range for E2 and
r
M 15000-20000 range for component X. This is best accounted for 
r
by the absence of a lipoyl domain from proteinXond£2.Cross-linking
studies revealed a species of M 100000 suggesting that component X
r
could only form a dimer which is in agreement with a single lipoyl 
domain on component X.
Limited amino acid sequence data confirmed that protein X 
contains a lipoyl domain located at its N-terminus and belongs to a 
family of enzymes which possess acetyltransferase activity although 
the high degree of homology established at the N-terminal between E2 
and X (45%) is not enough for cross reactivity to be observed.
7.4 Cloning and sequence analysis of protein X
Sequence data on component X from Saccharomyces cerevisiae 
has been reported (Behai et al., 1989). Two major observations were 
reported from the nucleotide and predicted amino acid sequence data: 
a) component X from yeast lacks the region which codes for 
acetyltransferase activity and b) little homology exists between E2 
and component X in yeast outwith the N-terminal regions of the 
proteins. Further investigation in our laboratory into the 
component X sequence has revealed a possible E3 binding domain on 
component X supporting the conclusion component X binds the E3 
component. A 250 base pair cDNA clone reveals approximately 70% 
homology with component X from yeast in the region of the carboxy 
terminus confirming that a mammalian clone of component X has been 
isolated. This fragment can now be employed as a probe to isolate 
the full-length cDNA clone. In conjunction with the N-terminal 
sequence and the 250 base pair fragment, PCR could be employed to 
create a larger fragment with the view to rapid sequence analysis and 
possible identification of active sites in the gene.
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